<body style="font-family: Times New Roman; font-size: 13px;"> <document>  <type>   10-K   <sequence>    1    <filename>     ptn_10k.htm     <description>      ANNUAL REPORT      <text>       <!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->       <!-- Copyright 2021 Issuer Direct Corporation -->       <title>        ptn_10k       </title>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">        <!--style header-->        <br/>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 13px">         UNITED STATES        </font>       </div>       <div style="text-align: center">        <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 13px">         SECURITIES AND EXCHANGE COMMISSION        </font>       </div>       <div style="text-align: center">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Washington,D.C. 20549        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         FORM 10 - K        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           ☑          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           ANNUALREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For thefiscal year ended June 30, 2021        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         or        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           ☐          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           TRANSITIONREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For thetransition period from ___________ to __________        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Commissionfile number: 001-15543        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <img src="ptn_logo.jpg"/>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         PALATIN TECHNOLOGIES, INC.        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         (Exactname of registrant as specified in its charter)        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 40%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Delaware             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 41%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              95-4078884             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 40%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              (Stateor other jurisdiction of             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              incorporationor organization)             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 41%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              (I.R.S.Employer Identification No.)             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 40%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 41%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 40%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              4B Cedar Brook Drive             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Cranbury, New Jersey             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 41%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              08512             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 40%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              (Addressof principal executive offices)             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 41%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              (ZipCode)             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         (609) 495-2200        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         (Registrant’stelephone number, including area code)        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Securitiesregistered pursuant to Section 12(b) of the Act:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: bottom; width: 40%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Title of Each Class             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 18%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Trading Symbol             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 41%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Name of Each Exchange             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              on Which Registered             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: bottom; width: 40%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              CommonStock, par value $.01 per share             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 18%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              PTN             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 41%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              NYSEAmerican             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Securitiesregistered pursuant to Section 12(g) of the Act: None        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indicateby check mark if the registrant is a well-known seasoned issuer, asdefined in Rule 405 of the Securities Act. Yes ☐ No☑        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indicateby check mark if the registrant is not required to file reportspursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No☑        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indicateby check mark whether the registrant (1) has filed all reportsrequired to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for suchshorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements forthe past 90 days.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Yes☑ No ☐        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indicateby check mark whether the registrant has submitted electronicallyevery Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T during the preceding 12 months (or forsuch shorter period that the registrant was required tosubmit).         <font style="font-size: 13px">         </font>         Yes ☑   No ☐        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indicateby check mark whether the registrant is a large accelerated filer,an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of“large accelerated filer,” “acceleratedfiler,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the ExchangeAct.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 240px">          <font style="font-family: Times New Roman; font-size: 13px">           Large acceleratedfiler          </font>         </div>         <div style="display: table-cell; width: 192px">          <font style="font-family: Times New Roman; font-size: 13px">           <a name="_Hlk522267250">            <!--anchor-->           </a>           ☐          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Acceleratedfiler☐          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 240px">          <font style="font-family: Times New Roman; font-size: 13px">           Non-acceleratedfiler          </font>         </div>         <div style="display: table-cell; width: 192px">          <font style="font-family: Times New Roman; font-size: 13px">           ☑          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Smaller reportingcompany ☑          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <div>        </div>        <div style="display: table">         <div style="display: table-row">          <div style="display: table-cell; width: 240px">           <font style="font-family: Times New Roman; font-size: 13px">            <br/>           </font>          </div>          <div style="display: table-cell; width: 192px">           <font style="font-family: Times New Roman; font-size: 13px">            <br/>           </font>          </div>          <div style="text-align: left; display: table-cell">           <font style="font-family: Times New Roman; font-size: 13px">            <font style="font-family: Times New Roman; font-size: 13px">             Emerging growthcompany            </font>            <font style="font-family: Times New Roman; font-size: 13px">             ☐            </font>           </font>          </div>         </div>        </div>        <font style="font-family: Times New Roman; font-size: 13px">         <br/>        </font>       </div>       <div style="text-align: left; margin-left: 336px; margin-right: 0px; text-indent: 48px">       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If anemerging growth company, indicate by check mark if the registranthas elected not to use the extended transition period for complyingwith any new or revised financial accounting standards providedpursuant to Section 13(a) of the Exchange Act. ☐        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indicateby check mark whether the registrant has filed a report on andattestation to its management’s assessment of theeffectiveness of its internal control over financial reportingunder Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b))by the registered public accounting firm that prepared or issuedits audit report. ☐        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indicateby check mark whether the registrant is a shell company (as definedin Rule 12b-2 of the Exchange Act). Yes ☐ No☑        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Statethe aggregate market value of the voting and non-voting commonequity held by non-affiliates, computed by reference to the priceat which the common equity was last sold, or the average bid andasked price of such common equity, as of the last business day ofthe registrant’s most recently completed second fiscalquarter (December 31, 2020): $156,423,329        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Indicatethe number of shares outstanding of each of the registrant’sclasses of common stock, as of the latest practicable date(September 24, 2021): 231,258,137        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-weight: bold">          PALATIN TECHNOLOGIES, INC         </font>         .        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Table of Contents        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td colspan="2" style="vertical-align: top; width: 84%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 16%; border-bottom: 2px solid #000000">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Page             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align: top; width: 100%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              PARTI             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#item1">              <font style="font-family: Times New Roman; font-size: 13px">               Item1.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#item1">              <font style="font-family: Times New Roman; font-size: 13px">               Business              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#item1">              <font style="font-family: Times New Roman; font-size: 13px">               1              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item1a">              <font style="font-family: Times New Roman; font-size: 13px">               Item1A.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item1a">              <font style="font-family: Times New Roman; font-size: 13px">               RiskFactors              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item1a">              <font style="font-family: Times New Roman; font-size: 13px">               16              </font>             </a>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item1b">              <font style="font-family: Times New Roman; font-size: 13px">               Item1B.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item1b">              <font style="font-family: Times New Roman; font-size: 13px">               Unresolved StaffComments              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item1b">              <font style="font-family: Times New Roman; font-size: 13px">               40               <br/>              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item2">              <font style="font-family: Times New Roman; font-size: 13px">               Item2.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item2">              <font style="font-family: Times New Roman; font-size: 13px">               Properties              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item2">              <font style="font-family: Times New Roman; font-size: 13px">               40               <br/>              </font>             </a>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item3">              <font style="font-family: Times New Roman; font-size: 13px">               Item3.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item3">              <font style="font-family: Times New Roman; font-size: 13px">               LegalProceedings              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item3">              <font style="font-family: Times New Roman; font-size: 13px">               40              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item4">              <font style="font-family: Times New Roman; font-size: 13px">               Item4.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item4">              <font style="font-family: Times New Roman; font-size: 13px">               Mine SafetyDisclosures              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item4">              <font style="font-family: Times New Roman; font-size: 13px">               40              </font>             </a>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td colspan="3" style="vertical-align: top; width: 100%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              PARTII             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item5">              <font style="font-family: Times New Roman; font-size: 13px">               Item5.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 60px; margin-right: 0px; text-indent: -60px">             <a href="#item5">              <font style="font-family: Times New Roman; font-size: 13px">               Market forRegistrant’s Common Equity, Related Stockholder Matters andIssuer Purchases of Equity Securities              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item5">              <font style="font-family: Times New Roman; font-size: 13px">               41              </font>             </a>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item6">              <font style="font-family: Times New Roman; font-size: 13px">               Item6.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 60px; margin-right: 0px; text-indent: -60px">             <a href="#item6">              <font style="font-family: Times New Roman; font-size: 13px">               [Reserved]              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item6">              <font style="font-family: Times New Roman; font-size: 13px">               41              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item7">              <font style="font-family: Times New Roman; font-size: 13px">               Item7.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 60px; margin-right: 0px; text-indent: -60px">             <a href="#item7">              <font style="font-family: Times New Roman; font-size: 13px">               Management’sDiscussion and Analysis of Financial Condition and Results ofOperations              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item7">              <font style="font-family: Times New Roman; font-size: 13px">               41              </font>             </a>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item7a">              <font style="font-family: Times New Roman; font-size: 13px">               Item7A.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 60px; margin-right: 0px; text-indent: -60px">             <a href="#item7a">              <font style="font-family: Times New Roman; font-size: 13px">               Quantitative andQualitative Disclosures About Market Risk              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item7a">              <font style="font-family: Times New Roman; font-size: 13px">               45              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item8">              <font style="font-family: Times New Roman; font-size: 13px">               Item8.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item8">              <font style="font-family: Times New Roman; font-size: 13px">               FinancialStatements and Supplementary Data              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item8">              <font style="font-family: Times New Roman; font-size: 13px">               46              </font>             </a>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item9">              <font style="font-family: Times New Roman; font-size: 13px">               Item9.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 60px; margin-right: 0px; text-indent: -60px">             <a href="#item9">              <font style="font-family: Times New Roman; font-size: 13px">               Changes in andDisagreements with Accountants on Accounting and FinancialDisclosure              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item9">              <font style="font-family: Times New Roman; font-size: 13px">               72              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item9a">              <font style="font-family: Times New Roman; font-size: 13px">               Item9A.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item9a">              <font style="font-family: Times New Roman; font-size: 13px">               Controls andProcedures              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item9a">              <font style="font-family: Times New Roman; font-size: 13px">               72              </font>             </a>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item9b">              <font style="font-family: Times New Roman; font-size: 13px">               Item9B.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item9b">              <font style="font-family: Times New Roman; font-size: 13px">               OtherInformation              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item9b">              <font style="font-family: Times New Roman; font-size: 13px">               72              </font>             </a>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align: top; width: 100%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              PARTIII             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item10">              <font style="font-family: Times New Roman; font-size: 13px">               Item10.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item10">              <font style="font-family: Times New Roman; font-size: 13px">               Directors,Executive Officers and Corporate Governance              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item10">              <font style="font-family: Times New Roman; font-size: 13px">               73              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item11">              <font style="font-family: Times New Roman; font-size: 13px">               Item11.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item11">              <font style="font-family: Times New Roman; font-size: 13px">               ExecutiveCompensation              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item11">              <font style="font-family: Times New Roman; font-size: 13px">               78              </font>             </a>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 60px; margin-right: 0px; text-indent: -60px">             <a href="#item12">              <font style="font-family: Times New Roman; font-size: 13px">               Item12.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 60px; margin-right: 0px; text-indent: -60px">             <a href="#item12">              <font style="font-family: Times New Roman; font-size: 13px">               Security Ownershipof Certain Beneficial Owners and Management and Related StockholderMatters              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item12">              <font style="font-family: Times New Roman; font-size: 13px">               88              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item13">              <font style="font-family: Times New Roman; font-size: 13px">               Item13.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item13">              <font style="font-family: Times New Roman; font-size: 13px">               CertainRelationships and Related Transactions, and DirectorIndependence              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item13">              <font style="font-family: Times New Roman; font-size: 13px">               90               <br/>              </font>             </a>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item14">              <font style="font-family: Times New Roman; font-size: 13px">               Item14.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item14">              <font style="font-family: Times New Roman; font-size: 13px">               PrincipalAccounting Fees and Services              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item14">              <font style="font-family: Times New Roman; font-size: 13px">               90               <br/>              </font>             </a>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align: top; width: 100%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              PARTIV             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item15">              <font style="font-family: Times New Roman; font-size: 13px">               Item15.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item15">              <font style="font-family: Times New Roman; font-size: 13px">               Exhibits, FinancialStatement Schedules              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item15">              <font style="font-family: Times New Roman; font-size: 13px">               92              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item16">              <font style="font-family: Times New Roman; font-size: 13px">               Item16.              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 70%">            <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item16">              <font style="font-family: Times New Roman; font-size: 13px">               Form 10-KSummary              </font>             </a>            </div>           </td>           <td style="vertical-align: bottom; width: 16%">            <div style="text-align: right; margin-left: 48px; margin-right: 0px; text-indent: -48px">             <a href="#item16">              <font style="font-family: Times New Roman; font-size: 13px">               95              </font>             </a>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #3B608D; font-family: Times New Roman; font-size: 16px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 16px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #3B608D; font-family: Times New Roman; font-size: 16px">         Special Note Regarding Forward-Looking Statements        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In thisAnnual Report on Form 10-K (this “Annual Report”)references to “we,” “our,”“us,” the “Company” or“Palatin” means Palatin Technologies, Inc. and itssubsidiary.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Statementsin this Annual Report, as well as oral statements that may be madeby us or by our officers, directors, or employees acting on ourbehalf, that are not historical facts constitute“forward-looking statements,” which are made pursuantto the safe harbor provisions of Section 21E of the SecuritiesExchange Act of 1934 (the “Exchange Act”). Theforward-looking statements in this Annual Report do not constituteguarantees of future performance. Investors are cautioned thatstatements that are not strictly historical facts contained in thisAnnual Report, including, without limitation, the following areforward looking statements:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our business,financial condition, and results of operations may be adverselyaffected by global health epidemics, including the novel strain ofcoronavirus (“COVID-19”) pandemic, such as, forexample, increase in costs of and delays in conducting humanclinical trials and the performance of our contractors andsuppliers, and reduction in our productivity or the productivity ofour contractors and suppliers;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability tosuccessfully commercialize Vyleesi® (the trade name forbremelanotide) for the treatment of premenopausal women withhypoactive sexual desire disorder (“HSDD”) in theUnited States, which may be adversely affected by delays ordisruptions related to the ongoing COVID-19 pandemic;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability tomanage the infrastructure to successfully manufacture, throughcontract manufacturers, Vyleesi, and to successfully market anddistribute Vyleesi in the United States;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability to meetpostmarketing commitments of the U.S. Food and Drug Administration(“FDA”);          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our expectationsregarding the potential market size and market acceptance forVyleesi for HSDD in the United States and elsewhere in theworld;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our expectationsregarding performance of our exclusive licensees of Vyleesi for thetreatment of premenopausal women with HSDD, which is a type offemale sexual dysfunction (“FSD”),including:          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 39px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           o          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Shanghai FosunPharmaceutical Industrial Development Co. Ltd.(“Fosun”), a subsidiary of Shanghai FosunPharmaceutical (Group) Co., Ltd., for the territories of thePeople’s Republic of China, Taiwan, Hong Kong S.A.R. andMacau S.A.R. (collectively, “China”), and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 39px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           o          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           KwangdongPharmaceutical Co., Ltd. (“Kwangdong”) for the Republicof Korea (“Korea”);          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our expectationsand the ability of our licensees to timely obtain approvals andsuccessfully commercialize Vyleesi in countries other than theUnited States;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the results ofclinical trials with our late stage products, including PL9643, anophthalmic peptide solution for dry eye disease(“DED”), which is scheduled to enter Phase 3 clinicaltrials in the fourth quarter of calendar year 2021, and PL8177, anoral peptide formulation for treatment of ulcerative colitis, whichis also scheduled to enter Phase 2 clinical trials in the firsthalf of calendar year 2022;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           estimates of ourexpenses, future revenue and capital requirements;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toachieve profitability;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toobtain additional financing on terms acceptable to us, or at all,including unavailability of funds or delays in receiving funds as aresult of the ongoing COVID-19 pandemic;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toadvance product candidates into, and successfully complete,clinical trials;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the initiation,timing, progress and results of future preclinical studies andclinical trials, and our research and developmentprograms;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the timing orlikelihood of regulatory filings and approvals;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our expectationsregarding the clinical efficacy and utility of our melanocortinagonist product candidates for treatment of inflammatory andautoimmune related diseases and disorders, including ocularindications;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability tocompete with other products and technologies treating the same orsimilar indications as our product candidates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the ability of ourthird-party collaborators to timely carry out their duties undertheir agreements with us;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the ability of ourcontract manufacturers to perform their manufacturing activitiesfor us in compliance with applicable regulations;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability torecognize the potential value of our licensing arrangements withthird parties;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the potential toachieve revenues from the sale of our productcandidates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toobtain adequate reimbursement from private insurers and otherhealthcare payers;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability tomaintain product liability insurance at a reasonable cost or insufficient amounts, if at all;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the performance ofour management team, senior staff professionals, and third-partycontractors and consultants;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the retention ofkey management, employees and third-party contractors;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the scope ofprotection we are able to establish and maintain for intellectualproperty rights covering our product candidates and technology inthe United States and throughout the world;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our compliance withfederal and state laws and regulations;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the timing andcosts associated with obtaining regulatory approval for our productcandidates, including delays and additional costs related to theongoing COVID-19 pandemic;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the impact offluctuations in foreign exchange rates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the impact oflegislative or regulatory healthcare reforms in the UnitedStates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toadapt to changes in global economic conditions as well as competingproducts and technologies; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 19px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toremain listed on the NYSE American stock exchange.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Suchforward-looking statements involve risks, uncertainties and otherfactors that could cause our actual results to be materiallydifferent from historical results or from any results expressed orimplied by such forward-looking statements. Our future operatingresults are subject to risks and uncertainties and are dependentupon many factors, including, without limitation, the risksidentified under the caption “Risk Factors” andelsewhere in this Annual Report, and any of those made in our otherreports filed with the U.S. Securities and Exchange Commission (the“SEC”). Except as required by law, we do not intend,and undertake no obligation, to publicly update forward-lookingstatements to reflect events or circumstances after the date ofthis document or to reflect the occurrence of unanticipatedevents.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #3B608D; font-family: Times New Roman; font-size: 16px">         Trademarks and Trade Names        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         PalatinTechnologies® and Vyleesi® are registered trademarks ofPalatin Technologies, Inc., and Palatin™ and the Palatin logoare trademarks of Palatin Technologies, Inc. Other trademarksreferred to in this report are the property of their respectiveowners.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #3B608D; font-family: Times New Roman; font-size: 16px">         Risk Factors Summary        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing is a summary of the principal risks that could adverselyaffect our business, financial condition, operating results, cashflows or stock price. Discussion of the risks listed below, andother risks that we face, are discussed in the section titled“Risk Factors” in Part I, Item 1A of this Annual Reporton Form 10-K.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Risks Related to Our Financial Results and Need forFinancing        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-weight: bold; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           We have a historyof substantial net losses, including a net loss of $33.6 millionfor the year ended June 30, 2021, and expect to incur substantialnet losses over the next few years, and we may never achieve ormaintain profitability.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           We will needadditional funding, including funding to complete clinical trialsfor our product candidates, which additional funding may not beavailable on acceptable terms, if at all.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           We have a limitedoperating history upon which to base an investmentdecision.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           We have limitedauthorized shares available to raise additional capital throughpublic or private equity offerings, which limits our ability toraise additional capital.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Raising additionalcapital may cause dilution to existing shareholders, restrict ouroperations or require us to relinquish rights.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Risks Related to Our Business, Strategy, and Industry        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           The commercialsuccess of Vyleesi for HSDD is a component of our corporatestrategy, but we and our licensees may never successfullycommercialize Vyleesi for HSDD or obtain approvals in countriesother than the United States.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Production andsupply of Vyleesi and our product supplies depend on contractmanufacturers over whom we do not have any control, and there maynot be adequate supplies of Vyleesi.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           The effect ofCOVID-19 and other possible pandemics and outbreaks could result inmaterial adverse effects on our clinical trials, business,financial condition, and results of operations.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Our productcandidates other than Vyleesi, including PL9643 for dry eye diseaseand PL8177 for the treatment of ulcerative colitis, are still inthe early stages of development and remain subject to clinicaltesting and regulatory approval. If we are unable to successfullydevelop and test our product candidates, we will not besuccessful.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           If clinical trialsfor our product candidates are prolonged or delayed, we may beunable to commercialize our product candidates on a timely basis,which would require us to incur additional costs and delay ourreceipt of any revenue from potential product sales.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Even if our productcandidates receive regulatory approval in the United States, theymay never achieve market acceptance in the United States orapproval outside the United States, in which case our business,financial condition and results of operation will be materiallyadversely affected.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           If side effectsemerge that can be linked to Vyleesi or any of our productcandidates (either while they are in development or after they areapproved and on the market), we may be required to perform lengthyadditional clinical trials, change the labeling of any suchproducts, or withdraw such products from the market, any of whichwould hinder or preclude our ability to generaterevenues.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Risks Related to Government Regulation        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Both before andafter marketing approval, our product candidates are subject toongoing regulatory requirements and, if we fail to comply withthese continuing requirements, we could be subject to a variety ofsanctions and the sale of any approved commercial products could besuspended.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           The FDA hasrequired that two postmarketing studies and a clinical trial beconducted on Vyleesi, and our failure to timely complete studies orthe clinical trial, and any adverse outcomes of the studies ortrial, could result in withdrawal of Vyleesi from themarket.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Risks Related to the Ownership of Our Common Stock        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Our stock price isvolatile and may fluctuate in a way that is disproportionate to ouroperating performance and we expect it to remain volatile, whichcould limit investors’ ability to sell stock at aprofit.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Because we do notanticipate paying any cash dividends on our common stock in theforeseeable future, capital appreciation, if any, will be your solesource of gains.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           As of September 24,2021 there were 39,896,902 shares of common stock underlyingoutstanding convertible preferred stock, options, restricted stockunits and warrants. Stockholders may experience dilution from theconversion of preferred stock, exercise of outstanding options andwarrants and vesting and delivery of restricted stockunits.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         PART I        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 1.         <a name="item1">          B         </a>         usiness.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Our Business Overview        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Palatin™is a biopharmaceutical company developing first-in-class medicinesbased on molecules that modulate the activity of the melanocortinand natriuretic peptide receptor systems. Our product candidatesare targeted, receptor-specific therapeutics for the treatment ofdiseases with significant unmet medical need and commercialpotential. Palatin’s strategy is to develop products and thenform marketing collaborations with industry leaders to maximizeproduct commercial potential.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Melanocortin Receptor System.         </font>         The melanocortin receptor(“MCr”) system has effects on inflammation and immunesystem response, food intake, metabolism, and sexual function.There are five melanocortin receptors, MC1r through MC5r.Modulation of these receptors, through use of receptor-specificagonists, which activate receptor function, or receptor-specificantagonists, which block receptor function, can have significantpharmacological effects.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Our newproduct development activities in inflammation disease indicationsfocus primarily on development of MCr peptides for ocularconditions, but also include conditions in the gut and kidney.Utilizing peptides which are agonists at MC1r, and in someinstances agonists at additional melanocortin receptors, we aredeveloping products to treat inflammatory and autoimmune diseasessuch as dry eye disease, which is also known askeratoconjunctivitis sicca, uveitis, diabetic retinopathy, andinflammatory bowel disease. We believe that our MC1r agonistpeptides have broad anti-inflammatory effects and utilizemechanisms engaged by the endogenous melanocortin system inregulation of the immune system and resolution of inflammatoryresponses. We are also developing peptides that are active at morethan one melanocortin receptor and small molecule MCragonists.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OurU.S. Food and Drug Administration (“FDA”) approvedmelanocortin receptor agonist, Vyleesi® (bremelanotideinjection), is an “as needed” therapy used inanticipation of sexual activity and self-administered in the thighor abdomen via a single-use subcutaneous auto-injector bypremenopausal women with hypoactive sexual desire disorder(“HSDD”). Vyleesi is the first FDA-approvedmelanocortin agent and the first and only FDA-approved as-neededtreatment for premenopausal women with HSDD.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Natriuretic Peptide Receptor System         </font>         . The natriuretic peptidereceptor (“NPR”) system regulates cardiovascularfunctions, and therapeutic agents modulating this system havepotential to treat fibrotic diseases, cardiovascular diseases,including reducing cardiac hypertrophy and fibrosis, heart failure,acute asthma, pulmonary diseases, and hypertension. We havedesigned and are developing potential NPR candidate drugs selectivefor one or more of the natriuretic peptide receptors, includingnatriuretic peptide receptor-A (“NPR-A”), natriureticpeptide receptor B (“NPR-B”), and natriuretic peptidereceptor C (“NPR-C”).        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Our Business Strategy.         </font>         Key elements of our business strategyinclude:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Maximizing revenuefrom Vyleesi by marketing Vyleesi in the United States, supportingour existing licensees for China and South Korea, and licensingVyleesi for the United States and additional regions;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Maintaining a teamto create, develop and commercialize MCr and NPR productsaddressing unmet medical needs;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Entering intostrategic alliances and partnerships with pharmaceutical companiesto facilitate the development, manufacture, marketing, sale, anddistribution of product candidates that we aredeveloping;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Partially fundingour product development programs with the cash flow generated fromVyleesi and existing license agreements, as well as any futureresearch, collaboration, or license agreements; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Completingdevelopment and seeking regulatory approval of certain of our otherproduct candidates.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Pipeline Overview        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing chart illustrates the status of our drug developmentprograms and Vyleesi, which has been approved by the FDA for thetreatment of premenopausal women with acquired, generalizedHSDD.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           1          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <img src="chart.jpg"/>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           2          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">         <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">          Melanocortin Receptor Programs         </font>         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Our Current Product Development Strategy.         </font>         We are designingand developing potent and highly selective MC1r agonist peptidesand agonist peptides specific for more than one melanocortinreceptor for treatment of a variety of inflammatory and autoimmuneindications. We believe that our agonist peptides suppress certaininflammatory cytokines, and modulate the activities of immunecells, such as monocytes and T cells, to reduce immune response,and may utilize mechanisms engaged by the endogenous melanocortinsystem in regulation of the immune system and resolution ofinflammatory responses.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We haveconducted preclinical animal studies with MC1r and multiple MCrpeptide drug candidates for selected inflammatory disease andautoimmune indications. MC1r plays a role in many diseases,including inflammatory bowel disease and ocular indications such asuveitis, diabetic retinopathy, and dry eye disease. Work withrodent animal models have demonstrated therapeutic responses thatare statistically significant compared to placebo, and that areequal to or superior to established positive controls in animalmodels. However, success in animal models does not necessarily meanthat any of our drug candidates will be able to successfully treatdiseases in human patients.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          PL9643 for Dry Eye Disease and Anti-Inflammatory OcularIndications.         </font>         PL9643, a peptide melanocortin agonist activeat multiple MCrs, including MC1r and MC5r, is our lead clinicaldevelopment candidate for anti-inflammatory ocular indications,including dry eye disease, which is also known askeratoconjunctivitis sicca. Dry eye disease is a syndrome withsymptoms including irritation, redness, discharge and blurredvision. It may result from an autoimmune disease suchSjögren’s syndrome, an ocular lipid or mucin deficiency,blink disorders, abnormal corneal sensitivity, or environmentalfactors. It is estimated to affect over 30 million people in theUnited States.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          We havedeveloped a PL9643 ophthalmic solution (topical eye drops) in asingle use delivery device, and a Phase 3 clinical trial designedto support a New Drug Application (“NDA”) will start inthe fourth quarter of calendar year 2021. Our Phase 2 clinicaltrial demonstrated improvements in both the signs and symptoms ofdry eye disease in moderate to severe patients after just two weeksof treatment, with no adverse safety signals and excellenttolerability. We held an end-of-Phase 2 meeting with the FDA inJune 2021, which included all aspects of the PL9643 developmentplan, including study design, endpoints, interim assessment, andpatient population for the Phase 3 program. Preliminary datareadout from the Phase 3 clinical trial is expected in the secondhalf of calendar year 2022. If results of the initial Phase 3clinical trial are positive, we will initiate a second Phase 3clinical trial, with an NDA submitted to the FDA as early as thesecond half of calendar year 2023.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="font-style: italic">           Oral PL8177 for Inflammatory Bowel Diseases.          </font>          PL8177, aselective MC1r agonist peptide, is our lead clinical developmentcandidate for inflammatory bowel diseases, including ulcerativecolitis. We have completed subcutaneous dosing of human subjects ina Phase 1 single and multiple ascending dose clinical safety study,and a human microdose pharmacokinetic study to evaluate apolymer-enabled, delayed-release, oral formulation ofPL8177.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          Forulcerative colitis and other inflammatory bowel diseases we willadminister PL8177 in our oral formulation to deliver PL8177 to theinterior wall of the diseased bowel. PL8177 activates MC1r presenton the interior wall of the bowel in ulcerative colitis and otherinflammatory bowel diseases. We believe that delivering PL8177directly to MC1r in the bowel wall will maximize treatment effectwhile minimizing any systemic or off-target effects.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          A Phase2 study in ulcerative colitis using our polymer-enabled,delayed-release, oral formulation of PL8177 is scheduled to startin the first half of calendar year 2022, and may take up to oneyear to complete.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="font-style: italic">           Melanocortin Peptides for Diabetic Retinopathy.          </font>          We conductedpreclinical studies with melanocortin peptides in diabeticretinopathy models and have selected a peptide candidate forfurther development work. We are working on a formulation foradministration. If results support advancing the program, we willconduct required safety studies and manufacture drug product underGood Manufacturing Practices (“GMP”) regulationspreparatory to filing an IND and initiating clinicalstudies.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="font-style: italic">           Ocular Research Programs.          </font>          We are conducting research inseveral additional ocular areas, including both front of the eyeand back of the eye indications, exploring use of our compounds totreat additional indications.         </font>        </div>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           3          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="font-style: italic">           Vyleesi for HSDD.          </font>          Vyleesi, the registered trademark forbremelanotide injection, was approved by the FDA on June 21, 2019for the treatment of premenopausal women with acquired, generalizedHSDD. AMAG Pharmaceuticals, Inc. (“AMAG”), which hadexclusively licensed Vyleesi for North America, initiated sales andmarketing efforts for Vyleesi in the United States in August 2019,with a national launch in September 2019. In July 2020, Palatin andAMAG entered into a termination agreement, pursuant to which thelicense agreement was terminated, Palatin regained all NorthAmerica rights for Vyleesi, and AMAG made a $12.0 million paymentto Palatin at closing and a $4.3 million payment to Palatin in thefirst quarter of calendar 2021. Palatin assumed Vyleesimanufacturing agreements, and AMAG transferred information, dataand assets related exclusively to Vyleesi, including existinginventory. AMAG provided certain transition services to Palatin fora period to ensure continued patient access to Vyleesi during thetransition period, for which Palatin reimbursed AMAG for the agreedupon costs of the transition services.         </font>        </div>        <font style="font-family: Times New Roman; font-size: 13px;">         <br/>        </font>       </div>       <div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          Vyleesifaces competition primarily from Addyi® (flibanserin), whichwas introduced into the market in October 2015 for the treatment ofHSDD in pre-menopausal women and is marketed by SproutPharmaceuticals, Inc. We are not aware of any company activelydeveloping another melanocortin receptor agonist drug for thetreatment of HSDD. However, we are aware of several other drugs atvarious stages of development, most of which are being developedfor the treatment of HSDD that are to be taken on a chronic,typically once-daily, basis. There may be other companiesdeveloping new drugs for FSD indications other than HSDD, which maycompete with Vyleesi, some of which may be in clinical trials inthe U.S. or elsewhere. Vyleesi may also face competition withproducts prescribed “off-label” by healthcareproviders.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          Vyleesiis distributed nationally through specialty pharmacies. Ourmarketing strategy focuses on efforts to establish Vyleesi as thepreferred option for women and healthcare providers seeking atreatment for HSDD, which we implement through media such asdirect-to-consumer marketing in search and social media channels.We also focus our Vyleesi marketing efforts towards healthcareprofessionals, who play a significant role in increasing HSDD andVyleesi awareness among their patients. As the commercial potentialof Vyleesi is demonstrated, Palatin will explore licensingmarketing and distribution rights for the United States to amarketing partner.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          Inearly September 2017, we entered into a license agreement withFosun for exclusive rights to commercialize Vyleesi in China. Wereceived an upfront payment of $5.0 million, less required taxwithholding, and when regulatory approval for a Vyleesi product isobtained in China we will receive a $7.5 million milestone payment.We may receive up to $92.5 million in sales related milestones andwill receive high-single digit to low double-digit royalties on netsales in China. In November 2017, we entered into a licenseagreement with Kwangdong for exclusive rights to commercializeVyleesi in Korea, and received an upfront payment of $0.5 million,less required tax withholding. Upon the first commercial sale ofVyleesi in Korea we will receive a $3.0 million milestone paymentand will receive mid-single digit to low double-digit royalties onall net sales and may receive up to $37.5 million in sales relatedmilestones.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          Weretain worldwide rights for Vyleesi for HSDD and all otherindications outside Korea and China. We are actively seekingpotential partners for marketing and commercialization rights forVyleesi for HSDD outside the licensed territories, includingentering into a license agreement for marketing andcommercialization rights for Vyleesi in the United States. However,we may not be able to enter into suitable agreements with potentialpartners on acceptable terms, if at all.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          Themost common adverse events which may occur with use of Vyleesi arenausea, flushing, injection site reactions, headache, and vomiting.Vyleesi is contraindicated in women with uncontrolled hypertensionor known cardiovascular disease. In addition, the Vyleesi labelincludes precautions that it may cause (i) small, transientincreases in blood pressure with a corresponding decrease in heartrate; (ii) focal hyperpigmentation (darkening of the skin oncertain parts of the body), including the face, gums (gingiva) andbreasts; and (iii) nausea.         </font>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Natriuretic Peptide Receptor Programs        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Natriuretic Peptide Receptor Systems.         </font>         The NPR system hasnumerous cardiovascular functions, and therapeutic agentsmodulating this system may be useful in treatment of cardiovascularand fibrotic diseases. While the therapeutic potential ofmodulating this system is well appreciated, development oftherapeutic agents has been difficult due, in part, to the shortbiological half-life of native peptide agonists. We have madepotential NPR candidate drugs that are selective for one or moredifferent natriuretic peptide receptors, including NPR-A, NPR-B,and NPR-C.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          PL3994 for Mechanism of Action Studies.         </font>         PL3994 is an NPR-Aagonist and synthetic mimetic of the endogenous neuropeptidehormone atrial natriuretic peptide (“ANP”). PL3994activates NPR-A, a receptor known to play a role in cardiovascularhomeostasis. Consistent with being an NPR-A agonist, PL3994increases plasma cyclic guanosine monophosphate(“cGMP”) levels, a pharmacological response consistentwith the effects of endogenous natriuretic peptides oncardiovascular function and smooth muscle relaxation. PL3994 alsodecreases activity of the renin-angiotensin-aldosterone system(“RAAS”), a hormone system that regulates bloodpressure and fluid balance. The RAAS system is frequentlyover-activated in heart failure patients, leading to worsening ofcardiovascular function.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inconjunction with clinicians at a major research institution, wehave entered into a Phase 2A clinical trial with PL3994 supportedby a grant from the American Heart Association. We have conductedPhase 1 safety studies with PL3994, with no serious or severeadverse events. Consistent with the PL3994 mechanism of action,elevations in plasma cGMP levels, increased diuresis and increasednatriuresis were all observed for several hours after singlesubcutaneous doses.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           4          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Becauseof the limited patent term remaining on PL3994, we do not intend topursue PL3994 as a pharmaceutical product but are utilizing it toestablish the mechanism of action and pharmaceutical utility ofsynthetic mimetics of ANP.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          PL5028 for Cardiovascular and Fibrotic Disease.         </font>         PL5028, anNPR-A agonist and NPR-binder we developed, is in preclinicaldevelopment for cardiovascular and fibrotic diseases, includingreducing cardiac hypertrophy and fibrosis. We have ongoing academiccollaborations with several institutions with PL5028.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Technologies We Use        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We useda rational drug design approach to discover and develop proprietarypeptide, peptide mimetic and small molecule agonist compounds,focusing on melanocortin and natriuretic peptide receptor systems.Computer-aided drug design models of receptors are optimized basedon experimental results obtained with peptides and small moleculesthat we develop. With our approach, we believe we are developing anadvanced understanding of the factors which driveagonism.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We havedeveloped a series of proprietary technologies used in our drugdevelopment programs. One technology employs novel amino acidmimetics in place of selected amino acids. These mimetics providethe receptor-binding functions of conventional amino acids whileproviding structural, functional and physiochemical advantages. Theamino acid mimetic technology is employed in PL3994.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Competition        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          General.         </font>         Our products under development will compete on thebasis of quality, performance, cost effectiveness and applicationsuitability with numerous established products and technologies. Wehave many competitors, including pharmaceutical, biopharmaceuticaland biotechnology companies. Furthermore, there are severalwell-established products in our target markets that we will haveto compete against. Other companies may also introduce productsusing new technologies that may be competitive with our proposedproducts. Most of the companies selling or developing competitiveproducts have financial, technological, manufacturing anddistribution resources significantly greater than ours and mayrepresent significant competition for us. In addition, approvedproducts such as Vyleesi may eventually face competition fromgeneric versions that will sell at significantly reduced prices, bepreferred by managed care and health insurance payers, and beeligible for automatic pharmacy substitution even when a prescriberwrites a prescription for our product. The timing and extent offuture generic competition is dependent upon both our intellectualproperty rights and the FDA regulatory process but cannot beaccurately predicted.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thepharmaceutical and biotechnology industries are characterized byextensive research efforts and rapid technological change. Manybiopharmaceutical companies have developed or are working todevelop products similar to ours or that address the same markets.Such companies may succeed in developing technologies and productsthat are more effective or less costly than any of those that wemay develop. Such companies may be more successful than us indeveloping, manufacturing, and marketing products.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Wecannot guarantee that we will be able to compete successfully inthe future or that developments by others will not render ourproposed products under development or any future productcandidates obsolete or noncompetitive or that our collaborators orcustomers will not choose to use competing technologies orproducts.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Vyleesi for Treatment of HSDD.         </font>         There is competition andfinancial incentive to develop, market and sell drugs for thetreatment of HSDD and other forms of FSD. Flibanserin, sold underthe trade name Addyi, is the only drug other than Vyleesi currentlyapproved in the United States for treatment of HSDD. Flibanserin, anon-hormonal oral serotonin 5-HT1A agonist, 5-HT2A antagonist,which requires chronic dosing, was approved by the FDA on August18, 2015 for treatment of premenopausal women with HSDD. The FDAapproval included a risk evaluation and mitigation strategy(“REMS”) because of the increased risk of severehypotension and syncope due to the interaction between flibanserinand alcohol, and a Boxed Warning to highlight the risks of severehypotension and syncope in patients who drink alcohol duringtreatment with flibanserin, in those who also use moderate orstrong CYP3A4 inhibitors, and in those who have liver impairment.The Boxed Warning was modified by FDA in April 2019 to clarify thatthere remains a concern about consuming alcohol close in time totaking flibanserin, but that alcohol does not have to be avoidedcompletely. Specifically, the Boxed Warning reflects women shoulddiscontinue drinking alcohol at least two hours before takingflibanserin at bedtime, or to skip the flibanserin dose thatevening. We are aware of several other drugs at various stages ofdevelopment, most of which are taken on a chronic, typicallyonce-daily, basis. There are other companies reported to bedeveloping new drugs for FSD indications, some of which may be inclinical trials in the United States or elsewhere. We are not awareof any other company actively developing a melanocortin receptoragonist drug for HSDD.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           5          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          PL9643 for Anti-Inflammatory Ocular Indications.         </font>         PL9643 isunder development for dry eye diseases and may also have utilityfor other inflammatory ocular indications. Currently mild tomoderate dry eye disease and other ocular inflammatory diseases maybe treated with artificial tear eye drops, lubricating tearointments, hot compresses or punctual plugs, and more severedisease may be treated with topical immunosuppressants such ascyclosporine ophthalmic emulsions, including Restasis®marketed in the United States by Allergan, Inc., or with drugsinhibiting inflammatory cell binding, such as lifitegrast,including Xiidra® marketed in the United States by Novartis.In addition, there are a number of drugs in clinical developmentfor treatment of dry eye disease, with over 20 agents reported tobe in or have completed Phase 2 development. Products underdevelopment include tumor necrosis factor agonists, alpha-2adrenergic receptor agonist, calcineurin inhibitors, and nicotinicreceptor agonists, among others. There are no reported MC1r agonistdrugs in clinical trials by third parties for dry eye disease. Ifone or more of these competing product candidates is approved andeither treats the signs and symptoms of dry eye disease or reducesthe frequency of flares of dry eye in patients, it could reduce themarket for PL9643 for dry eye disease.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Oral PL8177 for Inflammatory Bowel Diseases/UlcerativeColitis.         </font>         FDA-approved drugs used in treatment of ulcerativecolitis include aminosalicylates such as mesalazine and relateddrugs, immunosuppressive drugs such as cyclosporine andazathioprine, corticosteroids such as prednisone and othersteroids, and various biologic drugs, including tumor necrosisfactor inhibitors such as infliximab and adalimumab. There are anumber of drugs in development for ulcerative colitis, includingJanus kinase inhibitors, monoclonal antibodies specific for one ormore immune system cytokine signaling molecules, and additionalclasses of immunomodulatory drugs. There are no reported MC1ragonist drugs in clinical trials for inflammatory bowel diseases,including ulcerative colitis. If one or more of the competingproducts under development are approved and can effectively treatulcerative colitis with an acceptable side effect profile, suchproducts could reduce the market for oral PL8177 for inflammatorybowel diseases, including ulcerative colitis.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Diabetic Retinopathy.         </font>         FDA-approved drugs used in treatmentof diabetic retinopathy include steroids and anti-vascularendothelial growth factor compounds. At least two differentantibody fragment products are marketed in the United States inwhich either aflibercept or ranibizumab is the activepharmaceutical ingredient. Additional vascular endothelial growthfactor inhibitors are in clinical trials or in preclinicaldevelopment. There are no reported MC1r agonist drugs in clinicaltrials for diabetic retinopathy. If one or more of the competingproduct candidates under development is approved and can treatdiabetic retinopathy with an acceptable side effect profile, itcould reduce the market for MC1r peptide products for thisindication.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Melanocortin Receptor 1 Agonist Drug Products for Inflammatory andAutoimmune Diseases.         </font>         Many inflammatory disease-relatedindications are treated using systemic steroids orimmunosuppressant drugs, all of which have side effects that can bedose limiting. There are a number of approved biological drugs andother biological drugs under development for treatment ofinflammatory disease-related indications, which typically affectonly one pathway in the inflammatory response. Many of these drugsaddress symptoms, but do not resolve the underlying inflammatory orautoimmune disease process.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          PL5028 for Cardiovascular and Fibrotic Indications.         </font>         We areevaluating potential clinical indications for PL5028 and have notdetermined a specific indication for initial studies. There aremany approved drugs and drugs in clinical studies forcardiovascular diseases, including drugs that directly modulate theNPR system, such as nesiritide (sold under the trade nameNatrecor®), a recombinant NPR-B peptide drug, and acombination drug comprised of sacubitril and valsartan (sold underthe trade name Entresto®), which inhibits both the angiotensinII receptor and neprilysin, which is an enzyme that inactivatesendogenous active natriuretic peptides. This combination drugresults in increases of endogenous active natriuretic peptidelevels. In addition, there are a number of approved drugs and drugsin development for treatment of cardiovascular and fibroticdiseases through mechanisms or pathways other than agonism ofNPR-A.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           6          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Patents and Proprietary Information        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Patent Protection.         </font>         Our success will depend in substantialpart on our ability to obtain, defend and enforce patents, maintaintrade secrets and operate without infringing upon the proprietaryrights of others, both in the United States and abroad. We own anumber of issued United States patents and have pending UnitedStates patent applications, many with issued or pending counterpartpatents in selected foreign countries. We seek patent protectionfor our technologies and products in the United States and thoseforeign countries where we believe patent protection iscommercially important.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We ownthree issued United States patents and a pending patent applicationin the United States for methods of treating FSD with Vyleesi, withrelated patents issued or pending in selected countries in Europeand Asia and in Australia and New Zealand. We do not know the fullscope of patent coverage we will obtain, or whether any patentswill issue other than the patents already issued. Issued patentsand pending applications in the United States and elsewhere in theworld have a presumptive term, if a patent is issued, until2033.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We owntwo issued United States patents claiming the Vyleesi drugsubstance. One patent has expired, and the other patent, whichwould have otherwise expired in 2020, has been granted a five-yearextension, the maximum period as compensation for patent term lostduring drug development and the FDA regulatory review process,pursuant to the Drug Price Competition and Patent Term RestorationAct of 1984, or the Hatch-Waxman Amendments. This patent nowexpires on June 28, 2025. In addition, the claims of theoutstanding patent covering Vyleesi may not provide meaningfulprotection. Further, third parties may challenge the validity orscope of any issued patent, and under the Hatch-Waxman Amendments,potentially receive approval of a competing generic version of ourproduct or products even before a court rules on the validity orinfringement of our patents.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We ownpatents on an alternative class of melanocortin receptor-specificpeptides for treatment of sexual dysfunction and other indications,including obesity, consisting of two issued patents in the UnitedStates. The presumptive term of the issued patents is until 2029.We also have patents and pending patent applications for a secondclass of alternative melanocortin receptor-specific peptides fortreatment of sexual dysfunction and other indications, includingobesity, consisting of three issued patents in the United Statesand issued patents in Australia, Canada, China, France, Germany,Ireland, Japan, Israel, Korea, New Zealand, Russia, South Africa,Switzerland and the United Kingdom and pending patent applicationson the same class in Brazil, China, India, and Mexico. Thepresumptive term of the issued patents and pending patentapplications is until 2030. Until one or more product candidatescovered by a claim of one of these patents and patent applicationsare developed for commercialization, which may never occur, wecannot evaluate the duration of any potential patent term extensionunder the Hatch-Waxman Amendments.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We ownfive issued patents in the United States, and issued patents inAustralia, Belgium, Canada, China, France, Germany, Ireland,Israel, Japan, Korea, Mexico, New Zealand, Russia, South Africa,Sweden, Switzerland and the United Kingdom claiming highlyselective MC1r agonist peptides, including for treatment ofinflammation-related diseases and disorders and relatedindications, and pending patent applications in Australia, Brazil,and India. The presumptive term of the issued patents and pendingpatent applications is until 2030. Until one or more productcandidates covered by a claim of one of these patent applicationsare developed for commercialization, which may never occur, wecannot evaluate the duration of any potential patent term extensionunder the Hatch-Waxman Amendments.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We owntwo issued United States patents claiming the PL3994 substance andother natriuretic peptide receptor agonist compounds that we havedeveloped and an issued United States patent claiming a precursormolecule to the PL3994 substance, both of which expire in 2027.Corresponding patents on the PL3994 substance and other natriureticpeptide receptor agonist compounds were issued in a number ofcountries throughout the world, but we will cease maintainingpatents outside the United States. We also own an issued UnitedStates patent claiming use of the PL3994 substance for treatment ofacute asthma and chronic obstructive pulmonary disease, whichexpires in 2031.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We haveadditional issued United States patents on melanocortin receptorspecific peptides and small molecules, and on natriuretic peptidereceptor agonist compounds, but we are not actively developing anyproduct candidate covered by a claim of any of thesepatents.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We havefiled patent applications under the Patent Cooperation Treatyclaiming PL9643 and other peptides in development for ocular andinflammatory disease indications. If a patent is granted, thepatents will have a presumptive term until 2041. Until one or moreproduct candidates covered by a claim of one of these patentapplications are developed for commercialization, which may neveroccur, we cannot evaluate the duration of any potential patent termextension under the Hatch-Waxman Amendments.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In theevent that a third party has also filed a patent applicationrelating to an invention we claimed in a patent application, we maybe required to participate in an interference proceedingadjudicated by the United States Patent and Trademark Office(“USPTO”) to determine priority of invention. Thepossibility of an interference proceeding could result insubstantial uncertainties and cost, even if the eventual outcome isfavorable to us. An adverse outcome could result in the loss ofpatent protection for the subject of the interference, subjectingus to significant liabilities to third parties, the need to obtainlicenses from third parties at undetermined cost, or requiring usto cease using the technology. Additionally, the claims of ourissued patents may be narrowed or invalidated by administrativeproceedings, such as interference or derivation,         <font style="font-style: italic">          inter partes         </font>         review, post grant reviewor reexamination proceedings before the USPTO.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           7          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Future Patent Infringement.         </font>         We do not know for certain thatour commercial activities will not infringe upon patents or patentapplications of third parties, some of which may not even have beenissued. Although we are not aware of any valid United Statespatents which are infringed by Vyleesi or our other productcandidates, we cannot exclude the possibility that such patentsmight exist or arise in the future. We may be unable to avoidinfringement of any such patents and may have to seek a license,defend an infringement action, or challenge the validity of suchpatents in court. Patent litigation is costly and time consuming.If such patents are valid and we do not obtain a license under anysuch patents, or we are found liable for infringement, we may beliable for significant monetary damages, may encounter significantdelays in bringing products to market, or may be precluded fromparticipating in the manufacture, use or sale of products ormethods of treatment covered by such patents.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Proprietary Information.         </font>         We rely on proprietary information,such as trade secrets and know-how, which is not patented. We havetaken steps to protect our unpatented trade secrets and know-how,in part with confidentiality and intellectual property agreementswith our employees, consultants and certain contractors. If ouremployees, scientific consultants, collaborators or licenseesdevelop inventions or processes independently that may beapplicable to our product candidates, disputes may arise about theownership of proprietary rights to those inventions and processes.Such inventions and processes will not necessarily become ourproperty but may remain the property of those persons or theiremployers. Protracted and costly litigation could be necessary toenforce and determine the scope of our proprietaryrights.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Iftrade secrets are breached, our recourse will be solely against theperson who caused the secrecy breach. This might not be an adequateremedy to us because third parties other than the person who causesthe breach will be free to use the information withoutaccountability to us. This is an inherent limitation of the law oftrade secret protection.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         U.S. Governmental Regulation of PharmaceuticalProducts        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         General        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Regulationby governmental authorities in the United States and othercountries will continue to significantly impact our research,product development, manufacturing and marketing of anypharmaceutical products. The nature and the extent to whichregulations apply to us will vary depending on the nature of anysuch products. Our potential pharmaceutical products will requireregulatory approval by governmental agencies prior tocommercialization. The products we are developing are subject tofederal regulation in the United States, principally by the FDAunder the Federal Food, Drug, and Cosmetic Act(“FFDCA”), and by state and local governments, as wellas ministries of health and other authorities in foreigngovernments. Such regulations govern or influence, among otherthings, the research, development, testing, manufacture, safety andefficacy requirements, labeling, storage, recordkeeping, licensing,advertising, promotion, distribution and export of products,manufacturing, and the manufacturing process. In many foreigncountries, such regulations also govern the prices charged forproducts under their respective national social security systemsand availability to consumers.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Alldrugs intended for human use are subject to rigorous regulation bythe FDA in the United States and similar regulatory bodies in othercountries. The steps ordinarily required by the FDA before aninnovative new drug product may be marketed in the United Statesare similar to steps required in most other countries and include,but are not limited to:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           completion ofpreclinical laboratory tests, preclinical animal testing andformulation studies;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           submission to theFDA of an Investigational New Drug application (“IND”),which must be in effect before clinical trials maycommence;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           clinical studies toevaluate safety and efficacy;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           submission to theFDA of an NDA that includes preclinical data, clinical trial dataand manufacturing information;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           payment ofsubstantial user fees for filing the NDA and other recurring userfees;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           FDA review of theNDA;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           satisfactorycompletion of an FDA pre-approval inspection of the manufacturingfacilities; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           FDA approval of theNDA, including approval of all product labeling.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           8          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For newdrug products or for combination products deemed to have a“drug” primary mode of action, primary review of theproduct will be conducted by the appropriate division within theFDA’s Center for Drug Evaluation and Research(“CDER”). For combination products, CDER will consultwith the Center for Devices and Radiological Health to ensure thatthe device components of the product meet all applicable devicerequirements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theresearch, development and approval process requires substantialtime, effort and financial resources, and approvals may not begranted on a timely or commercially viable basis, if atall.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Preclinicaltesting includes laboratory evaluations to characterize theproduct’s composition, impurities, stability, and mechanismof its pharmacologic effect, as well as animal studies to assessthe potential safety and efficacy of each product. Preclinicalsafety tests must be conducted by laboratories that comply with FDAregulations regarding Good Laboratory Practices and the U.S.Department of Agriculture’s Animal Welfare Act. Violations ofthese laws and regulations can, in some cases, lead to invalidationof the tests, requiring such tests to be repeated and delayingapproval of the NDA. The results of the preclinical tests, togetherwith manufacturing information and analytical data, are submittedto the FDA as part of an IND and are reviewed by the FDA before thecommencement of human clinical trials. Unless the FDA objects to anIND by placing the study on clinical hold, the IND will go intoeffect 30 days following its receipt by the FDA. The FDA mayauthorize trials only on specified terms and may suspend ongoingclinical trials at any time on various grounds, including a findingthat patients are being exposed to unacceptable health risks. Ifthe FDA places a study on clinical hold, the sponsor must resolveall of the FDA’s concerns before the study may begin orcontinue. The IND application process may become extremely costlyand substantially delay development of products. Similarrestrictive requirements also apply in other countries.Additionally, positive results of preclinical tests will notnecessarily indicate positive results in clinicaltrials.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Clinicaltrials involve the administration of the investigational product tohumans under the supervision of qualified principal investigators.Our clinical trials must be conducted in accordance with GoodClinical Practice regulations under protocols submitted to the FDAas part of an IND. In addition, each clinical trial is approved andconducted under the auspices of an institutional review board(“IRB”) and requires the patients’ informedconsent. An IRB considers, among other things, ethical factors, thesafety of human subjects, and the possibility of liability of theinstitutions conducting the trial. The IRB at each institution atwhich a clinical trial is being performed may suspend a clinicaltrial at any time for a variety of reasons, including a belief thatthe test subjects are being exposed to an unacceptable health risk.As the sponsor, we can also suspend or terminate a clinical trialat any time.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Clinicaldevelopment is typically conducted in three sequential phases,Phases 1, 2, and 3, involving clinical trials with increasingnumbers of human subjects. These phases may sometimes overlap or becombined. Phase 1 trials are performed in a small number of healthyhuman subjects or subjects with the targeted condition, and involvetesting for safety, dosage tolerance, absorption, distribution,metabolism and excretion. Phase 2 studies, which may involve up tohundreds of subjects, seek to identify possible adverse effects andsafety risks, preliminary information related to the efficacy ofthe product for specific targeted diseases, dosage tolerance, andoptimal dosage. Finally, Phase 3 trials may involve up to thousandsof individuals, often at geographically dispersed clinical trialsites, and are intended to provide the data demonstrating theeffectiveness and safety required for approval. Prior to commencingPhase 3 clinical trials many sponsors elect to meet with FDAofficials to discuss the conduct and design of the proposed trialor trials.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, federal law requires the listing, on a publicly availablewebsite, of detailed information on clinical trials forinvestigational drugs. Some states have similar or supplementalclinical trial reporting laws.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Successin early-stage animal studies and clinical trials does notnecessarily assure success in later-stage clinical trials. Dataobtained from animal studies and clinical activities are not alwaysconclusive and may be subject to alternative interpretations thatcould delay, limit or even prevent regulatoryapproval.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           9          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Alldata obtained from the preclinical studies and clinical trials, inaddition to detailed information on the manufacture and compositionof the product, would be submitted in an NDA to the FDA for reviewand approval for the manufacture, marketing and commercialshipments of any of our products. FDA approval of the NDA isrequired before commercial marketing or non-investigationalinterstate shipment may begin in the United States. The FDA mayalso conduct an audit of the clinical trial data used to supportthe NDA.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The FDAmay deny or delay approval of an NDA that does not meet applicableregulatory criteria. For example, the FDA may determine that thepreclinical or clinical data or the manufacturing information doesnot adequately establish the safety and efficacy of the drug. TheFDA has substantial discretion in the approval process and maydisagree with an applicant’s interpretation of the datasubmitted in its NDA. The FDA can request additional information,seek clarification regarding information already provided in thesubmission or ask that new additional clinical trials be conducted,all of which can delay approval. Similar types of regulatoryprocesses will be encountered as efforts are made to market anydrug internationally. We will be required to assure productperformance and manufacturing processes from one country toanother.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Even ifthe FDA approves a product, it may limit the approved uses for theproduct as described in the product labeling, require thatcontraindications, warning statements or precautions be included inthe product labeling, require that additional studies be conductedfollowing approval as a condition of the approval, imposerestrictions and conditions on product distribution, prescribing ordispensing in the form of a REMS, or otherwise limit the scope ofany approval or limit labeling. Once it approves an NDA, the FDAmay revoke or suspend the product approval if compliance withpostmarketing regulatory commitments is not maintained or ifproblems occur after the product reaches the marketplace. Inaddition, the FDA may require postmarketing studies to monitor theeffect of approved products and may limit further marketing of theproduct based on the results of these postmarketing studies. TheFDA and other government agencies have broad postmarket regulatoryand enforcement powers, including the ability to levy civil andcriminal penalties, suspend or delay issuance of approvals, seizeor recall products and revoke approvals.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Pharmaceuticalmanufacturers, distributors and their subcontractors are requiredto register their facilities with the FDA and state agencies.Manufacturers are required to list their marketed drugs with theFDA, are subject to periodic inspection by the FDA’s currentGMP regulations, and the product specifications set forth in theapproved NDA. The GMP requirements for pharmaceutical products areextensive and compliance with them requires considerable time,resources and ongoing investment. The regulations requiremanufacturers and suppliers of raw materials and components toestablish validated systems and to employ and train qualifiedemployees to ensure that products meet high standards of safety,efficacy, stability, sterility (where applicable), purity, andpotency. The requirements apply to all stages of the manufacturingprocess, including the synthesis, processing, sterilization,packaging, labeling, storage and shipment of the drug product. Forall drug products, the regulations require investigation andcorrection of any deviations from GMP requirements and imposedocumentation requirements upon us and any third-partymanufacturers that we may decide to use. Manufacturingestablishments are subject to mandatory user fees, and to periodicunannounced inspections by the FDA and state agencies forcompliance with all GMP requirements. The FDA is authorized toinspect manufacturing facilities without a warrant at reasonabletimes and in a reasonable manner.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We orour present or future suppliers may not be able to comply with GMPand other FDA regulatory requirements. Failure to comply with thestatutory and regulatory requirements subjects the manufacturerand/or the NDA sponsor or distributor to possible legal orregulatory action, such as a delay or refusal to approve an NDA,suspension of manufacturing, seizure or recall of a product, orcivil or criminal prosecution of the company or individual officersor employees.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Postmarketing Regulation        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Vyleesiand any other drug products manufactured or distributed by uspursuant to FDA approvals, as well as the materials and componentsused in our products, are subject to pervasive and continuingregulation by the FDA, including:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           recordkeepingrequirements;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           periodic reportingrequirements;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           GMP requirementsrelated to all stages of manufacturing, testing, storage,packaging, labeling and distribution of finished dosage forms ofthe product;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           monitoring andreporting of adverse experiences with the product; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           advertising andpromotional reporting requirements and restrictions.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           10          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Adverseexperiences with the product must be reported to the FDA and couldresult in the imposition of market restriction through labelingchanges or product removal. Product approvals may be revoked ifcompliance with regulatory requirements is not maintained or ifproblems concerning safety or effectiveness of the product occurfollowing approval. The FDA is developing a national electronicdrug safety tracking system known as SENTINEL that may imposeadditional safety monitoring burdens, and enhanced FDA enforcementauthority, beyond the extensive requirements already in effect. Asa condition of NDA approval, the FDA may require post-approvaltesting and surveillance to monitor a product’s safety orefficacy. The FDA also may impose other conditions, includinglabeling restrictions which can materially impact the potentialmarket and profitability of a product.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Withrespect to post-market product advertising and promotion, the FDAand other government agencies including the Department of Healthand Human Services and the Department of Justice, and individualStates, impose a number of complex regulations on entities thatadvertise and promote pharmaceuticals, including, among others,standards and restrictions on direct-to-consumer advertising,off-label promotion, industry-sponsored scientific and educationalactivities and promotional activities involving the Internet. TheFDA has very broad enforcement authority under the FFDCA, andfailure to abide by these regulations can result in administrativeand judicial enforcement actions, including the issuance of aWarning Letter directing correction of deviations from FDAstandards, a requirement that future advertising and promotionalmaterials be pre-cleared by the FDA, False Claims Act prosecutionbased on alleged off-label marketing seeking monetary and otherpenalties, including potential exclusion of the drug and/or thecompany from participation in government health care programs, andstate and federal civil and criminal investigations andprosecutions. Foreign regulatory bodies also strictly enforce theseand other regulatory requirements and drug marketing may beprohibited in whole or in part in other countries.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We, ourcollaborators, licensees or third-party contract manufacturers maynot be able to comply with the applicable regulations. Afterregulatory approvals are obtained, the subsequent discovery ofpreviously unknown problems, or the failure to maintain compliancewith existing or new regulatory requirements, may resultin:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           restrictions on themarketing or manufacturing of a product;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Warning Letters orUntitled Letters from the FDA asking us, our collaborators orthird-party contractors to take or refrain from taking certainactions;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           withdrawal of theproduct from the market;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the FDA’srefusal to approve pending applications or supplements to approvedapplications;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           voluntary ormandatory product recall;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           fines ordisgorgement of profits or revenue;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           suspension orwithdrawal of regulatory approvals;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           refusals to permitthe import or export of products;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           product seizure;and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           injunctions or theimposition of civil or criminal penalties.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We mayalso be subject to healthcare laws, regulations and enforcement andour failure to comply with any such laws, regulations orenforcement could adversely affect our business, operations andfinancial condition. Certain federal and state healthcare laws andregulations pertaining to fraud and abuse and patients’rights are and will be applicable to our business. We are subjectto regulation by both the federal government and the states inwhich we or our partners conduct our business. The laws andregulations that may affect our ability to operateinclude:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the federalAnti-Kickback Statute, which prohibits, among other things, anyperson or entity from knowingly and willfully offering, soliciting,receiving or providing any remuneration (including any kickback,bribe or rebate), directly or indirectly, overtly or covertly, incash or in kind, to induce either the referral of an individual orin return for the purchase, lease, or order of any good, facilityitem or service, for which payment may be made, in whole or inpart, under federal healthcare programs such as the Medicare andMedicaid programs;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           11          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           federal civil andcriminal false claims laws and civil monetary penalty laws,including, for example, the federal civil False Claims Act, whichimpose criminal and civil penalties, including civil whistlebloweror qui tam actions, against individuals or entities for, amongother things, knowingly presenting, or causing to be presented, tothe federal government, including the Medicare and Medicaidprograms, claims for payment that are false or fraudulent or makinga false statement to avoid, decrease or conceal an obligation topay money to the federal government;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the federal HealthInsurance Portability and Accountability Act of 1996(“HIPAA”), which created new federal criminal statutesthat prohibit knowingly and willfully executing, or attempting toexecute, a scheme to defraud any healthcare benefit program orobtain, by means of false or fraudulent pretenses, representationsor promises, any of the money or property owned by, or under thecustody or control of, any healthcare benefit program, regardlessof the payer (e.g., public or private), knowingly and willfullyembezzling or stealing from a health care benefit program,willfully obstructing a criminal investigation of a health careoffense and knowingly and willfully falsifying, concealing orcovering up by any trick or device a material fact or making anymaterially false statements in connection with the delivery of, orpayment for, healthcare benefits, items or services relating tohealthcare matters;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           HIPAA, as amendedby the Health Information Technology for Economic and ClinicalHealth Act, and their implementing regulations, which imposeobligations on covered entities, including healthcare providers,health plans, and healthcare clearinghouses, as well as theirrespective business associates that create, receive, maintain ortransmit individually identifiable health information for or onbehalf of a covered entity, with respect to safeguarding theprivacy, security and transmission of individually identifiablehealth information;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the federalphysician sunshine requirements under the Patient Protection andAffordable Care Act (“Affordable Care Act”), whichrequire manufacturers of drugs, devices, biologics and medicalsupplies to report annually to the Centers for Medicare &amp;Medicaid Services information related to payments and othertransfers of value provided to physicians and teaching hospitals,and ownership and investment interests held by physicians and theirimmediate family members; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           state lawequivalents of each of the above federal laws, such asanti-kickback and false claims laws, which may apply to items orservices reimbursed by any third-party payer, including commercialinsurers; state laws that require pharmaceutical companies tocomply with the pharmaceutical industry’s voluntarycompliance guidelines and the applicable compliance guidancepromulgated by the federal government, or otherwise restrictpayments that may be provided to healthcare providers and otherpotential referral sources; state laws that require drugmanufacturers to report information related to payments and othertransfers of value to healthcare providers or marketingexpenditures; and state laws governing the privacy and security ofhealth information in certain circumstances, many of which differfrom each other in significant ways and may not have the sameeffect, thus complicating compliance efforts.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Becauseof the breadth of these laws and the narrowness of the statutoryexceptions and safe harbors available, it is possible that some ofour business activities could be subject to challenge under one ormore of such laws. In addition, recent health care reformlegislation has strengthened these laws. For example, theAffordable Care Act, among other things, amended the intentrequirement of the federal Anti-Kickback Statute and certaincriminal healthcare fraud statutes. A person or entity no longerneeds to have actual knowledge of the statute or specific intent toviolate it. In addition, the Affordable Care Act provided that thegovernment may assert that a claim including items or servicesresulting from a violation of the federal Anti-Kickback Statuteconstitutes a false or fraudulent claim for purposes of the federalcivil False Claims Act.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Achievingand sustaining compliance with these laws may prove costly. Inaddition, any action against us for violation of these laws, evenif we successfully defend against it, could cause us to incursignificant legal expenses and divert our management’sattention from the operation of our business. If our operations arefound to be in violation of any of the laws described above or anyother governmental laws or regulations that apply to us, we may besubject to penalties, including administrative, civil and criminalpenalties, damages, fines, disgorgement, the exclusion fromparticipation in federal and state healthcare programs, individualimprisonment or the curtailment or restructuring of our operations,any of which could adversely affect our ability to operate ourbusiness and our financial results.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           12          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Generic Competition        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Orange Book Listing.         </font>         In seeking approval for a drug throughan NDA, applicants are required to list with the FDA each patentwhose claims cover the applicant’s product. Upon approval ofa drug, the applicant identifies all patents that claim theapproved product’s active ingredient(s), the drugproduct’s approved formulation, or an approved method of useof the drug. Each of the identified patents are then published inthe FDA’s Approved Drug Products with Therapeutic EquivalenceEvaluations, commonly known as the Orange Book. Drugs listed in theOrange Book can, in turn, be cited by potential generic competitorsin support of approval of an abbreviated new drug application(“ANDA”). An ANDA provides for marketing of a drugproduct that has the same active ingredients in the same strengthsand dosage form as the listed drug and has been shown throughbioequivalence testing, unless such testing is waived by the FDA,as is the case with some injectable drug products, to betherapeutically equivalent to the listed drug. Other thanbioequivalence testing, ANDA applicants are not required toconduct, or submit results of, preclinical or clinical tests toprove the safety or effectiveness of their drug product. Drugsapproved in this way are commonly referred to as “genericequivalents” to the listed drug, and can usually besubstituted by pharmacists under prescriptions written for theoriginal listed drug.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheANDA applicant is required to certify to the FDA concerning anypatents listed for the approved product in the FDA’s OrangeBook. Specifically, the applicant must certify either that: (1) therequired patent information has not been filed (a Paragraph ICertification); (2) the listed patent has expired (a Paragraph IICertification); (3) the listed patent has not expired, but willexpire on a particular date and the generic approval is beingsought only after patent expiration (a Paragraph IIICertification); or (4) the listed patent is invalid, unenforceable,or will not be infringed by the proposed generic product (aParagraph IV Certification). In certain circumstances, the ANDAapplicant may also elect to submit a “section (viii)”statement instead of a Paragraph IV Certification, certifying thatits proposed ANDA label does not contain (or carves out) anylanguage regarding the patented method-of-use rather than certifyto a listed method-of-use patent. If the application contains onlyParagraph I or Paragraph II Certifications, the ANDA may beapproved as soon as FDA completes its review and concludes that allapproval requirements have been met. If the ANDA contains one ormore Paragraph III Certifications, the ANDA cannot not be approveduntil each listed patent for which a Paragraph III Certificationwas filed have expired.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If theANDA applicant has provided a Paragraph IV certification to theFDA, the applicant must also send notice of the Paragraph IVcertification to the NDA holder and patent owner once the ANDA hasbeen accepted for filing by the FDA. The patent owner or NDA holdermay then commence a patent infringement lawsuit in response to thenotice of the Paragraph IV certification. The filing of a patentinfringement lawsuit within 45 days of the receipt of a ParagraphIV certification automatically prevents the FDA from approving theANDA until the earlier of 30 months (the “30-monthstay”), expiration of the patent, settlement of the lawsuitin which the patent owner admits that the patent is invalid or notinfringed by the ANDA product, or a decision in the infringementcase that holds the patent to be invalid or not infringed, or anorder by the court shortening the 30-month stay due to actions bythe patent holder to delay the litigation. In most circumstances,the NDA holder is only eligible for one 30-month stay against anANDA.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If apatent infringement action is filed against an ANDA applicant, anysettlement of the litigation must be submitted to the Federal TradeCommission (“FTC”). If the FTC believes the terms oreffects of the settlement are anticompetitive, the FTC may bring anantitrust enforcement action against the parties. Private partiesmay also bring antitrust lawsuits against drug companies based onsuch patent litigation settlements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheANDA also will not be approved until any applicable non-patentregulatory exclusivity listed in the Orange Book for the referencedproduct has expired.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Regulatory Exclusivity.         </font>         Upon NDA approval of a new chemicalentity (“NCE”), which is a drug that contains no activemoiety that has been approved by the FDA in any other NDA, thatdrug receives five years of marketing exclusivity during which theFDA cannot receive for review any ANDA seeking approval of ageneric version of that drug. An ANDA containing a Paragraph IVCertification may be received by the FDA 4 years after the NCEdrug’s approval, but any 30-month stay that ensues would beextended so that it expires seven and one half years after the NCEapproval date, subject to early termination by reason of a courtdecision or settlement as described above.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           13          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Certainchanges to an NDA drug, such as the addition of a new indication tothe package insert, for which new clinical trials, conducted orsponsored by the applicant are deemed by the FDA to be essential tothe approval of the change, can be eligible for a three-year periodof exclusivity during which the FDA cannot approve an ANDA for ageneric drug that includes the change. An ANDA that contains asection (viii) statement to a method of use patent may be approvedwith labeling that omits the patented use before the use patentexpires. Generic drugs approved with such a labeling carve out maybe substituted by pharmacists for the original branded drug beforethe method of use patent expires.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Section 505(b)(2) NDAs.         </font>         Most drug products obtain FDAmarketing approval pursuant to an NDA or an ANDA. A thirdalternative is a special type of NDA, commonly referred to as a505(b)(2) NDA, which enables the applicant to rely, in part, on theFDA’s previous approval of a similar product, or publishedliterature, in support of its application.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         505(b)(2)NDAs often provide an alternate path to FDA approval for new orimproved formulations or new uses of previously approved products.A 505(b)(2) NDA may be used where at least some of the informationrequired for approval comes from studies not conducted by, or for,the applicant and for which the applicant has not obtained a rightof reference. If the 505(b)(2) applicant can establish thatreliance on the FDA’s previous approval is scientificallyappropriate, it may eliminate the need to conduct certainpreclinical or clinical studies of the new product. The FDA mayalso require companies to perform additional studies ormeasurements to support the change from the approved product. TheFDA may then approve the new product candidate for all, or some, ofthe label indications for which the referenced product has beenapproved, as well as for any new indication or conditions of usesought by the Section 505(b)(2) applicant.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         To theextent that the Section 505(b)(2) applicant is relying on studiesconducted for an already approved product, the applicant isrequired to certify to the FDA concerning any patents listed forthe approved product in the Orange Book to the same extent that anANDA applicant would. As a result, approval of a 505(b)(2) NDA canbe stalled until all the listed patents claiming the referencedproduct have expired, until any non-patent exclusivity, such asexclusivity for obtaining approval of a new chemical entity, listedin the Orange Book for the referenced product has expired, and, inthe case of a Paragraph IV certification and subsequent patentinfringement suit, until the expiration of any 30-month stay,subject to early termination of the stay as describedabove.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Changing Legal and Regulatory Landscape        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Periodically,legislation is introduced in the U.S. Congress that could changethe statutory and regulatory provisions governing the approval,manufacturing and marketing of our drugs. In addition, the FFDCA,FDA regulations and guidance are often revised or reinterpreted bythe FDA or the courts in ways that may significantly affect ourbusiness and products. We cannot predict whether or whenlegislation or court decisions impacting our business will beenacted or issued, what FDA regulations, guidance orinterpretations may change, or what the impact of such changes, ifany, may be in the future.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Third-Party Reimbursements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Successfulsales of our proposed products in the United States and othercountries depend, in large part, on the availability of adequatereimbursement from third-party payers such as governmentalentities, managed care organizations, health maintenanceorganizations (“HMOs”), and private insurance plans.Reimbursement by a third-party payer depends on a number offactors, including the payer’s determination that the producthas been approved by the FDA for the indication for which the claimis being made, that it is neither experimental nor investigational,and that the use of the product is safe and efficacious, medicallynecessary, appropriate for the specific patient and costeffective.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Sincereimbursement by one payer does not guarantee reimbursement byanother, we or our licensees may be required to seek approval fromeach payer individually. Seeking such approvals is a time-consumingand costly process. Third-party payers routinely limit the productsthat they will cover and the amount of money that they will payand, in many instances, are exerting significant pressure onmedical suppliers to lower their prices.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Payersfrequently employ a tiered system in reimbursing end users forpharmaceutical products, with tier designation affecting copay ordeductible amounts. Vyleesi is classified as a Tier 3 drug byinsurers covering Vyleesi. Thus, reimbursement is limited forVyleesi for treatment of premenopausal women with HSDD.Flibanserin, sold under the trade name Addyi, is similarlyclassified as a Tier 3 drug. Less than full reimbursement bythird-party payers may adversely affect the market acceptance ofVyleesi. Further, healthcare reimbursement systems vary fromcountry to country, and third-party reimbursement might not be madeavailable for Vyleesi for HSDD under other reimbursementsystems.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           14          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Manufacturing and Marketing        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         To besuccessful, our proposed products will need to be manufactured incommercial quantities under GMP prescribed by the FDA and atacceptable costs. We do not have the facilities to manufacture anyof our proposed products under GMP. We intend to rely oncollaborators, licensees, or contract manufacturers for thecommercial manufacture of our proposed products.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Vyleesiis manufactured using contract manufacturing companies. Pursuant tothe termination of the license agreement with AMAG, we have assumedcontracts relating to manufacturing, and intend to manufactureVyleesi for sales in the United States and to our licenseesthroughout the world.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OurPL3994 product candidate is a peptide mimetic molecule,incorporating a proprietary amino acid mimetic structure and aminoacids. We have had a contract manufacturer make the activepharmaceutical ingredient in quantities sufficient for Phase 1 andPhase 2.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OurMC1r and MCr agonist product candidates are synthetic peptides. Wehave had a contract manufacturer make both the PL8177 and PL9643peptides in suitable scale for toxicity studies and under GMP forclinical trial use. The PL8177 drug product for uveitis has beenmanufactured for clinical trial use, and manufacturing processdevelopment is ongoing for an oral formulation of PL8177preparatory to manufacturing oral PL8177 drug product for clinicaltrial use. While the production process for making peptide activepharmaceutical ingredient involves well-established technology,there are a limited number of manufacturers capable of scaling upto commercial quantities under GMP at acceptable costs.Additionally, scaling up to commercial quantities may involveproduction, purification, formulation and other problems notpresent in the scale of manufacturing done to date. Manufacturingdrug product, such as the oral formulation of PL8177, similarly mayinvolve production, formulation and other problems not present inmanufacturing at laboratory scale.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefailure of any manufacturer or supplier to comply with FDAregulations, including GMP or medical device quality systemsregulations (“QSR”), or to supply the device componentor drug substance and services as agreed, would force us or ourlicensees to seek alternative sources of supply and could interferewith our and our licensees’ ability to deliver product on atimely and cost-effective basis or at all. Establishingrelationships with new manufacturers or suppliers, any of whom mustbe FDA-approved, is a time-consuming and costlyprocess.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Product Liability and Insurance        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourbusiness may be affected by potential product liability risks thatare inherent in the testing, manufacturing, marketing and use ofour proposed products. We have liability insurance providing $10million coverage in the aggregate as to certain product liabilityand commercialization risks and certain clinical trialrisks.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Employees        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As ofSeptember 24, 2021 we employed 26 people full time, of whom 17 areengaged in research and development activities and nine are engagedin administration and management, and did not have any part-timeemployees. While we have been successful in attracting skilled andexperienced scientific personnel, competition for personnel in ourindustry is intense. None of our employees are covered by acollective bargaining agreement. All of our employees have executedconfidentiality and intellectual property agreements. We considerrelations with our employees to be good.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We relyon contractors and scientific consultants to work on specificresearch and development programs. We rely on consultants andcontractors to provide services for marketing and distribution ofVyleesi. We also rely on independent organizations, advisors, andconsultants to provide services, including aspects ofmanufacturing, testing, preclinical evaluation, clinicalmanagement, regulatory strategy, and market research. Ourindependent advisors, contractors and consultants sign agreementsthat provide for confidentiality of our proprietary information andthat we have the rights to any intellectual property developedwhile working for us.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Corporate Information        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We wereincorporated under the laws of the State of Delaware on November21, 1986 and commenced operations in the biopharmaceutical area in1996. Our corporate offices are located at 4B Cedar Brook Drive,Cranbury, New Jersey 08512 and our telephone number is (609)495-2200. We maintain an Internet site at         <font style="font-style: italic">          www.palatin.com         </font>         , where among otherthings, we make available free of charge on and through thiswebsite our Forms 3, 4 and 5, annual reports on Form 10-K,quarterly reports on Form 10-Q, current reports on Form 8-K, andamendments to those reports filed or furnished pursuant to Section13(a) or 15(d) and Section 16 of the Exchange Act as soon asreasonably practicable after we electronically file such materialwith, or furnish it to, the SEC. Our website and the informationcontained in it or connected to it are not incorporated into thisAnnual Report. The reference to our website is an inactive textualreference only.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           15          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The SECmaintains an Internet site that contains reports, proxy andinformation statements, and other information regarding issuersthat file electronically with the SEC (         <font style="font-style: italic">          www.sec.gov         </font>         ).        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 1A.         <a name="item1a">          R         </a>         iskFactors.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Risks Related to Our Financial Results and Need forFinancing        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We have a history of substantial net losses, including a net lossof $33.6 million for the year ended June 30, 2021, and expect toincur substantial net losses over the next few years, and we maynever achieve or maintain profitability.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As ofJune 30, 2021, we had an accumulated deficit of $351.8 million. Wehad $33.6 million in net loss for the year ended June 30, 2021,compared to $22.4 million in net loss for the year ended June 30,2020. We may not sustain profitability in future years, dependingon numerous factors, including profitability of Vyleesi, whetherand when development and sales milestones are met, whether and whenwe enter into license agreements for any of our products underdevelopment, regulatory actions by the FDA and other regulatorybodies, the performance of our licensees, and market acceptance ofour products.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weexpect to incur significant expenses as we continue our developmentof MC1r, MCr and natriuretic peptide receptor products. Theseexpenses, among other things, have had and will continue to have anadverse effect on our stockholders’ equity, total assets andworking capital.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Untilwe commenced selling Vyleesi in July 2020 upon termination of ourlicense agreement with AMAG, since 2005 we have not had anyproducts available for commercial sale and have not received anyrevenues from the sale of our product candidates. Because ourmarketing program for Vyleesi is relatively new, and because of theimpact of COVID-19 on marketing outreach, we cannot accuratelyforecast sales of Vyleesi. However, we had negative sales afterproduct allowances for the year ended June 30, 2021, and may havesales and marketing expenditures in excess of product sales infuture years. For the foreseeable future, we will have to fund ouroperations and capital expenditures from license, royalty andcontract revenue under license agreements, existing cash balancesand outside sources of financing, which may not be available onacceptable terms, if at all. We will not have product revenue fromour products in development unless and until we receive approvalfrom the FDA or other equivalent regulatory authorities outside theUnited States, and to date the only approved product is Vyleesi inthe United States. We have devoted substantially all of our effortsto research and development, including preclinical and clinicaltrials. Because of the numerous risks associated with developingdrugs, we are unable to predict the extent of future losses,whether or when any of our product candidates will becomecommercially available, or when we will become profitable, if atall.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We will need additional funding, including funding to completeclinical trials for our product candidates other than Vyleesi,which may not be available on acceptable terms, if atall.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weintend to focus future efforts on our MC1r product candidates,primarily for ocular indications, and secondarily on ournatriuretic peptide product candidates. As of June 30, 2021, we hadcash and cash equivalents of $60.1 million, with currentliabilities of $10.5 million. We believe we have sufficientexisting capital resources to fund our planned operations throughat least September 2022. We will need additional funding tocomplete development activities and required clinical trials forour MC1r product candidates and, if those clinical trials aresuccessful (which we cannot predict), to complete submission ofrequired regulatory applications to the FDA.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Wecannot predict product sales for Vyleesi for HSDD in the UnitedStates, so we may not have significant recurring revenue and mayneed to depend on financing or partnering to sustain ouroperations. We may raise additional funds through public or privateequity or debt financings, collaborative arrangements on ourproduct candidates, or other sources. However, such financingarrangements may not be available on acceptable terms, or at all.To obtain additional funding, we may need to enter intoarrangements that require us to develop only certain of our productcandidates or relinquish rights to certain technologies, productcandidates and/or potential markets.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If weare unable to raise sufficient additional funds when needed, we maybe required to curtail operations significantly, cease clinicaltrials and decrease staffing levels. We may seek to license, sellor otherwise dispose of our product candidates, technologies andcontractual rights on the best possible terms available. Even if weare able to license, sell or otherwise dispose of our productcandidates, technologies and contractual rights, it is likely to beon unfavorable terms and for less value than if we had thefinancial resources to develop or otherwise advance our productcandidates, technologies and contractual rightsourselves.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           16          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourfuture capital requirements depend on many factors,including:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability todevelop and maintain manufacturing, marketing and distributioncapability for sales of Vyleesi in the United States, including ourability to enter into agreements with one or more third parties toconduct activities relating to the commercialization ofVyleesi;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toenter into one or more licensing or similar agreements for Vyleesioutside of Korea and China;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the timing ofobtaining regulatory approvals for Vyleesi for HSDD in marketsoutside the United States;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the expense andtiming of obtaining regulatory approvals for our other productcandidates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the number andcharacteristics of any additional product candidates we develop oracquire;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the scope,progress, results and costs of researching and developing ourfuture product candidates, and conducting preclinical and clinicaltrials;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the cost ofcommercialization activities if any future product candidates areapproved for sale, including marketing, sales and distributioncosts;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the cost ofmanufacturing any future product candidates and any products wesuccessfully commercialize;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toestablish and maintain strategic collaborations, licensing or otherarrangements and the terms and timing of sucharrangements;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the degree and rateof market acceptance of any future approved products;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the emergence,approval, availability, perceived advantages, relative cost,relative safety and relative efficacy of alternative and competingproducts or treatments;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           any productliability or other lawsuits related to our products;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the expenses neededto attract and retain skilled personnel;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the costs involvedin preparing, filing, prosecuting, maintaining, defending andenforcing patent claims, including litigation costs and the outcomeof such litigation; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the timing, receiptand amount of sales of, or royalties on, future approved products,if any.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We have a limited operating history upon which to base aninvestment decision.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ouroperations are primarily focused on acquiring, developing andsecuring our proprietary technology, conducting preclinical andclinical studies and formulating and manufacturing, throughcontract manufacturers, our principal product candidates on asmall-scale basis. These operations provide a limited basis forstockholders to assess our ability to commercialize our productcandidates.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Whilewe completed Phase 3 clinical trials on Vyleesi for HSDD inpremenopausal women, together with AMAG filed an NDA on Vyleesi forHSDD with the FDA, and received approval on Vyleesi from the FDA,we have not yet demonstrated our ability to perform the functionsnecessary for the successful commercialization of any of ourcurrent product candidates. The successful commercialization of ourproduct candidates will require us to perform a variety offunctions, including:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           continuing toconduct preclinical development and clinical trials;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           participating inregulatory approval processes;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           formulating andmanufacturing products, or having third parties formulate andmanufacture products;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           post-approvalmonitoring and surveillance of our products;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           conducting salesand marketing activities, either alone or with a partner;and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           obtainingadditional capital.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           17          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If weare unable to obtain regulatory approval of any of our productcandidates, to successfully commercialize any products for which wereceive regulatory approval or to obtain additional capital, we maynot be able to recover our investment in our developmentefforts.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theclinical and commercial success of our product candidates willdepend on a number of factors, including thefollowing:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the ability toraise additional capital on acceptable terms, or atall;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           timely completionof our clinical trials, which may be significantly slower or costmore than we currently anticipate and will depend substantiallyupon the performance of third-party contractors;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           whether we arerequired by the FDA or similar foreign regulatory agencies toconduct additional clinical trials beyond those planned to supportthe approval and commercialization of our product candidates or anyfuture product candidates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           acceptance of ourproposed indications and primary endpoint assessments relating tothe proposed indications of our product candidates by the FDA andsimilar foreign regulatory authorities;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability todemonstrate to the satisfaction of the FDA and similar foreignregulatory authorities, the safety and efficacy of our productcandidates or any future product candidates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the prevalence,duration and severity of potential side effects experienced withour product candidates or future approved products, ifany;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the timely receiptof necessary marketing approvals from the FDA and similar foreignregulatory authorities;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           achieving andmaintaining, and, where applicable, ensuring that our third-partycontractors achieve and maintain, compliance with our contractualobligations and with all regulatory requirements applicable to ourproduct candidates or any future product candidates or approvedproducts, if any;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the ability ofthird parties with whom we contract to manufacture clinical trialand commercial supplies of our product candidates or any futureproduct candidates, remain in good standing with regulatoryagencies and develop, validate and maintain commercially viablemanufacturing processes that are compliant with the FDA’scurrent GMP regulations;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           a continuedacceptable safety profile and efficacy during clinical developmentand following approval of our product candidates or any futureproduct candidates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability tosuccessfully commercialize our product candidates or any futureproduct candidates in the United States and internationally, ifapproved for marketing, sale and distribution in such countries andterritories, whether alone or in collaboration withothers;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           acceptance byphysicians and patients of the benefits, safety and efficacy of ourproduct candidates or any future product candidates, if approved,including relative to alternative and competingtreatments;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our and ourpartners’ ability to establish and enforce intellectualproperty rights in and to our product candidates or any futureproduct candidates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our and ourpartners’ ability to avoid third-party patent interference orintellectual property infringement claims; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability todevelop, in-license or acquire additional product candidates orcommercial-stage products that we believe can be successfullydeveloped and commercialized.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If wedo not achieve one or more of these factors, many of which arebeyond our control, in a timely manner or at all, we couldexperience significant delays or an inability to obtain regulatoryapprovals or commercialize our product candidates. Even ifregulatory approvals are obtained, we may never be able tosuccessfully commercialize any of our product candidates.Accordingly, we cannot assure you that we will be able to generatesufficient revenue through the sale of our product candidates orany future product candidates to continue ourbusiness.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           18          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We have limited authorized shares available to raise additionalcapital through public or private equity offerings, which limitsour ability to raise additional capital.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We arecurrently authorized to issue up to 300,000,000 shares of commonstock, and approximately 90% of our authorized common stock is nowissued, reserved for issuance on conversion of Series A preferredstock, or reserved for issuance under existing warrants, options,restricted stock units and stock incentive plans. The amount ofcommon stock that is not issued or reserved for issuance isinsufficient for future financings that will be required tocontinue product development and is insufficient for certainactions designed to increase value to stockholders, including,without limitation, strategic acquisitions or granting equityincentives to key employees or contractors. We may be required toraise required additional fund through alternative means which mayultimately be detrimental to existing stockholders, which mayinclude:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           issuance ofpreferred stock which would have rights and preferences superior tocommon stock, which may be more dilutive than issuing commonstock;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           entering intolicense or similar agreements relating to one or more of ourproducts, which may require us to relinquish valuable rights to ourtechnologies or product candidates, or grant licenses on terms thatare not favorable to us, and ultimately raise less money thanthrough the issuance of common stock; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           entering into debtfacilities and/or product-specific financing agreements withfinancial or investment institutions, which may significantlyreduce prospective upfront license or similar payments and revenuesor royalties on the sale of our products.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Raising additional capital may cause dilution to existingshareholders, restrict our operations, or require us to relinquishrights.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We mayseek the additional capital necessary to fund our operationsthrough public or private equity offerings, collaborationagreements, debt financings or licensing arrangements. To theextent that we raise additional capital through the sale of equityor convertible debt securities, existing shareholders’ownership interests will be diluted, and the terms may includeliquidation or other preferences that adversely affect their rightsas a shareholder. Debt financing, if available, may involveagreements that include covenants limiting or restricting ourability to take specific actions such as incurring additional debt,making capital expenditures, or declaring dividends. If we raiseadditional funds through collaborations and licensing arrangementswith third parties, we may have to relinquish valuable rights toour technologies or product candidates or grant licenses on termsthat are not favorable to us.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Risks Related to Our Business, Strategy, and Industry        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         The commercial success of Vyleesi for HSDD is a component of ourcorporate strategy, but we and our licensees may never successfullycommercialize Vyleesi for HSDD or obtain approvals in countriesother than the United States.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weinvested most of our efforts and financial resources in theresearch and development of Vyleesi for HSDD until it was approvedby the FDA in June 2019. Since July 24, 2020, the effective date ofthe termination of our license agreement with AMAG for Vyleesi, wehave been responsible for manufacturing, marketing, anddistribution of Vyleesi in the United States. We licensed allrights to commercialize Vyleesi in China to Fosun and in Korea toKwangdong. We have not yet received regulatory approval tocommercialize Vyleesi in China or Korea, and regulatory approval inthese countries cannot be assured.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ournear-term prospects, including our ability to finance our companyand generate revenue, will be impacted by the successfulcommercialization of Vyleesi for HSDD, as well as preclinical andclinical results with our future product candidates. The clinicaland commercial success of Vyleesi and our product candidates willdepend on a number of factors, including thefollowing:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           timely completionof, or need to conduct additional clinical trials and studies, forour product candidates, which may be significantly slower or costmore than we currently anticipate and will depend substantiallyupon the accurate and satisfactory performance of third-partycontractors;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the ability todemonstrate to the satisfaction of the FDA the safety and efficacyof future product candidates through clinical trials;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           whether we or ourlicensees are required by the FDA or other similar foreignregulatory agencies to conduct additional clinical trials tosupport the approval of Vyleesi and future productcandidates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           19          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability tosuccessfully manufacture Vyleesi for worldwidemarkets;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our success and thesuccess of our licensees in educating physicians and patients aboutthe benefits, administration and use of Vyleesi forHSDD;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the prevalence andseverity of adverse events experienced with Vyleesi for HSDD or anyfuture product candidates or approved products;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the adequacy andregulatory compliance of the autoinjector device, supplied by anunaffiliated third party, used as part of the Vyleesi combinationproduct;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the timely receiptof necessary marketing approvals from the FDA and similar foreignregulatory authorities;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           whether ourstockholders agree, in a future meeting, to increase our authorizedshares of common stock to permit us to implement future financingsto ensure the advancement of our development programs and forpossible acquisitions of other product assets orcompanies;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toraise additional capital on acceptable terms to achieve ourgoals;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           achieving andmaintaining compliance with all regulatory requirements applicableto Vyleesi for HSDD or any future product candidates or approvedproducts;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the availability,perceived advantages, relative cost, relative safety and relativeefficacy of alternative and competing treatments;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the effectivenessof our own or our future potential strategic collaborators’marketing, sales and distribution strategy andoperations;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the ability tomanufacture clinical trial supplies of any future productcandidates and to develop, validate and maintain a commerciallyviable manufacturing process that is compliant with currentGMP;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability tosuccessfully commercialize Vyleesi for HSDD in the UnitedStates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability tosuccessfully commercialize any future product candidates, ifapproved for marketing and sale, whether alone or in collaborationwith others;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toenforce our intellectual property rights in and to Vyleesi for HSDDor any future product candidates;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability toavoid third-party patent interference or intellectual propertyinfringement claims;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           acceptance ofVyleesi for HSDD or any future product candidates, if approved, assafe and effective by patients and the medical community;and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           a continuedacceptable safety profile and efficacy of Vyleesi for HSDD or anyfuture product candidates following approval.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If wefail to satisfy any one of these prerequisites to our commercialsuccess, many of which are beyond our control, in a timely manneror at all, we could experience significant delays or an inabilityto successfully commercialize our product candidates. Accordingly,we cannot assure you that we will be able to generate sufficientrevenue through direct sales of Vyleesi for HSDD in the UnitedStates and the license agreements with Fosun and Kwangdong, orthrough the sale of any future product candidate, to continue ourbusiness. In addition to preventing us from executing our currentbusiness plan, any delays in our clinical trials, or inability tosuccessfully commercialize our products could impair our reputationin the industry and the investment community and could hinder ourability to fulfill our existing contractual commitments. As aresult, our share price would likely decline significantly, and wewould have difficulty raising necessary capital for futureprojects.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Production and supply of Vyleesi depend on contract manufacturersover whom we do not have any control, and there may not be adequatesupplies of Vyleesi.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We donot have the facilities to manufacture the Vyleesi active drugingredient or the autoinjector pen component of the Vyleesicombination product, or to fill, assemble and package the Vyleesicombination product. We have contracts with third parties to makethe Vyleesi combination product. The contract manufacturers mustperform these manufacturing activities in a manner that complieswith FDA regulations. Our ability to control third-party compliancewith FDA requirements is limited to contractual remedies and rightsof inspection. The manufacturers of approved products and theirmanufacturing facilities will be subject to ongoing review andperiodic inspections by the FDA and other authorities whereapplicable, and must comply with regulatory requirements, includingFDA regulations concerning GMP. Failure of third-partymanufacturers to comply with GMP, medical device quality systemregulations, or other FDA requirements may result in enforcementaction by the FDA. Failure to conduct their activities incompliance with FDA regulations could delay or negatively impactour ability to market Vyleesi. Establishing relationships with newsuppliers, who must be FDA-approved, is a time-consuming and costlyprocess. If we are not able to obtain adequate supplies of Vyleesi,it will be difficult for us to market and commercialize Vyleesi andcompete effectively.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           20          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         The effect of COVID-19 and other possible pandemics andoutbreaks could result in material adverse effects on our clinicaltrials, business, financial condition. and results ofoperations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We haveactive and planned clinical trial sites in the United States andplanned clinical trial sites in Europe, and our licensees haveplanned clinical trial sites in Asia-Pacific countries. As theCOVID-19 pandemic continues around the globe, we will likelyexperience disruptions that could severely impact our plannedclinical trials, including Phase 3 clinical trials with PL9643 inthe United States for dry eye disease, a Phase 2 clinical trialwith PL8177 for ulcerative colitis, a Phase 2 clinical trial withPL3994, an NPR-A agonist, in heart failure patients incollaboration with two major academic medical centers, and clinicaltrials planned to be conducted in the People’s Republic ofChina and the Republic of Korea by our licensees for Vyleesi, Fosunand Kwangdong.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         It ispossible that the COVID-19 pandemic may delay enrollment in ourclinical trials due to prioritization of medical and hospitalresources toward the outbreak, and some patients may be unwillingto enroll in our trials or be unable to comply with clinical trialprotocols if quarantines impede patient movement or interrupthealthcare services, which would delay our ability to conductclinical trials or release clinical trial results.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCOVID-19 pandemic may also result in the inability of our suppliersto deliver clinical drug supplies on a timely basis or at all. Inaddition, medical centers and hospitals may reduce staffing andreduce or postpone certain treatments in response to the spread ofan infectious disease. Such events may result in a period ofbusiness disruption, and in reduced operations, or doctors andmedical providers may be unwilling to participate in our clinicaltrials.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCOVID-19 pandemic and measures to prevent the spread of COVID-19subject us to various risks and uncertainties that could materiallyadversely affect our clinical trials, business, financialcondition, and results of operation, including thefollowing:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability torecruit subjects for clinical trials and studies for our productcandidates and to timely complete clinical trials and otherstudies;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our ability tosuccessfully market Vyleesi, given significant limitations inperson-to-person marketing and contacts, including limitations ineducating physicians and other health care professionals about thebenefits, administration and use of Vyleesi for HSDD;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           adverse impacts onour ability to manufacture and distribute Vyleesi, including due tothe negative impact of COVID-19 on air travel, as well as temporarydisruptions, restrictions or closures of facilities of oursuppliers and contract manufacturers in the Vyleesi manufacturingchain;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           adverse impacts ofCOVID-19 on our ability to successful manufacture productcandidates for clinical trials and to successfully manufactureVyleesi for the United States market and clinical trials elsewherein the world;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           adverse impacts onour operations resulting from remote workingarrangements;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           limitations inemployee resources that would otherwise be focused on the conductof our clinical trials, including because of sickness of employeesor their families, delays or difficulties in conducting site visitsand other required travel, and the desire of employees to avoidcontact with large groups of people;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the inability ofglobal suppliers of raw materials or components used in themanufacture of our products, or contract manufacturers of ourproducts, to supply and/or transport those raw materials,components and products to us in a timely and cost effective mannerdue to shutdowns, interruptions or delays, limiting and precludingthe production of our finished products, impacting our ability tosupply customers, reducing our sales, increasing our costs of goodssold, and reducing our absorption of overhead;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           21          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the illiquidity orinsolvency of our suppliers, vendors and customers, or theirinability to pay our invoices in full or in a timely manner, due tothe reduction in their revenues caused by the cancellation or delayof procedures and other factors, which could potentially reduce ourcash flow and our liquidity;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           delays in ourability, and the ability of our development partners, to conduct,enroll and complete clinical development programs;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the instability toworldwide economies, financial markets, social institutions, labormarkets and the healthcare systems as a result of the COVID-19pandemic, which could result in an economic downturn that couldadversely impact our business, results of operations and financialcondition, as well as that of our investors, suppliers, customersor other business partners;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           changes in customerbehavior and preferences for Vyleesi, as customers may experiencefinancial difficulties or may delay or reduce their spending inlight of COVID-19; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the continuation orexacerbation of the COVID-19 pandemic after social distancing andother similar measures have been relaxed.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Most ofour employees have transitioned to remote working arrangements, andwe have not determined how long these arrangements will last. Whileremote working has not had a significant adverse impact on ourfinancial results or our operations to date, there can be noassurance that these arrangements will not ultimately result inlower work efficiency and productivity, which in turn may adverselyaffect our business. Certain employees, such as laboratorypersonnel, cannot work remotely, and COVID-19 may adversely affectour ability to conduct research and preclinical studies, andundertake other activities related to development of potentialproducts.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theextent to which the global COVID-19 pandemic impacts our businesswill depend on future developments, which are highly uncertain andcannot be predicted, including new information that may emergeconcerning the severity of COVID-19 and the actions to contain ortreat its impact, among others. The COVID-19 pandemic has adverselyaffected economies and financial markets worldwide, resulting in aneconomic downturn that could impact our business, financialcondition, and results of operations, including our ability toobtain additional funding, if needed.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Our product candidates other than Vyleesi, including PL9643 for dryeye disease and PL8177 for the treatment of ulcerative colitis, arestill in the early stages of development and remain subject toclinical testing and regulatory approval. If we are unable tosuccessfully develop and test our product candidates, we will notbe successful.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourproduct candidates, including PL9643 for dry eye disease and PL8177for the treatment of ulcerative colitis, are at various stages ofresearch and development, will require regulatory approval, and maynever be successfully developed or commercialized. Our productcandidates will require significant further research, developmentand testing before we can seek regulatory approval to market andsell them. We must demonstrate that our product candidates are safeand effective for use in patients in order to receive regulatoryapproval for commercial sale. Preclinical studies in animals, usingvarious doses and formulations, must be performed before we canbegin human clinical trials. Even if we obtain favorable results inthe preclinical studies, the results in humans may be different.Numerous small-scale human clinical trials may be necessary toobtain initial data on a product candidate’s safety andefficacy in humans before advancing to large scale human clinicaltrials. We face the risk that the results of our trials in laterphases of clinical trials may be inconsistent with those obtainedin earlier phases. Adverse or inconclusive results could delay theprogress of our development programs and may prevent us from filingfor regulatory approval of our product candidates. Additionalfactors that could inhibit the successful development of ourproduct candidates include:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           lack ofeffectiveness of any product candidate during clinical trials orthe failure of our product candidates to meet specifiedendpoints;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           failure to designappropriate clinical trial protocols;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           uncertaintyregarding proper dosing;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           for injectableproducts, inability to develop or obtain a supplier for a suitableautoinjector device that meets the FDA’s medical devicerequirements;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           insufficient datato support regulatory approval;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           inability orunwillingness of medical investigators to follow our clinicalprotocols;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           inability to add asufficient number of clinical trial sites; or          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           22          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the availability ofsufficient capital to sustain operations and clinicaltrials.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Youshould evaluate us in light of these uncertainties, difficultiesand expenses commonly experienced by early stage biopharmaceuticalcompanies, as well as unanticipated problems and additional costsrelating to:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           product approval orclearance;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           regulatorycompliance;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           good manufacturingpractices;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           intellectualproperty rights;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           productintroduction; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           marketing andcompetition.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If clinical trials for our product candidates are prolonged ordelayed, we may be unable to commercialize our product candidateson a timely basis, which would require us to incur additional costsand delay our receipt of any revenue from potential productsales.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We maybe unable to commercialize our product candidates on a timely basisdue to unexpected delays in our human clinical trials. Potentialdelaying events include:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           discovery ofserious or unexpected toxicities or side effects experienced bystudy participants or other safety issues;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           slower thanexpected rates of subject recruitment and enrollment rates inclinical trials resulting from numerous factors, including theprevalence of other companies’ clinical trials for theirproduct candidates for the same indication, or clinical trials forindications for which patients do not as commonly seektreatment;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           difficulty inretaining subjects who have initiated a clinical trial but maywithdraw at any time due to adverse side effects from the therapy,insufficient efficacy, fatigue with the clinical trial process orfor any other reason;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           difficulty inobtaining IRB approval for studies to be conducted at eachsite;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           delays inmanufacturing or obtaining, or inability to manufacture or obtain,sufficient quantities of materials for use in clinicaltrials;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           inadequacy of orchanges in our manufacturing process or the product formulation ormethod of delivery;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           changes inapplicable laws, regulations and regulatory policies;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           delays or failurein reaching agreement on acceptable terms in clinical trialcontracts or protocols with prospective contract researchorganizations (“CROs”), clinical trial sites and otherthird-party contractors;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           failure of our CROsor other third-party contractors to comply with contractual andregulatory requirements or to perform their services in a timely oracceptable manner;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           failure by us, ouremployees, our CROs or their employees or any partner with which wemay collaborate or their employees to comply with applicable FDA orother regulatory requirements relating to the conduct of clinicaltrials or the handling, storage, security and recordkeeping fordrug, medical device and biologic products;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           delays in thescheduling and performance by the FDA of required inspections ofus, our CROs, our suppliers, or our clinical trial sites, andviolations of law or regulations discovered in the course of FDAinspections;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           schedulingconflicts with participating clinicians and clinical institutions;or          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           difficulty inmaintaining contact with subjects during or after treatment, whichmay result in incomplete data.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Any ofthese events or other delaying events, individually or in theaggregate, could delay the commercialization of our productcandidates and have a material adverse effect on our business,results of operations and financial condition.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           23          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We may not be able to secure and maintain relationships withresearch institutions and other organizations to conduct ourclinical trials.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We relyon research institutions and other organizations to conduct ourclinical trials, and we therefore have limited control over thetiming and cost of clinical trials and our ability to recruitsubjects. If we are unable to reach agreements with suitableresearch institutions or organizations on acceptable terms, or ifany such agreement is terminated, we may be unable to quicklyreplace the research institution or organization with anotherqualified institution or organization on acceptable terms. We maynot be able to secure and maintain suitable research institutionsor organizations to conduct our clinical trials.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Even if our product candidates receive regulatory approval, theymay never achieve market acceptance, in which case our business,financial condition and results of operation will be materiallyadversely affected.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Regulatoryapproval for the marketing and sale of any of our productcandidates does not assure the product’s commercial success.Any approved product will compete with other products manufacturedand marketed by major pharmaceutical and other biotechnologycompanies. If any of our product candidates are approved by the FDAand do not achieve adequate market acceptance, our business,financial condition, and results of operations will be materiallyadversely affected. The degree of market acceptance of any suchproduct will depend on a number of factors, including:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           perceptions bymembers of the healthcare community, including physicians, aboutthe safety and effectiveness of any such product;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           cost-effectivenessrelative to competing products and technologies;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           availability ofreimbursement for our products from third-party payers such ashealth insurers, HMOs and government programs such as Medicare andMedicaid; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 24px">        <div style="display: table-row">         <div style="display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           advantages overalternative treatment methods.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thereis one other FDA approved product for treatment of HSDD,flibanserin, which is sold under the trade name Addyi, and startedmarketing in October 2015. While we believe that an on-demand drugfor HSDD has competitive advantages compared to chronic or dailyuse drugs, we may not be able to realize this perceived advantagein the market. Vyleesi is administered by subcutaneous injection.While the single-use, disposable autoinjector pen format isdesigned to maximize market acceptability, Vyleesi as asubcutaneous injectable drug for HSDD may never achieve significantmarket acceptance. In addition, we believe reimbursement of Vyleesifrom third-party payers such as health insurers, HMOs or otherthird-party payers of healthcare costs will be similar toreimbursement for flibanserin and erectile dysfunction(“ED”) drugs, and that the ultimate user may pay asubstantial part of the cost of Vyleesi for HSDD. If the marketopportunity for Vyleesi is smaller than we anticipate, it may alsobe difficult for us to find marketing partners and, as a result, wemay be unable to generate revenue and business from Vyleesi. IfVyleesi for HSDD does not achieve adequate market acceptance at anacceptable price point, our business, financial condition, andresults of operations will be materially adverselyaffected.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Even if our product candidates receive regulatory approval in theUnited States, we may never receive approval or commercialize ourproducts outside of the United States.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inorder to market any products outside of the United States, we mustestablish and comply with numerous and varying regulatoryrequirements of other countries regarding safety and efficacy.Approval procedures vary among countries and can involve additionalproduct testing and additional administrative review periods. Thetime required to obtain approval in other countries might differfrom that required to obtain FDA approval. The regulatory approvalprocess in other countries may include all of the risks detailedabove regarding FDA approval in the United States as well as otherrisks. Regulatory approval in one country does not ensureregulatory approval in another, but a failure or delay in obtainingregulatory approval in one country may have a negative effect onthe regulatory process in others. Failure to obtain regulatoryapproval in other countries or any delay or setbacks in obtainingsuch approval would impair our ability to develop foreign marketsfor our product candidates and may have a material adverse effecton our results of operations and financial condition.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If side effects emerge that can be linked to Vyleesi or any of ourproduct candidates (either while they are in development or afterthey are approved and on the market), we may be required to performlengthy additional clinical trials, change the labeling of any suchproducts, or withdraw such products from the market, any of whichwould hinder or preclude our ability to generaterevenues.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           24          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If weidentify side effects or other problems occur in future clinicaltrials, we may be required to terminate or delay clinicaldevelopment of the product candidate. Furthermore, even if any ofour product candidates receive marketing approval, as greaternumbers of patients use a drug following its approval, if theincidence of side effects increases or if other problems areobserved after approval that were not seen or anticipated duringpre-approval clinical trials, or if the incidence of side effectsincrease or other problems are observed with Vyleesi, a number ofpotentially significant negative consequences could result,including:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           regulatoryauthorities may withdraw their approval of theproduct;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           we may be requiredto reformulate such products or change the way the product ismanufactured;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           we may become thetarget of lawsuits, including class action suits; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           our reputation inthe marketplace may suffer resulting in a significant drop in thesales of such products.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Any ofthese events could substantially increase the costs and expenses ofdeveloping, commercializing, and marketing any such productcandidates or could harm or prevent sales of any approvedproducts.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We may not be able to keep up with the rapid technological changein the biotechnology and pharmaceutical industries, which couldmake any future approved products obsolete and reduce ourrevenue.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Biotechnologyand related pharmaceutical technologies have undergone and continueto be subject to rapid and significant change. Our future willdepend in large part on our ability to maintain a competitiveposition with respect to these technologies. Our competitors mayrender our technologies obsolete by advances in existingtechnological approaches or the development of new or differentapproaches, potentially eliminating the advantages in our drugdiscovery process that we believe we derive from our researchapproach and proprietary technologies. In addition, any futureproducts that we develop, including our clinical productcandidates, may become obsolete before we recover expenses incurredin developing those products, which may require that we raiseadditional funds to continue our operations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Competing products and technologies may make our proposed productsnoncompetitive.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Flibanserin,a daily-use oral drug sold under the trade name Addyi, has beenapproved by the FDA for HSDD in premenopausal women. There areother products reported as being developed for HSDD and other FSDindications, including oral combination drugs, some of whichincorporate testosterone, antidepressants, or PDE-5 inhibitors.There is competition to develop drugs for treatment of HSDD and FSDin both premenopausal and postmenopausal patients. Our Vyleesi drugproduct is administered by subcutaneous injection, and an on-demanddrug product for the same indication which utilizes another routeof administration, such as a conventional oral drug product, maymake subcutaneous Vyleesi noncompetitive.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thereare a number of products approved for use in treating inflammatorydiseases and indications, and other products are being developed,including products in clinical trials. The dry eye disease andocular inflammatory disease markets are highly competitive, with anumber of marketed products and products reported to be inlate-stage clinical trials. Similarly, the inflammatory boweldisease and ulcerative colitis markets are highly competitive, witha number of marketed products and products reported to be inlate-stage clinical trials.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ingeneral, the biopharmaceutical industry is highly competitive. Weare likely to encounter significant competition with respect toVyleesi, MC1r product candidates, MCr product candidates and NPRproduct candidates. Most of our competitors have substantiallygreater financial and technological resources than we do. Many ofthem also have significantly greater experience in research anddevelopment, marketing, distribution, and sales than we do.Accordingly, our competitors may succeed in developing, marketing,distributing, and selling products and underlying technologies morerapidly than we can. These competitive products or technologies maybe more effective and useful or less costly than Vyleesi or ourMC1r product candidates, MCr product candidates and NPR productcandidates. In addition, academic institutions, hospitals,governmental agencies, and other public and private researchorganizations are also conducting research and may developcompeting products or technologies on their own or throughstrategic alliances or collaborative arrangements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           25          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We rely on third parties over whom we have no control to conductpreclinical studies, clinical trials and other research for ourproduct candidates and their failure to timely perform theirobligations could significantly harm our productdevelopment.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We havelimited research and development staff. We rely on third partiesand independent contractors, such as researchers at CROs anduniversities, in certain areas that are particularly relevant toour research and product development plans. We engage suchresearchers to conduct our preclinical studies, clinical trials andassociated tests. These outside contractors are not our employeesand may terminate their engagements with us at any time. Inaddition, we have limited control over the resources that thesecontractors devote to our programs, and they may not assign asgreat a priority to our programs or pursue them as diligently as wewould if we were undertaking such programs ourselves. There is alsocompetition for these relationships, and we may not be able tomaintain our relationships with our contractors on acceptableterms. If our third-party contractors do not carry out their dutiesunder their agreements with us, fail to meet expected deadlines orfail to comply with appropriate standards for preclinical orclinical research, our ability to develop our product candidatesand obtain regulatory approval on a timely basis, if at all, may bematerially adversely affected.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Production and supply of our product candidates depend on contractmanufacturers over whom we have no control, with the risk that wemay not have adequate supplies of our product candidates orproducts.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We donot have the facilities to manufacture our early-stage potentialproducts such as PL8177, PL9643, PL3994 and other natriureticpeptide and melanocortin receptor agonist compounds for use inpreclinical studies and clinical trials. Contract manufacturersmust perform these manufacturing activities in a manner thatcomplies with FDA regulations. Our ability to control third-partycompliance with FDA requirements is limited to contractual remediesand rights of inspection. The manufacturers of our potentialproducts and their manufacturing facilities will be subject tocontinual review and periodic inspections by the FDA and otherauthorities where applicable, and must comply with ongoingregulatory requirements, including FDA regulations concerning GMP.Failure of third-party manufacturers to comply with GMP, medicaldevice QSR, or other FDA requirements may result in enforcementaction by the FDA. Failure to conduct their activities incompliance with FDA regulations could delay our developmentprograms or negatively impact our ability to receive FDA approvalof our potential products. Establishing relationships with newsuppliers, who must be FDA-approved, is a time-consuming and costlyprocess.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If we are unable to establish sales and marketing capabilitieswithin our organization or enter into and maintain agreements withthird parties to market and sell Vyleesi and our productcandidates, we may be unable to generate productrevenue.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We donot currently have any experience in sales, marketing, anddistribution of pharmaceutical products. We are currently workingto establish sales and marketing capabilities for Vyleesi in theUnited States, including through establishing agreements with thirdparties to market and sell Vyleesi. We may not be able to enterinto suitable agreements on acceptable terms, if at all, with thirdparties to market and sell Vyleesi. Engaging a third party toperform these services could impede sales of Vyleesi. If we areunable to establish adequate sales, marketing, and distributioncapabilities for Vyleesi, whether independently or with thirdparties, we may not be able to generate sufficient product revenueto support Vyleesi-associated costs and expenses, and our businesswould suffer. In addition, if we enter into arrangements with thirdparties to perform sales, marketing and distribution services, wewill be dependent on the performance of third parties over whom wehave limited control.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If anyof our products candidates are approved by the FDA or otherregulatory authorities, we must enter into agreements with thirdparties to market these product candidates or develop marketing,distribution and selling capacity and expertise, which will becostly and time consuming, or enter into agreements with othercompanies to provide these capabilities. We may not be able toenter into suitable agreements on acceptable terms, if at all.Engaging a third party to perform these services could delay thecommercialization of any of our product candidates, if approved forcommercial sale. If we are unable to establish adequate sales,marketing, and distribution capabilities, whether independently orwith third parties, we may not be able to generate product revenueand our business would suffer. In addition, if we enter intoarrangements with third parties to perform sales, marketing anddistribution services, our product revenues are likely to be lowerthan if we could market and sell any products that we developourselves.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We need to hire additional employees in order to commercializeVyleesi and our product candidates in the future. Any inability tomanage future growth could harm our ability to commercializeVyleesi and ultimately our product candidates, increase our costsand adversely impact our ability to competeeffectively.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Tocommercialize Vyleesi and ultimately our product candidates, wewill need to hire or contract with experienced sales and marketingpersonnel to sell and market those product candidates we decide tocommercialize, and we will need to expand the number of ourmanagerial, operational, financial and other employees to supportcommercialization. Competition exists for qualified personnel inthe biopharmaceutical field.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           26          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Futuregrowth will impose significant added responsibilities on members ofmanagement, including the need to identify, recruit, maintain andintegrate additional employees. Our future financial performanceand our ability to commercialize our product candidates and tocompete effectively will depend, in part, on our ability to manageany future growth effectively.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Our ability to achieve revenues from the sale of our products willdepend, in part, on our ability to obtain adequate reimbursementfrom private insurers and other healthcare payers.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourability to successfully commercialize our products, includingVyleesi and our products in development, will depend, insignificant part, on the extent to which we or our marketingpartners can obtain reimbursement for our products and alsoreimbursement at appropriate levels for the cost of our products.Obtaining reimbursement from governmental payers, insurancecompanies, HMOs and other third-party payers of healthcare costs isa time-consuming and expensive process. Vyleesi for HSDD isclassified as a Tier 3 drug, so reimbursement for Vyleesi islimited for treatment of premenopausal women withHSDD.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Even if we receive regulatory approval for our products in Europe,we may not be able to secure adequate pricing and reimbursement inEurope for us or any strategic partner to achieveprofitability.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Even ifone or more of our products are approved in Europe, we may beunable to obtain appropriate pricing and reimbursement for suchproducts. In most European markets, demand levels for healthcare ingeneral and for pharmaceuticals in particular are principallyregulated by national governments. Therefore, pricing andreimbursement for our products will have to be negotiated on a“Member State by Member State” basis according tonational rules, as there does not exist a centralized Europeanprocess. As each Member State has its own national rules governingpricing control and reimbursement policy for pharmaceuticals, thereare likely to be uncertainties attaching to the review process, andthe level of reimbursement that national governments are preparedto accept. In the current economic environment, governments andprivate payers or insurers are increasingly looking to containhealthcare costs, including costs on drug therapies. If we areunable to obtain adequate pricing and reimbursement for ourproducts in Europe, we or a potential strategic partner orcollaborator may not be able to cover the costs necessary tomanufacture, market and sell the product, limiting or preventingour ability to achieve profitability.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We may incur substantial liabilities and may be required to limitcommercialization of our products in response to product liabilitylawsuits.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thetesting and marketing of medical products entails an inherent riskof product liability. If we cannot successfully defend ourselvesagainst product liability claims, we may incur substantialliabilities or be required to limit commercialization of ourproducts or cease clinical trials. Our inability to obtainsufficient product liability insurance at an acceptable cost toprotect against potential product liability claims could prevent orinhibit the commercialization of pharmaceutical products wedevelop, alone or with corporate collaborators. We currently carry$10 million liability insurance in the aggregate as to certainproduct liability and commercialization risks and certain clinicaltrial risks. We, or any corporate collaborators, may not in thefuture be able to obtain insurance at a reasonable cost or insufficient amounts, if at all. Even if our agreements with anyfuture corporate collaborators entitle us to indemnificationagainst losses, such indemnification may not be available oradequate should any claim arise.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Our internal computer systems, or those of our third-partycontractors or consultants, may fail or suffer security breaches,which could result in a material disruption of our productdevelopment programs.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In theordinary course of our business, we collect, store and transmitconfidential information. Despite the implementation of securitymeasures, our internal computer systems and those of ourthird-party contractors and consultants are vulnerable to damagefrom computer viruses, unauthorized access, natural disasters,terrorism, war and telecommunication and electrical failures. Werely on industry accepted measures and technology to secureconfidential and proprietary information maintained on our computersystems. However, these measures and technology may not adequatelyprevent security breaches. While we do not believe that we haveexperienced any such system failure, accident, or security breachto date, if such an event were to occur and cause interruptions inour operations, it could result in a loss of clinical trial datafor our product candidates that could result in delays in ourregulatory approval efforts and significantly increase our costs torecover or reproduce the data. Cyberattacks are increasing in theirfrequency, sophistication, and intensity. Cyberattacks couldinclude the deployment of harmful malware, denial-of-serviceattacks, social engineering, and other means to affect servicereliability and threaten the confidentiality, integrity andavailability of information. Significant disruptions of ourinformation technology systems or security breaches could adverselyaffect our business operations and/or result in the loss,misappropriation, and/or unauthorized access, use or disclosure of,or the prevention of access to, confidential information (includingtrade secrets or other intellectual property, proprietary businessinformation and personal information), and could result infinancial, legal, business, and reputational harm to us. To theextent that any disruption or security breach results in a loss ofor damage to our data or applications or other data or applicationsrelating to our technology, intellectual property, research anddevelopment or product candidates, or inappropriate disclosure ofconfidential or proprietary information, we could incur liabilitiesand the further development of our product candidates could bedelayed.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           27          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We may be subject to claims that our employees, consultants, orindependent contractors have wrongfully used or disclosedconfidential information of third parties or that our employeeshave wrongfully used or disclosed alleged trade secrets of theirformer employers.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We mayin the future employ individuals who were previously employed atuniversities or other biotechnology or pharmaceutical companies,including our competitors or potential competitors. Although we tryto ensure that our employees, consultants, and independentcontractors do not use the proprietary information or know-how ofothers in their work for us, we may be subject to claims that we orour employees, consultants or independent contractors haveinadvertently or otherwise used or disclosed intellectual property,including trade secrets or other proprietary information, of any ofour employee’s former employer or other third parties.Litigation may be necessary to defend against these claims. If wefail in defending any such claims, in addition to paying monetarydamages, we may lose valuable intellectual property rights orpersonnel, which could adversely impact our business. Even if weare successful in defending against such claims, litigation couldresult in substantial costs and be a distraction to management andother employees.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We may be subject, directly or indirectly, to federal and statehealthcare fraud and abuse laws, false claims laws, and healthinformation privacy and security laws. If we are unable to comply,or have not fully complied, with such laws, we could facesubstantial penalties.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If webegin commercializing any of our products in the United States, ouroperations may be directly, or indirectly through our customers,subject to various federal and state fraud and abuse laws,including, without limitation, the federal Anti-Kickback Statute,the federal False Claims Act, and physician sunshine laws andregulations. These laws may impact, among other things, ourproposed sales, marketing, and education programs. In addition, wemay be subject to patient privacy regulation by both the federalgovernment and the states in which we conduct our business. Thelaws that may affect our ability to operate include:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the federalAnti-Kickback Statute, which prohibits, among other things, personsor entities from soliciting, receiving, offering or providingremuneration, directly or indirectly, in return for or to induceeither the referral of an individual for, or the purchase order orrecommendation of, any item or services for which payment may bemade under a federal health care program such as the Medicare andMedicaid programs;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           federal civil andcriminal false claims laws and civil monetary penalty laws, whichprohibit, among other things, individuals or entities fromknowingly presenting, or causing to be presented, claims forpayment from Medicare, Medicaid, or other third-party payors thatare false or fraudulent;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           HIPAA, whichcreated new federal criminal statutes that prohibit executing ascheme to defraud any healthcare benefit program and making falsestatements relating to healthcare matters;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           HIPAA, as amendedby the Health Information Technology and Clinical Health Act, andits implementing regulations, which imposes certain requirementsrelating to the privacy, security, and transmission of individuallyidentifiable health information;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           The federalphysician sunshine requirements under the Affordable Care Act,which require manufacturers of drugs, devices, biologics, andmedical supplies to report annually to the U.S. Department ofHealth and Human Services information related to payments and othertransfers of value to physicians, other healthcare providers, andteaching hospitals, and ownership and investment interests held byphysicians and other healthcare providers and their immediatefamily members and applicable group purchasing organizations;and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           28          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           state lawequivalents of each of the above federal laws, such asanti-kickback and false claims laws that may apply to items orservices reimbursed by any third-party payor, including commercialinsurers, state laws that require pharmaceutical companies tocomply with the pharmaceutical industry’s voluntarycompliance guidelines and the relevant compliance guidancepromulgated by the federal government, or otherwise restrictpayments that may be made to healthcare providers and otherpotential referral sources; state laws that require drugmanufacturers to report information related to payments and othertransfers of value to physicians and other healthcare providers ormarketing expenditures; and state laws governing the privacy andsecurity of health information in certain circumstances, many ofwhich differ from each other in significant ways and may not havethe same effect, thus complicating compliance efforts.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Becauseof the breadth of these laws and the narrowness of the statutoryexceptions and safe harbors available, it is possible that some ofour business activities could be subject to challenge under one ormore of such laws. In addition, recent health care reformlegislation has strengthened these laws. For example, theAffordable Care Act, among other things, amends the intentrequirement of the federal anti-kickback and criminal healthcarefraud statutes. A person or entity no longer needs to have actualknowledge of this statute or specific intent to violate it.Moreover, the Affordable Care Act provides that the government mayassert that a claim including items or services resulting from aviolation of the federal anti-kickback statute constitutes a falseor fraudulent claim for purposes of the False ClaimsAct.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If ouroperations are found to be in violation of any of the lawsdescribed above or any other governmental regulations that apply tous, we may be subject to penalties, including civil and criminalpenalties, damages, fines, exclusion from participation ingovernment health care programs, such as Medicare and Medicaid,imprisonment, and the curtailment or restructuring of ouroperations, any of which could adversely affect our ability tooperate our business and our results of operations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We are highly dependent on our management team, senior staffprofessionals and third-party contractors and consultants, and theloss of their services could materially adversely affect ourbusiness.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We relyon our relatively small management team and staff as well asvarious contractors and consultants to provide critical services.Our ability to execute our clinical programs for Vyleesi, PL8177,PL9643, PL3994 and our other preclinical programs for MC1r and MC4rpeptide or small molecule drug candidates and natriuretic peptidedrug candidates depends on our continued retention and motivationof our management and senior staff professionals, includingexecutive officers and senior members of product development andmanagement, including commercialization, who possess significanttechnical expertise and experience and oversee our development andcommercialization programs. If we lose the services of existing keypersonnel, our development programs could be adversely affected ifsuitable replacement personnel are not recruited quickly. Oursuccess also depends on our ability to develop and maintainrelationships with contractors, consultants, and scientificadvisors.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thereis competition for qualified personnel, contractors, andconsultants in the pharmaceutical industry, which makes itdifficult to attract and retain the qualified personnel,contractors and consultants necessary for the development andgrowth of our business. Our failure to attract and retain suchpersonnel, contractors and consultants could have a materialadverse effect on our business, results of operations and financialcondition.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Existing coverage for Vyleesi for the treatment of HSDD isclassified as a Tier 3 drug by third-party payers, so that demandfor Vyleesi is tied to discretionary spending levels of ourtargeted patient population and particularly affected byunfavorable economic conditions.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Themarket for HSDD may be particularly vulnerable to unfavorableeconomic conditions. Vyleesi for the treatment of HSDD hassignificant copay or deductible requirements and is frequently onlypartially reimbursed by third-party payers and, as a result, demandfor this product may be tied to discretionary spending levels ofour targeted patient population. A severe or prolonged economicdownturn could result in a variety of risks to our business,including weakened demand for Vyleesi for HSDD.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Risks Related to Government Regulation        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Both before and after marketing approval, our product candidatesare subject to ongoing regulatory requirements and, if we fail tocomply with these continuing requirements, we could be subject to avariety of sanctions and the sale of any approved commercialproducts could be suspended.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           29          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Bothbefore and after regulatory approval to market a particular productcandidate, the manufacturing, labeling, packaging, adverse eventreporting, storage, advertising and promotion and record keepingrelated to the product candidates are subject to extensiveregulatory requirements. If we fail to comply with the regulatoryrequirements of the FDA and other applicable U.S. and foreignregulatory authorities, we could be subject to administrative orjudicially imposed sanctions, including:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           restrictions on theproducts or manufacturing process;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           warningletters;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           civil or criminalpenalties;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           fines;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           injunctions;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           imposition of aCorporate Integrity Agreement requiring heightened monitoring ofour compliance functions, overseen by outside monitors, andenhanced reporting requirements to, and oversight by, the FDA andother government agencies;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           product seizures ordetentions and related publicity requirements;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           suspension orwithdrawal of regulatory approvals;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           regulators or IRBsmay not authorize us or any potential future collaborators tocommence a clinical trial or conduct a clinical trial at aprospective trial site;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           total or partialsuspension of production; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           refusal to approvepending applications for marketing approval of new productcandidates.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Changesin the regulatory approval policy during the development period,changes in or the enactment of additional regulations or statutes,or changes in the regulatory review for each submitted productapplication may cause delays in the approval or rejection of anapplication. Even if the FDA approves a product candidate, theapproval may impose significant restrictions on the indicated uses,conditions for use, labeling, advertising, promotion, marketingand/or production of such product, and may impose ongoingrequirements for post-approval studies, including additionalresearch and development and clinical trials. The approval may alsoimpose REMS on a product if the FDA believes there is a reason tomonitor the safety of the drug in the marketplace. REMS may includerequirements for additional training for health care professionals,safety communication efforts and limits on channels ofdistribution, among other things. The sponsor would be required toevaluate and monitor the various REMS activities and adjust them ifneed be. The FDA also may impose various civil or criminalsanctions for failure to comply with regulatory requirements,including withdrawal of product approval.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Furthermore,the approval procedure and the time required to obtain approvalvaries among countries and can involve additional testing beyondthat required by the FDA. Approval by one regulatory authority doesnot ensure approval by regulatory authorities in otherjurisdictions. The FDA has substantial discretion in the approvalprocess and may refuse to accept any application or may decide thatour data are insufficient for approval and require additionalpreclinical, clinical or other studies.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, varying interpretations of the data obtained forpreclinical and clinical testing could delay, limit or preventregulatory approval of a product candidate. Even if we submit anapplication to the FDA for marketing approval of a productcandidate, it may not result in marketing approval from theFDA.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We donot expect to receive regulatory approval for the commercial saleof any of our product candidates that are in development in thenear future, if at all. The inability to obtain FDA approval orapproval from comparable authorities in other countries for ourproduct candidates would prevent us or any potential futurecollaborators from commercializing these product candidates in theUnited States or other countries.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           30          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         The regulatory approval process is lengthy, expensive anduncertain, and may prevent us from obtaining the approvals that werequire.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Governmentauthorities in the United States and other countries extensivelyregulate the advertising, labeling, storage, record-keeping,safety, efficacy, research, development, testing, manufacture,promotion, marketing, and distribution of drug products. Drugs aresubject to rigorous regulation in the United States by the FDA andsimilar regulatory bodies in other countries. The steps ordinarilyrequired by the FDA before a new drug may be marketed in the UnitedStates include:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           completion ofnon-clinical tests including preclinical laboratory and formulationstudies and animal testing and toxicology;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           submission to theFDA of an IND application, which must become effective beforeclinical trials may begin, and which may be placed on“clinical hold” by the FDA, meaning the trial may notcommence, or must be suspended or terminated prior tocompletion;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           performance ofadequate and well-controlled Phase 1, 2 and 3 human clinical trialsto establish the safety and efficacy of the drug for each proposedindication, and potentially post-approval or Phase 4 studies tofurther define the drug’s efficacy and safety, generally orin specific patient populations;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           submission to theFDA of an NDA that must be accompanied by a substantial “userfee” payment;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           FDA review andapproval of the NDA before any commercial marketing or sale;and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           compliance withpost-approval commitments and requirements.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           31          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Satisfactionof FDA pre-market approval requirements for new drugs typicallytakes a number of years and the actual time required for approvalmay vary substantially based upon the type, complexity and noveltyof the product or disease to be treated by the drug. The results ofproduct development, preclinical studies and clinical trials aresubmitted to the FDA as part of an NDA. The NDA also must containextensive manufacturing information, demonstrating compliance withapplicable GMP requirements. Once the submission has been acceptedfor filing, the FDA generally has twelve months to review theapplication and respond to the applicant. Such response may be anapproval or may be a “complete response letter”outlining additional data or steps that must be completed prior tofurther FDA review of the NDA. The review process is oftensignificantly extended by FDA requests for additional informationor clarification. Success in early-stage clinical trials does notassure success in later stage clinical trials. Data obtained fromclinical trials is not always conclusive and may be susceptible tovarying interpretations that could delay, limit or preventregulatory approval. The FDA may refer the NDA to an advisorycommittee for review, evaluation and recommendation as to whetherthe application should be approved, but the FDA is not bound by therecommendation of the advisory committee. The FDA may deny or delayapproval of applications that do not meet applicable regulatorycriteria or if the FDA determines that the clinical data do notadequately establish the safety and efficacy of the drug.Therefore, our proposed products could take a significantly longertime than we expect or may never gain approval. If regulatoryapproval is delayed or never obtained, our business, financialcondition and results of operations would be materially adverselyaffected.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Some ofour products or product candidates may be used in combination witha drug delivery device, such as an injector or other deliverysystem. Vyleesi is considered a drug-device combination productbecause of its injection delivery device. Medical productscontaining a combination of new drugs, biological products ormedical devices are regulated as “combination products”in the United States. A combination product generally is defined asa product comprised of components from two or more regulatorycategories (e.g., drug/device, device/biologic, drug/biologic).Each component of a combination product is subject to therequirements established by the FDA for that type of component,whether a new drug, biologic or device. In order to facilitatepre-market review of combination products, the FDA designates oneof its centers to have primary jurisdiction for the pre-marketreview and regulation of the overall product based upon adetermination by the FDA of the primary mode of action of thecombination product. The determination whether a product is acombination product or two separate products is made by the FDA ona case-by-case basis. Our product candidates intended for use withsuch devices, or expanded indications that we may seek for ourproducts used with such devices, may not be approved or may besubstantially delayed in receiving approval if the devices do notgain and/or maintain their own regulatory approvals or clearances.Where approval of the drug product and device is sought under asingle application, the increased complexity of the review processmay delay approval. In addition, because these drug deliverydevices are provided by single source unaffiliated third-partycompanies, we are dependent on the sustained cooperation and effortof those third-party companies both to supply the devices, maintaintheir own regulatory compliance, and, in some cases, to conduct thestudies required for approval or other regulatory clearance of thedevices. We are also dependent on those third-party companiescontinuing to maintain such approvals or clearances once they havebeen received. Failure of third-party companies to supply thedevices, to successfully complete studies on the devices in atimely manner, or to obtain or maintain required approvals orclearances of the devices, and maintain compliance with allregulatory requirements, could result in increased developmentcosts, delays in or failure to obtain regulatory approval anddelays in product candidates reaching the market or in gainingapproval or clearance for expanded labels for newindications.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           32          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Uponapproval, a product candidate may be marketed only in those dosageforms and for those indications approved by the FDA. Once approved,the FDA may withdraw the product approval if compliance withregulatory requirements is not maintained or if problems occurafter the product reaches the marketplace. In addition, the FDA mayrequire postmarketing studies, referred to as Phase 4 studies, tomonitor the approved products in a specific subset of patients or alarger number of patients than were required for product approvaland may limit further marketing of the product based on the resultsof these post-market studies. The FDA has broad post-marketregulatory and enforcement powers, including the ability to seekinjunctions, levy fines and civil penalties, criminal prosecution,withdraw approvals and seize products or requestrecalls.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ifregulatory approval of any of our product candidates is granted, itwill be limited to certain disease states or conditions, patientpopulations, duration, or frequency of use, and will be subject toother conditions as set forth in the FDA-approved labeling. Adverseexperiences with the product must be reported to the FDA and couldresult in the imposition of market restriction through labelingchanges or in product removal. Product approvals may be withdrawnif compliance with regulatory requirements is not maintained or ifproblems concerning safety or efficacy of the product occurfollowing approval.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Outsidethe United States, our ability to market our product candidateswill also depend on receiving marketing authorizations from theappropriate regulatory authorities. The foreign regulatory approvalprocess generally includes all of the risks associated with FDAapproval described above. The requirements governing the conduct ofclinical trials and marketing authorization vary widely fromcountry to country. At present, foreign marketing authorizationsare applied for at a national level, although within the EuropeanCommunity (“EC”), registration procedures are availableto companies wishing to market a product to more than one EC memberstate. If the regulatory authority is satisfied that adequateevidence of safety, quality and efficiency has been presented, amarketing authorization will be granted. If we do not obtain, orexperience difficulties in obtaining, such marketingauthorizations, our business, financial condition and results ofoperations may be materially adversely affected.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         The FDA has required that two postmarketing studies and a clinicaltrial be conducted on Vyleesi.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In itsapproval of Vyleesi, under the FFDCA the FDA imposed certainpostmarketing requirements, consisting of two studies, one aprospective, registry-base, observational cohort study thatcompares obstetrical, maternal, fetal/neonatal, and infant outcomesin women exposed to Vyleesi during pregnancy to an internal,unexposed cohort of pregnant women, and the other a retrospectivecohort study using electronic claims data that compares maternal,fetal/neonatal, and infant outcomes in women exposed to Vyleesiduring pregnancy to an internal, unexposed cohort of pregnantwomen, and one clinical trial in lactating women who have receivedVyleesi to assess potential adverse effects in the breastfed infantand measure bremelanotide concentrations in breast milk using avalidated assay. We are evaluating requirements, timelines andcosts for these studies and the clinical trial. We do not know theoutcomes of the studies or the clinical trial, and do not knowwhether the outcomes would adversely affect approvals ofVyleesi.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Legislative or regulatory healthcare reforms in the United Statesmay make it more difficult and costly for us to obtain regulatoryclearance or approval of any future product candidates and toproduce, market and distribute our products after clearance orapproval is obtained.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Fromtime to time, legislation is drafted and introduced in Congress,and court decisions are issued, that could significantly change thestatutory provisions governing the regulatory clearance orapproval, manufacture and marketing of regulated products or thereimbursement thereof. In addition, FDA regulations and guidanceare often revised or reinterpreted by the FDA in ways that maysignificantly affect our business and our products. Any newregulations or revisions or reinterpretations of existingregulations may impose additional costs or lengthen review times ofVyleesi for HSDD or any future product candidates. We cannotdetermine what effect changes in regulations, statutes, courtdecisions, legal interpretation or policies, when and ifpromulgated, enacted, issued or adopted may have on our business inthe future. Such changes could, among other things:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           require changes tomanufacturing methods;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           require recall,replacement or discontinuance of one or more of ourproducts;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           require additionalrecordkeeping;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           limit or restrictour ability to engage in certain types of marketing or promotionalactivities;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           alter or eliminatethe scope or terms of any currently available regulatoryexclusivities; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           restrict oreliminate our ability to settle any patent litigation we may bringagainst potential generic competitors.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           33          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Each ofthese would likely entail substantial time and cost and couldmaterially harm our business and our financial results. Inaddition, delays in receipt of or failure to receive regulatoryclearances or approvals for any future products would harm ourbusiness, financial condition, and results ofoperations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Changes in healthcare policy could adversely affect ourbusiness.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourindustry is highly regulated, and changes in law may adverselyimpact our business, operations, or financial results. In the U.S.,there have been and continue to be a number of legislativeinitiatives to contain healthcare costs. For example, the PatientProtection and Affordable Care Act of 2010, as amended by theHealth Care and Education Reconciliation Act of 2010 (the“PPACA”) is a sweeping measure intended to, among otherthings, expand healthcare coverage within the U.S., primarilythrough the imposition of health insurance mandates on employersand individuals and expansion of the Medicaid program. Severalprovisions of the law have affected us and increased certain of ourcosts. Since its enactment, there have been executive, judicial,and congressional challenges to certain aspects of the PPACA. Inaddition, other legislative changes have been adopted since thePPACA was enacted. Some of these changes have resulted inadditional reductions in Medicare and other healthcarefunding.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weanticipate that the PPACA, as well as other healthcare reformmeasures that may be adopted in the future in the U.S. or abroad,may result in more rigorous coverage criteria and an additionaldownward pressure on the reimbursement our customers may receivefor our products. Recently there has been heightened governmentalscrutiny in countries worldwide over the manner in whichmanufacturers set prices for their marketed products.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In theU.S., there have been several recent congressional inquiries andproposed and enacted federal and state legislation designed to,among other things, bring more transparency to drug pricing, reviewthe relationship between pricing and manufacturer patient programs,reduce the cost of drugs under Medicare, and reform governmentprogram reimbursement methodologies for drug products. For example,at the federal level, during the former Trump administration therewere multiple executive orders issued, initiatives implemented andcalls for legislation form Congress to reduce drug prices, increasecompetition and reduce out of pocket costs of drugs for patients.The likelihood of implementation of any of the former Trumpadministration healthcare reform initiatives is uncertain,particularly in light of the new Biden administration and itsimplementation of a regulatory freeze. Any reduction inreimbursement from Medicare and other government programs mayresult in a similar reduction in payments from private payers. Inaddition, individual states in the U.S. have also increasinglypassed legislation and implemented regulations designed to controlpharmaceutical product pricing, including price or patientreimbursement constraints, discounts, restrictions on certainproduct access and marketing cost disclosure and transparencymeasures, and, in some cases, designed to encourage importationfrom other countries and bulk purchasing. Moreover, regionalhealthcare authorities and individual hospitals are increasinglyusing bidding procedures to determine what pharmaceutical productsand which suppliers will be included in their prescription drug andother healthcare programs. Further, it is possible that additionalgovernmental action is taken in response to the COVID-19pandemic.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Legallymandated price controls on payment amounts by governmental andprivate third-party payers or other restrictions could harm ourbusiness, results of operations, financial condition, andprospects. The implementation of cost containment measures or otherhealthcare reforms may prevent us from being able to generaterevenue, attain profitability or commercialize ourproducts.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Formore information regarding government healthcare reform, see“U.S. Governmental Regulation of PharmaceuticalProducts” in Part I, Item 1 of this Annual Report on Form10-K.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Risks Related to Our Intellectual Property        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If we fail to adequately protect or enforce our intellectualproperty rights or secure rights to patents of others, the value ofour intellectual property rights would diminish.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Oursuccess, competitive position and future revenues will depend inpart on our ability and the abilities of our licensors to obtainand maintain patent protection for our products, methods,processes, and other technologies, to preserve our trade secrets,to prevent third parties from infringing on our proprietary rightsand to operate without infringing the proprietary rights of thirdparties. We cannot predict:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the degree andrange of protection any patents will afford us against competitors,including whether third parties will find ways to invalidate orotherwise circumvent our patents;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           if and when patentswill be issued;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           whether or notothers will obtain patents claiming aspects similar to thosecovered by our patents and patent applications; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           whether we willneed to initiate litigation or administrative proceedings, whichmay be costly whether we win or lose.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           34          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If ourproducts, methods, processes, and other technologies infringe theproprietary rights of other parties we could incur substantialcosts and we may have to:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           obtain licenses,which may not be available on commercially reasonable terms, if atall;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           redesign ourproducts or processes to avoid infringement;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           stop using thesubject matter claimed in the patents held by others;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           pay damages;or          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           defend litigationor administrative proceedings, which may be costly whether we winor lose, and which could result in a substantial diversion of ourmanagement resources.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We may become involved in lawsuits to protect or enforce ourpatents or other intellectual property or the patents of ourlicensors, which could be expensive and timeconsuming.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Competitorsmay infringe our intellectual property, including our patents orthe patents of our licensors. As a result, we may be required tofile infringement claims to stop third-party infringement orunauthorized use. This can be expensive, particularly for a companyof our size, and time-consuming. In addition, in an infringementproceeding, a court may decide that a patent of ours is not validor is unenforceable, or may refuse to stop the other party fromusing the technology at issue on the grounds that our patent claimsdo not cover its technology or that the factors necessary to grantan injunction against an infringer are not satisfied.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Anadverse determination of any litigation or other proceedings couldput one or more of our patents at risk of being invalidated orinterpreted narrowly and could put our patent applications at riskof not issuing.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Interference,derivation, or other proceedings brought at the USPTO may benecessary to determine the priority or patentability of inventionswith respect to our patent applications or those of our licensorsor collaborators. Litigation or USPTO proceedings brought by us mayfail or may be invoked against us by third parties. Even if we aresuccessful, domestic, or foreign litigation or USPTO or foreignpatent office proceedings may result in substantial costs anddistraction to our management. We may not be able, alone or withour licensors or collaborators, to prevent misappropriation of ourproprietary rights, particularly in countries where the laws maynot protect such rights as fully as in the UnitedStates.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Furthermore,because of the substantial amount of discovery required inconnection with intellectual property litigation or otherproceedings, there is a risk that some of our confidentialinformation could be compromised by disclosure during this type oflitigation or proceedings. In addition, during the course of thiskind of litigation or proceedings, there could be publicannouncements of the results of hearings, motions or other interimproceedings or developments or public access to related documents.If investors perceive these results to be negative, the marketprice for our common stock could be significantlyharmed.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If we infringe or are alleged to infringe intellectual propertyrights of third parties, our business could be harmed.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourresearch, development and commercialization activities may infringeor otherwise violate or be claimed to infringe or otherwise violatepatents owned or controlled by other parties. There may also bepatent applications that have been filed but not published that,when issued as patents, could be asserted against us. These thirdparties could bring claims against us that would cause us to incursubstantial expenses and, if successful against us, could cause usto pay substantial damages. Further, if a patent infringement suitwere brought against us, we could be forced to stop or delayresearch, development, manufacturing or sales of the product orproduct candidate that is the subject of the suit.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As aresult of patent infringement claims, or to avoid potential claims,we may choose or be required to seek licenses from third parties.These licenses may not be available on acceptable terms, or at all.Even if we are able to obtain a license, the license would likelyobligate us to pay license fees or royalties or both, and therights granted to us might be nonexclusive, which could result inour competitors gaining access to the same intellectualproperty.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           35          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ultimately,we could be prevented from commercializing a product, or be forcedto cease some aspect of our business operations, if, as a result ofactual or threatened patent infringement claims, we are unable toenter into licenses on acceptable terms, if at all.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Therehas been substantial litigation and other proceedings regardingpatent and other intellectual property rights in the pharmaceuticalindustry. In addition to infringement claims against us, we maybecome a party to other patent litigation and other proceedings,including interference, derivation or post-grant proceedingsdeclared or granted by the USPTO and similar proceedings in foreigncountries, regarding intellectual property rights with respect toour current or future products. The cost to us of any patentlitigation or other proceeding, even if resolved in our favor,could be substantial. Some of our competitors may be able tosustain the costs of such litigation or proceedings moreeffectively than we can because of their substantially greaterfinancial resources. Patent litigation and other proceedings mayalso absorb significant management time. Uncertainties resultingfrom the initiation and continuation of patent litigation or otherproceedings could impair our ability to compete in the marketplace.The occurrence of any of the foregoing could have a materialadverse effect on our business, financial condition, or results ofoperations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Our patent applications and the enforcement or defense of ourissued patents may be impacted by the application of or changes inU.S. and foreign standards.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thestandards that the USPTO and foreign patent offices use to grantpatents are not always applied predictably or uniformly and canchange. Consequently, our pending patent applications may not beallowed and, if allowed, may not contain the type and extent ofpatent claims that will be adequate to conduct our business asplanned. Additionally, any issued patents we currently own orobtain in the future may have a shorter patent term than expectedor may not contain claims that will permit us to stop competitorsfrom using our technology or similar technology or from copying ourproduct candidates. Similarly, the standards that courts use tointerpret patents are not always applied predictably or uniformlyand may evolve, particularly as new technologies develop. Inaddition, changes to patent laws in the United States or othercountries may be applied retroactively to affect the validationenforceability, or term of our patent. For example, the U.S.Supreme Court has recently modified some legal standards applied bythe USPTO in examination of U.S. patent applications, which maydecrease the likelihood that we will be able to obtain patents andmay increase the likelihood of challenges to patents we obtain orlicense. In addition, changes to the U.S. patent system have comeinto force under the Leahy-Smith America Invents Act, or theLeahy-Smith Act, which was signed into law in September 2011. TheLeahy-Smith Act included significant changes to U.S. patent law.These include provisions that affect the way patent applicationsare prosecuted and also affect patent litigation. Under theLeahy-Smith Act, the United States transitioned in March 2013 to a“first to file” system in which the first inventor tofile a patent application will be entitled to the patent. Thirdparties are allowed to submit prior art before the issuance of apatent by the USPTO, and may become involved in opposition,derivation, reexamination,         <font style="font-style: italic">          interpartes         </font>         review or interference proceedings challenging ourpatent rights or the patent rights of others. An adversedetermination in any such submission, proceeding or litigationcould reduce the scope of, or invalidate, our patent rights, whichcould adversely affect our competitive position.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Whilewe cannot predict with certainty the impact the Leahy-Smith Act orany potential future changes to the U.S. or foreign patent systemswill have on the operation of our business, the Leahy-Smith Act andsuch future changes could increase the uncertainties and costssurrounding the prosecution of our patent applications and theenforcement or defense of our issued patents, all of which couldhave a material adverse effect on our business, results ofoperations, financial condition and cash flows and futureprospects.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We may not be able to protect our intellectual property rightsthroughout the world.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Filing,prosecuting, and defending patents on product candidates in allcountries throughout the world would be prohibitively expensive,and our intellectual property rights in some countries outside theUnited States can be less extensive than those in the UnitedStates. In addition, the laws of some foreign countries do notprotect intellectual property rights to the same extent as federaland state laws in the United States and in some cases may evenforce us to grant a compulsory license to competitors or otherthird parties. Consequently, we may not be able to prevent thirdparties from practicing our inventions in all countries outside theUnited States, or from selling or importing products made using ourinventions in and into the United States or other jurisdictions.Competitors may use our technologies in jurisdictions where we havenot obtained patent protection to develop their own products andfurther, may export otherwise infringing products to territorieswhere we have patent protection, but enforcement is not as strongas that in the United States. These products may compete with ourproducts and our patents or other intellectual property rights maynot be effective or sufficient to prevent them fromcompeting.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           36          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Manycompanies have encountered significant problems in protecting anddefending intellectual property rights in foreign jurisdictions.The legal systems of certain countries, particularly certaindeveloping countries, do not favor the enforcement of patents andother intellectual property protection, particularly those relatingto biopharmaceuticals, which could make it difficult for us to stopthe infringement of our patents or marketing of competing productsin violation of our proprietary rights generally. Proceedings toenforce our patent rights in foreign jurisdictions could result insubstantial costs and divert our efforts and attention from otheraspects of our business, could put our patents at risk of beinginvalidated or interpreted narrowly and our patent applications atrisk of not issuing and could provoke third parties to assertclaims against us. We may not prevail in any lawsuits that weinitiate, and the damages or other remedies awarded, if any, maynot be commercially meaningful. Accordingly, our efforts to enforceour intellectual property rights around the world may be inadequateto obtain a significant commercial advantage from the intellectualproperty that we develop or license.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, our ability to protect and enforce our intellectualproperty rights may be adversely affected by unforeseen changes indomestic and foreign intellectual property laws.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If we are unable to keep our trade secrets confidential, ourtechnologies and other proprietary information may be used byothers to compete against us.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition to our reliance on patents, we attempt to protect ourproprietary technologies and processes by relying on trade secretlaws and agreements with our employees and other persons who haveaccess to our proprietary information. These agreements andarrangements may not provide meaningful protection for ourproprietary technologies and processes in the event of unauthorizeduse or disclosure of such information and may not provide anadequate remedy in the event of unauthorized disclosure ofconfidential information. In addition, our competitors mayindependently develop substantially equivalent technologies andprocesses or gain access to our trade secrets or technology, eitherof which could materially or adversely affect our competitiveposition.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Risks Related to the Ownership of Our Common Stock        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Our stock price is volatile and may fluctuate in a way that isdisproportionate to our operating performance and we expect it toremain volatile, which could limit investors’ ability to sellstock at a profit.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thevolatile price of our stock makes it difficult for investors topredict the value of their investment, to sell shares at a profitat any given time or to plan purchases and sales in advance. Avariety of factors may affect the market price of our common stock.These include, but are not limited to:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           publicity regardingactual or potential clinical results relating to products underdevelopment by our competitors or us;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           delay or failure ininitiating, completing or analyzing preclinical or clinical trialsor unsatisfactory designs or results of these trials;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           interim decisionsby regulatory agencies, including the FDA, as to clinical trialdesigns, acceptable safety profiles and the benefit/risk ratio ofproducts under development;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           achievement orrejection of regulatory approvals by our competitors or byus;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           announcements oftechnological innovations or new commercial products by ourcompetitors or by us;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           developmentsconcerning proprietary rights, including patents;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           developmentsconcerning our collaborations;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           regulatorydevelopments in the United States and foreigncountries;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           economic or othercrises and other external factors;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           period-to-periodfluctuations in our revenue and other results ofoperations;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           changes in thestructure of healthcare payment systems or other actions thataffect the effective reimbursement rates for treatment regimenscontaining our products;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           changes infinancial estimates and recommendations by securities analystsfollowing our business or our industry;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           sales of our commonstock, or the perception that such sales could occur;and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the other factorsdescribed in this “Risk Factors” section.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           37          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We willnot be able to control many of these factors, and we believe thatperiod-to-period comparisons of our financial results will notnecessarily be indicative of our future performance. If ourrevenues, if any, in any particular period do not meetexpectations, we may not be able to adjust our expenditures in thatperiod, which could cause our operating results to suffer further.If our operating results in any future period fall below theexpectations of securities analysts or investors, our stock pricemay fall by a significant amount.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For the12-month period ended June 30, 2021, the price of our stock hasbeen volatile, ranging from a high of $1.30 per share to a low of$0.38 per share. In addition, the stock market in general, and themarket for biotechnology companies in particular, has experiencedextreme price and volume fluctuations that may have been unrelatedor disproportionate to the operating performance of individualcompanies. These broad market and industry factors may seriouslyharm the market price of our common stock, regardless of ouroperating performance.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         As a public company in the United States, we are subject to theSarbanes-Oxley Act of 2002 (“Sarbanes-Oxley”). We canprovide no assurance that we will, at all times, in the future beable to report that our internal controls over financial reportingare effective.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Companiesthat file reports with the SEC, including us, are subject to therequirements of Section 404 of Sarbanes-Oxley. Section 404 requiresmanagement to establish and maintain a system of internal controlover financial reporting. Ensuring that we have adequate internalfinancial and accounting controls and procedures in place toproduce accurate financial statements on a timely basis is a costlyand time-consuming effort that needs to be re-evaluated frequently.Failure on our part to have effective internal financial andaccounting controls would cause our financial reporting to beunreliable, could have a material adverse effect on our business,operating results, and financial condition, and could cause thetrading price of our common stock to falldramatically.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         If securities or industry analysts do not publish research orpublish unfavorable research about our business, our stock priceand trading volume could decline.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As asmaller company, it may be difficult for us to attract or retainthe interest of equity research analysts. A lack of researchcoverage may adversely affect the liquidity of and market price ofour common stock. We do not have any control of the equity researchanalysts or the content and opinions included in their reports. Theprice of our stock could decline if one or more equity researchanalysts downgrade our stock or issue other unfavorable commentaryor research. If one or more equity research analysts ceasescoverage of us, or fails to publish reports on us regularly, demandfor our stock could decrease, which in turn could cause our stockprice or trading volume to decline.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Holders of our preferred stock may have interests different fromour common stockholders.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We arepermitted under our certificate of incorporation to issue up to10,000,000 shares of preferred stock. We can issue shares of ourpreferred stock in one or more series and can set the terms of thepreferred stock without seeking any further approval from ourcommon stockholders. 4,030 shares of our Series A Preferred Stockremain outstanding as of September 24, 2021. Each share of Series APreferred Stock is convertible at any time, at the option of theholder, and such conversion could dilute the value of our commonstock to current stockholders and could adversely affect the marketprice of our common stock. The conversion price decreases if wesell common stock (or equivalents) for a price per share less thanthe conversion price or less than the market price of the commonstock and is also subject to adjustment upon the occurrence of amerger, reorganization, consolidation, reclassification, stockdividend or stock split which results in an increase or decrease inthe number of shares of common stock outstanding. Upon (i)liquidation, dissolution or winding up of the Company, whethervoluntary or involuntary, (ii) sale or other disposition of all orsubstantially all of the assets of the Company, or (iii) anyconsolidation, merger, combination, reorganization or othertransaction in which the Company is not the surviving entity or inwhich the shares of common stock constituting in excess of 50% ofthe voting power of the Company are exchanged for or changed intoother stock or securities, cash and/or any other property, afterpayment or provision for payment of the debts and other liabilitiesof the Company, the holders of Series A Preferred Stock will beentitled to receive, pro rata and in preference to the holders ofany other capital stock, an amount per share equal to $100 plusaccrued but unpaid dividends, if any. Any preferred stock that weissue may rank ahead of our common stock in terms of dividendpriority or liquidation premiums and may have greater voting rightsthan our common stock.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           38          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Because we do not anticipate paying any cash dividends on ourcommon stock in the foreseeable future, capital appreciation, ifany, will be your sole source of gains.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We donot anticipate paying any cash dividends in the foreseeable futureand intend to retain future earnings, if any, for the developmentand expansion of our business. Our outstanding Series A PreferredStock, consisting of 4,030 shares on September 24, 2021, providesthat we may not pay a dividend or make any distribution to holdersof any class of stock unless we first pay a special dividend ordistribution of $100 per share to the holders of the Series APreferred Stock. In addition, the terms of existing or futureagreements may limit our ability to pay dividends. As a result,capital appreciation, if any, of our common stock will be your solesource of gain for the foreseeable future.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Anti-takeover provisions of Delaware law and our charter documentsmay make potential acquisitions more difficult and could result inthe entrenchment of management.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We areincorporated in Delaware. Anti-takeover provisions of Delaware lawand our charter documents may make a change in control or effortsto remove management more difficult. Also, under Delaware law, ourboard of directors may adopt additional anti-takeover measures.Under Section 203 of the Delaware General Corporation Law, acorporation may not engage in a business combination with an“interested stockholder” for a period of three yearsafter the date of the transaction in which the person first becomesan “interested stockholder,” unless the businesscombination is approved in a prescribed manner.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We areauthorized to issue up to 300,000,000 shares of common stock. Tothe extent that we sell or otherwise issue authorized but currentlyunissued shares, this could have the effect of making it moredifficult for a third party to acquire a majority of ouroutstanding voting stock.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourcharter authorizes us to issue up to 10,000,000 shares of preferredstock and to determine the terms of those shares of stock withoutany further action by our stockholders. If we exercise this right,it could be more difficult for a third party to acquire a majorityof our outstanding voting stock.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaddition, our equity incentive plans generally permit us toaccelerate the vesting of options and other stock rights grantedunder these plans in the event of a change of control. If weaccelerate the vesting of options or other stock rights, thisaction could make an acquisition more costly.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theapplication of these provisions could have the effect of delayingor preventing a change of control, which could adversely affect themarket price of our common stock.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         We are a smaller reporting company and the reduced disclosurerequirements applicable to smaller reporting companies may make ourcommon stock less attractive to investors.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We arecurrently a “smaller reporting company” as defined inthe Exchange Act. Smaller reporting companies are able to providesimplified executive compensation disclosures in their filings andhave certain other decreased disclosure obligations in their SECfilings. We cannot predict whether investors will find our commonstock less attractive because of our reliance on the smallerreporting company exemption. If some investors find our commonstock less attractive as a result, there may be a less activetrading market for our common stock and our stock price may be morevolatile.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         As of September 24, 2021 there were 39,896,902 shares of commonstock underlying outstanding convertible preferred stock, options,restricted stock units and warrants. Stockholders may experiencedilution from the conversion of preferred stock, exercise ofoutstanding options and warrants and vesting and delivery ofrestricted stock units.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As ofSeptember 24, 2021 holders of our outstanding dilutive securitieshad the right to acquire the following amounts of underlying commonstock:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           66,059 sharesissuable on the conversion of our immediately convertible Series AConvertible Preferred Stock, subject to adjustment, for no furtherconsideration;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           21,918,500 sharesissuable upon the exercise of stock options at a weighted-averageexercise price of $0.72 per share;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           6,495,979 sharesissuable under restricted stock units which vest on dates betweenDecember 12, 2021 and June 22, 2025, subject to the fulfillment ofservice or performance conditions;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           6,776,750 shares ofcommon stock which have vested under restricted stock unitagreements, but are subject to provisions to delay delivery;and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           4,639,614 sharesissuable upon the exercise of warrants at an exercise price of$0.80 per share, all of which expire by December 6,2021.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           39          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If theholders convert, exercise, or receive these securities, or similardilutive securities we may issue in the future, stockholders mayexperience dilution in the net book value of their common stock. Inaddition, the sale or availability for sale of the underlyingshares in the marketplace could depress our stock price. We haveregistered or agreed to register for resale substantially all ofthe underlying shares listed above. Holders of registeredunderlying shares could resell the shares immediately uponissuance, which could result in significant downward pressure onour stock price.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">         Our failure to meet the continued listing requirements of the NYSEAmerican could result in a de-listing of our commonstock.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourcommon shares are listed on the NYSE American, a nationalsecurities exchange, under the symbol “PTN”. Althoughwe currently meet the NYSE American’s listing standards,which generally mandate that we meet certain requirements relatingto stockholders’ equity, market capitalization, aggregatemarket value of publicly held shares and distribution requirements,we cannot assure you that we will be able to continue to meet theNYSE American’s listing requirements. If we fail to satisfythe continued listing requirements of the NYSE American, such asthe corporate governance requirements or the minimum closing bidprice requirement, the NYSE American may take steps to de-list ourcommon stock. If the NYSE American delists our securities fortrading on its exchange, we could face significant material adverseconsequences, including:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           a limitedavailability of market quotations for our securities;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           reduced liquiditywith respect to our securities;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           a determinationthat our shares of common stock are “penny stock” whichwill require brokers trading in our shares of common stock toadhere to more stringent rules, possibly resulting in a reducedlevel of trading activity in the secondary trading market for ourshares of common stock;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           a limited amount ofnews and analyst coverage for our company; and          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           a decreased abilityto issue additional securities or obtain additional financing inthe future.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Such ade-listing would likely have a negative effect on the price of ourcommon stock and would impair your ability to sell or purchase ourcommon stock when you wish to do so. In the event of a de-listing,we may take actions to restore our compliance with the NYSEAmerican’s listing requirements, but we can provide noassurance that any such action taken by us would allow our commonstock to become listed again, stabilize the market price or improvethe liquidity of our common stock, prevent our common stock fromdropping below the NYSE American minimum bid price requirement orprevent future non-compliance with the NYSE American’slisting requirements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheNational Securities Markets Improvement Act of 1996, which is afederal statute, prevents or preempts the states from regulatingthe sale of certain securities, which are referred to as“covered securities.” Our common shares are consideredto be covered securities because they are listed on the NYSEAmerican. Although the states are preempted from regulating thesale of our securities, the federal statute does allow the statesto investigate companies if there is a suspicion of fraud, and, ifthere is a finding of fraudulent activity, then the states canregulate or bar the sale of covered securities in a particularcase. Further, if we were no longer listed on the NYSE American,our common stock would not be covered securities and we would besubject to regulation in each state in which we offer oursecurities.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">           Item1B.           <a name="item1b">            U           </a>           nresolved StaffComments          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         None.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">           <font style="color: #27405E">            Item 2.           </font>           <a name="item2">            P           </a>           roperties          </font>          <font style="font-family: Times New Roman; font-size: 13px;">           .           <br/>          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourcorporate offices are located at 4B Cedar Brook Drive, Cedar BrookCorporate Center, Cranbury, NJ 08512, where we lease approximately10,000 square feet of office space under a lease that expires inJune 2025. We also lease approximately 3,600 square feet oflaboratory space in the Township of South Brunswick, NJ under alease that expires in October 2023. We believe our presentfacilities are adequate for our current needs. We do not own anyreal property.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">           <font style="color: #27405E">            Item 3.           </font>           Legal           <a name="item3">            P           </a>           roceedings          </font>          <font style="font-family: Times New Roman; font-size: 13px;">           .          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>        <br/>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We areinvolved, from time to time, in various claims and legalproceedings arising in the ordinary course of our business. We arenot currently a party to any claim or legalproceeding.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">           <font style="color: #27405E">            Item 4.           </font>           Mine Safety           <a name="item4">            D           </a>           isclosures          </font>          <font style="font-family: Times New Roman; font-size: 13px;">           .          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>        <br/>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Notapplicable.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           40          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         PART II        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 5. Market for Registrant’s Common         <a name="item5">          E         </a>         quity, Related Stockholder Matters and IssuerPurchases of Equity Securities.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourcommon stock has been listed on NYSE American under the symbol“PTN” since December 21, 1999. It previously traded onThe Nasdaq SmallCap Market under the symbol“PLTN.”        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OnSeptember 24, 2021 we had approximately 106 record holders of common stockand the closing sales price of our common stock as reported on theNYSE American was $0.46 per share. The aggregate marketvalue of the common and non-voting common equity held bynon-affiliates on such date, computed by reference to the closingsales price of our common stock on that date, was$104,429,540.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Issuer purchases of equity securities.         </font>         In certain instanceswe provide our employees with the option to withhold shares tosatisfy tax withholding amounts due from the employees upon thevesting of restricted stock units and stock options in connectionwith our 2011 Stock Incentive Plan. There were no shares withheldduring the quarter ended June 30, 2021, at the direction of theemployees as permitted under the 2011 Stock Incentive Plan in orderto pay the minimum amount of tax liability owed by the employeefrom the vesting of those units and options.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Dividends and dividend policy         </font>         . We have never declared orpaid any dividends. We currently intend to retain earnings, if any,for use in our business. We do not anticipate paying dividends inthe foreseeable future.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Dividend restrictions         </font>         . Our outstanding Series A PreferredStock, consisting of 4,030 shares on September 24, 2021, providesthat we may not pay a dividend or make any distribution to holdersof any class of stock unless we first pay a special dividend ordistribution of $100 per share to the holders of the Series APreferred Stock.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Equity compensation plan information.         </font>         <font style="font-weight: bold; font-style: italic">         </font>         Reference ismade to the information contained in the Equity Compensation Plantable contained in Item 11 of this Annual Report.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">           <font style="color: #27405E">            Item 6.           </font>           [           <a name="item6">            R           </a>           eserved]          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table;">        <div style="display: table-row;">         <div style="text-align: justify; display: table-cell; margin-left: 0px; text-indent: 0px; margin-right: 0px;">          <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">           <font style="color: #27405E">            Item 7.           </font>           Management’s           <a name="item7">            D           </a>           iscussion and Analysis of Financial Condition andResults of Operations          </font>          <font style="font-family: Times New Roman; font-size: 13px;">           .          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>        <br/>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing discussion and analysis should be read in conjunctionwith the consolidated financial statements and notes to theconsolidated financial statements filed as part of this AnnualReport.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Forward-Looking Statements        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing discussion and analysis contains forward-lookingstatements within the meaning of the federal securities laws. Youare urged to carefully review our description and examples offorward-looking statements included earlier in this Annual Reportimmediately prior to Part I, under the heading“Forward-Looking Statements.” Forward-lookingstatements are subject to risk that could cause actual results todiffer materially from those expressed in the forward-lookingstatements. You are urged to carefully review the disclosures wemake concerning risks and other factors that may affect ourbusiness and operating results, including those made in Part I,Item 1A of this Annual Report, and any of those made in our otherreports filed with the SEC. You are cautioned not to place unduereliance on the forward-looking statements included herein, whichspeak only as of the date of this document. We do not intend, andundertake no obligation, to publish revised forward-lookingstatements to reflect events or circumstances after the date ofthis document or to reflect the occurrence of unanticipatedevents.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Critical Accounting Policies and Estimates        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Oursignificant accounting policies are described in Note 2 to theconsolidated financial statements included in this Annual Report.We believe that our accounting policies and estimates relating torevenue recognition, accrued expenses and stock-based compensationare the most critical         <font style="font-style: italic">          .         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; color: #000000; font-family: Times New Roman; font-size: 13px">         Revenue Recognition        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Werecognize product revenues in accordance with Accounting StandardsCodification (“ASC”) 606, Revenue from Contracts withCustomers (ASC 606). The provisions of ASC 606 require thefollowing steps to determine revenue recognition: (1) Identify thecontract(s) with a customer; (2) Identify the performanceobligations in the contract; (3) Determine the transaction price;(4) Allocate the transaction price to the performance obligationsin the contract; and (5) Recognize revenue when (or as) the entitysatisfies a performance obligation.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           41          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaccordance with ASC 606, we recognize revenue when our performanceobligation is satisfied by transferring control of the product to acustomer. Per our contracts with customers, control of the productis transferred upon the conveyance of title, which occurs when theproduct is sold to and received by a customer. Trade accountsreceivable due to us from contracts with our customers are statedseparately in the balance sheet, net of various allowances asdescribed in the Trade Accounts Receivable policy in Note 2-Summary of Significant Accounting Policies in the accompanyingFinancial Statements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Productrevenues consist of sales of Vyleesi in the United States. We sellVyleesi to specialty pharmacies at the wholesale acquisition costand payment is currently made within approximately 30 days. Inaddition to distribution agreements with customers, we enter intoarrangements with healthcare payers that provide for privatelynegotiated rebates, chargebacks, and discounts with respect to thepurchase of our products.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Werecord product revenues net of allowances for direct and indirectfees, discounts, co-pay assistance programs, estimated chargebacksand rebates. Certain of these allowances represent estimates of therelated obligations and, as such, knowledge and judgement arerequired when estimating the impact of these allowances on grossproduct sales for a reporting period. If any of our judgments madeduring a reporting period are not indicative or accurate estimatesof our future experience, our results could be materially affected.Product sales are also subject to return rights, which have notbeen significant to date.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Inventories        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inventoryis stated at the lower of cost or net realizable value, with costbeing determined on a first-in, first-out basis.  Ourinventory, consisting of Vyleesi, has a shelf-life of three yearsfrom the date of manufacture.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On aquarterly basis, we review inventory levels to determine whetherany obsolete, expired, or excess inventory exists. If any inventoryis expected to expire prior to being sold, has a cost basis inexcess of its net realizable value, is in excess of expected salesrequirements as determined by internal sales forecasts, or fails tomeet commercial sale specifications, the inventory is written downthrough a charge to operating expense. This analysis requires us tomake estimates of forecasted future sales, which are inherentlyuncertain, and changes in demand, insurance overages, economicconditions, and other factors could have a significant impact onour forecasts and therefore the estimated net realizable value ofour inventory.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <font style="font-family: Times New Roman; font-size: 13px">        <font style="font-style: italic">         Purchase Commitment Liabilities        </font>       </font>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Losseson firm commitment contractual obligations are recognized basedupon the terms of the respective agreement and similar factorsconsidered for the write-down of inventory, including expectedsales requirements as determined by internal salesforecasts        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Accrued Expenses        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thirdparties perform a significant portion of our developmentactivities. We review the activities performed under all contractseach quarter and accrue expenses and the amount of anyreimbursement to be received from our collaborators based upon theestimated amount of work completed. Estimating the value or stageof completion of certain services requires judgment based onavailable information. If we do not identify services performed forus but not billed by the service-provider, or if we underestimateor overestimate the value of services performed as of a given date,reported expenses will be understated or overstated.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Stock-Based Compensation        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weexpense the fair value of stock options and other equity awardsgranted. Compensation costs for stock-based awards with time-basedvesting are determined using the quoted market price of our commonstock on the date of grant or for stock options, the valuedetermined utilizing the Black-Scholes option pricing model, andare recognized on a straight-line basis, while awards containing amarket condition are valued using multifactor Monte Carlosimulations and are recognized over the derived service period.Compensation costs for awards containing a performance conditionare determined using the quoted price of our common stock on thedate of grant or for stock options, the value is determinedutilizing the Black Scholes option pricing model and are recognizedbased on the probability of achievement of the performancecondition over the service period. The Black-Scholes option pricingmodel requires us to make estimates of expected volatility andinterest rates, which we estimate based on prior experience andpublic sources of information. The expected term of the option usedis based upon the simplified method, which represents the averageof the vesting and contractual term. Compensation expense is notadjusted for subsequent changes in the estimates used to calculatefair value or for actual experience. Forfeitures are recognized asthey occur. As the amount and timing of compensation expense to berecorded in future periods may be affected by the achievement ofperformance conditions and employee terminations, stock-basedcompensation may vary significantly period to period.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           42          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         SeeNote 3 to the consolidated financial statements included in thisAnnual Report for a description of recent accounting pronouncementsthat affect us.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Results of Operations        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Year Ended June 30, 2021 Compared to the Year Ended June 30,2020:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Revenue –         </font>         For the fiscal year ended June 30, 2021(“fiscal 2021”) we recognized $283,286 of negativeproduct revenue, net of allowances as the result of our regainingall North American development and commercialization rights toVyleesi in July 2020 and $94,689 in license and contract revenuepursuant to our license agreement with Kwangdong. For the fiscalyear ended June 30, 2020 (“fiscal 2020”), we recognized$117,989 in revenue pursuant to our license agreement withAMAG.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Cost of Products Sold –         </font>         Cost of products sold was$147,840 for the fiscal year ended June 30, 2021.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Research and Development         </font>         – Total research anddevelopment expenses, including general research and developmentspending, were $12,926,559 for fiscal 2021 compared to $13,959,397for fiscal 2020. The decrease is a result of lower spending on ourMCr programs offset by an increase in compensation costs in fiscal2021.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Researchand development expenses related to our Vyleesi, MCr programs, andother preclinical programs were $8,634,713 and $10,187,786 infiscal 2021 and fiscal 2020, respectively. The decrease isprimarily related to a decrease in spending on our MCrprograms.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theamounts of project spending above exclude general research anddevelopment spending, which was $4,291,846 and $3,771,611 fiscal2021 and fiscal 2020, respectively. The increase in generalresearch and development spending is primarily attributable toincreased compensation costs in fiscal 2021.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Cumulativespending from inception to June 30, 2020 was approximately$311,900,000 on our Vyleesi program and approximately $167,500,000on all our other programs (which include PL8177, PL9643, othermelanocortin receptor agonists, NPR programs and terminatedprograms). Due to various risk factors described herein under“Risk Factors,” including the difficulty in currentlyestimating the costs and timing of future Phase 1 clinical trialsand larger-scale Phase 2 and Phase 3 clinical trials for anyproduct under development, we cannot predict with reasonablecertainty when, if ever, a program will advance to the next stageof development or be successfully completed, or when, if ever,related net cash inflows will be generated.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Selling, General and Administrative         </font>         – Selling, generaland administrative expenses, which consist mainly of costs relatedto Vyleesi in addition to compensation and related costs, were$17,336,913 for fiscal 2021 compared to $9,765,372 for fiscal 2020.The increase is primarily attributable to $6,605,901 of sellingexpenses related to Vyleesi and an increase in compensation relatedexpenses offset by the final payment made in connection with theGreenhill agreement and professional fees related to the Vyleesidivestiture during fiscal 2020.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Loss on License Termination Agreement         </font>         – – OnJuly 27, 2020, Palatin and AMAG announced that they had mutuallyterminated the license agreement for Vyleesi effective July 24,2020. Under the terms of the termination agreement, we regained allNorth American development and commercialization rights forVyleesi. AMAG made a $12,000,000 payment to us at closing and a$4,300,000 payment on March 31, 2021. We assumed all Vyleesimanufacturing agreements, for which we initially recorded aliability related to estimated losses of $18,194,000, as well asaccrued expenses for an inventory production run, and AMAGtransferred information, data, and assets related exclusively toVyleesi, including, but not limited to, existing inventory. AMAGprovided certain transitional services to us for a period of timeto ensure continued patient access to Vyleesi during the transitionback to us. We reimbursed AMAG for the costs of the transitionservices.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringfiscal 2021, we recorded a loss of $2,784,192 as a result of theVyleesi Termination Agreement. (See Note 4 of the accompanyingconsolidated financial statements).        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Other (Expense) Income         </font>         – Total other expense, net was$212,394 for fiscal 2021 and total other income, net was $1,180,757for fiscal 2020. For fiscal 2021, we recognized $212,526 ofunrealized foreign currency loss and $23,440 of interest expenseoffset by $23,572 of investment income. For fiscal 2020, werecognized $1,200,898 of investment income offset by $20,141 ofinterest expense. Other expense for fiscal 2021 compared to otherincome for fiscal 2020 is a result of foreign currency losses andlower interest rates earned on our cash and cashequivalents.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           43          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Income Taxes         </font>         – For fiscal 2021 and fiscal 2020, theCompany recorded no income tax benefit or expense as a result ofthe generation of and utilization of net operating losses that weresubject to a full valuation allowance.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Effects of Inflation        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We donot believe that inflation has had a material impact on ourbusiness, revenues or operating results during the periodspresented.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Liquidity and Capital Resources        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Sinceinception, we have generally incurred net operating losses,primarily related to spending on our research and developmentprograms. We have financed our net operating losses primarilythrough debt and equity financings and amounts received undercollaborative and license agreements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourproduct candidates are at various stages of development and willrequire significant further research, development and testing andsome may never be successfully developed or commercialized. We mayexperience uncertainties, delays, difficulties and expensescommonly experienced by early-stage biopharmaceutical companies,which may include unanticipated problems and additional costsrelating to:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           the development andtesting of products in animals and humans;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <br/>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px;">           dependence onthird party contractors and collaborators for part of our researchand development;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <br/>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px;">           ability to attractand retain experienced personnel;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <br/>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           product approval orclearance;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <br/>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           regulatorycompliance;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <br/>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           good manufacturingpractices (“GMP”) compliance;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <br/>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           intellectualproperty rights;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <br/>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           productintroduction;          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <br/>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           marketing, salesand competition; and          </font>         </div>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <br/>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          ●         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           obtainingsufficient capital.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Failureto enter into or successfully perform under collaborationagreements and obtain timely regulatory approval for our productcandidates and indications would impact our ability to generaterevenues and could make it more difficult to attract investmentcapital for funding our operations. Any of these possibilitiescould materially and adversely affect our operations and require usto curtail or cease certain programs.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringfiscal 2021, net cash used in operating activities was $22,647,991compared to net cash provided by operating activities of$41,326,415 in fiscal 2020. The difference in cash used inoperations in fiscal 2021 compared with cash provided by operationsin fiscal 2020 was primarily related to the timing of the receiptof payments related to revenue recorded for the AMAG LicenseAgreement, including for the FDA’s approval ofVyleesi.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringfiscal 2021, net cash used in investing activities consisted of$5,722 compared to $62,880 during fiscal 2020, which consisted ofleasehold improvements and the acquisition ofequipment.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringfiscal 2021, net cash used in financing activities was $93,638which consisted of payment of withholding taxes related torestricted stock units. During fiscal 2020 net cash used infinancing activities was $1,921,687 which consisted of payment onnotes payable obligations of $832,851, repurchase and cancellationof outstanding warrants of $2,547,466 and payment of withholdingtaxes related to restricted stock units of $122,868 offset by netproceeds from the sale of common stock of $1,581,498 in our“at-the-market” offering program.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We haveincurred cumulative negative cash flows from operations since ourinception, and have expended, and expect to continue to expend inthe future, substantial funds to develop the capability to marketand distribute Vyleesi in the United States and to complete ourplanned product development efforts. Continued operations aredependent upon our ability to generate future income from sales ofVyleesi in the United States and from existing licenses, includingroyalties and milestones, to complete equity or debt financingactivities and enter into additional licensing or collaborationarrangements. As of June 30, 2021, our cash and cash equivalentswere $60,104,919 with current liabilities of$10,511,788        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weintend to utilize existing capital resources for general corporatepurposes and working capital, including establishing marketing anddistribution capabilities for Vyleesi in the United States andpreclinical and clinical development of our MC1r and MC4r peptideprograms and natriuretic peptide program, and development of otherportfolio products.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           44          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Webelieve that our existing capital resources will be adequate tofund our planned operations through at least twelve months from thedate of issuance of these consolidated financial statements. Wewill need additional funding to complete required clinical trialsfor our product candidates and development programs and, if thoseclinical trials are successful (which we cannot predict), tocomplete submission of required regulatory applications to the FDA.However, the COVID-19 pandemic may negatively impact ouroperations, including possible effects on our financial condition,ability to access the capital markets on attractive terms or atall, liquidity, operations, suppliers, industry, and workforce. Wewill continue to evaluate the impact that these events could haveon the operations, financial position, and the results ofoperations and cash flows during fiscal year 2022 andbeyond.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We hada net loss for fiscal 2021 of $33,596,495. We may not attainprofitability in future years, which is dependent on numerousfactors, including whether and when development and salesmilestones are met, regulatory actions by the FDA and otherregulatory bodies, the performance of our licensees, and marketacceptance of our products.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weexpect to incur significant expenses as we continue to developmarketing and distribution capability for Vyleesi in the UnitedStates and continue to develop our MC1r and natriuretic peptideproduct candidates. These expenses, among other things, have hadand will continue to have an adverse effect on ourstockholders’ equity, total assets, and workingcapital.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Off-Balance Sheet Arrangements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         None.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 7A. Quantitative and         <a name="item7a">          Q         </a>         ualitative Disclosures About MarketRisk.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Notapplicable.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           45          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 8. Financial Statements and         <a name="item8">          S         </a>         upplementary Data.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Table of Contents        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         Consolidated Financial Statements        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing consolidated financial statements are filed as part ofthis Annual Report:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-bottom: 2px solid #000000">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Page             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <a href="#Report">              <font style="font-family: Times New Roman; font-size: 13px">               Report ofIndependent Registered Public Accounting Firm              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Report">              <font style="font-family: Times New Roman; font-size: 13px">               47              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <a href="#Balance">              <font style="font-family: Times New Roman; font-size: 13px">               ConsolidatedBalance Sheets              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Balance">              <font style="font-family: Times New Roman; font-size: 13px">               49              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <a href="#Operations">              <font style="font-family: Times New Roman; font-size: 13px">               ConsolidatedStatements of Operations              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Operations">              <font style="font-family: Times New Roman; font-size: 13px">               50              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <a href="#Equity">              <font style="font-family: Times New Roman; font-size: 13px">               ConsolidatedStatements of Stockholders’ Equity              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Equity">              <font style="font-family: Times New Roman; font-size: 13px">               51              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <a href="#Cash">              <font style="font-family: Times New Roman; font-size: 13px">               ConsolidatedStatements of Cash Flows              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Cash">              <font style="font-family: Times New Roman; font-size: 13px">               52              </font>             </a>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 77%">            <div style="text-align: left; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <a href="#Notes">              <font style="font-family: Times New Roman; font-size: 13px">               Notes toConsolidated Financial Statements              </font>             </a>            </div>           </td>           <td style="vertical-align: top; width: 14%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <a href="#Notes">              <font style="font-family: Times New Roman; font-size: 13px">               53              </font>             </a>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           46          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         <a name="Report">          R         </a>         eport of Independent RegisteredPublic Accounting Firm        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         To theStockholders and Board of Directors        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         PalatinTechnologies, Inc.:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Opinion on the Consolidated Financial Statements        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We haveaudited the accompanying consolidated balance sheets of PalatinTechnologies, Inc. and subsidiary (the Company) as of June 30, 2021and 2020, the related consolidated statements of operations,stockholders’ equity, and cash flows for the years thenended, and the related notes (collectively, the consolidatedfinancial statements). In our opinion, the consolidated financialstatements present fairly, in all material respects, the financialposition of the Company as of June 30, 2021 and 2020, and theresults of its operations and its cash flows for the years thenended, in conformity with U.S. generally accepted accountingprinciples.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Basis for Opinion        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theseconsolidated financial statements are the responsibility of theCompany’s management. Our responsibility is to express anopinion on these consolidated financial statements based on ouraudits. We are a public accounting firm registered with the         <font style="color: #000000">          Public Company Accounting OversightBoard (United States) (PCAOB)         </font>         and are required to beindependent with respect to the Company in accordance with the U.S.federal securities laws and the applicable rules and regulations ofthe Securities and Exchange Commission and the PCAOB.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weconducted our audits in accordance with the standards of the PCAOB.Those standards require that we plan and perform the audit toobtain reasonable assurance about whether the consolidatedfinancial statements are free of material misstatement, whether dueto error or fraud. The Company is not required to have, nor were weengaged to perform, an audit of its internal control over financialreporting. As part of our audits, we are required to obtain anunderstanding of internal control over financial reporting but notfor the purpose of expressing an opinion on the effectiveness ofthe Company’s internal control over financial reporting.Accordingly, we express no such opinion.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ouraudits included performing procedures to assess the risks ofmaterial misstatement of the consolidated financial statements,whether due to error or fraud, and performing procedures thatrespond to those risks. Such procedures included examining, on atest basis, evidence regarding the amounts and disclosures in theconsolidated financial statements. Our audits also includedevaluating the accounting principles used and significant estimatesmade by management, as well as evaluating the overall presentationof the consolidated financial statements. We believe that ouraudits provide a reasonable basis for our opinion.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Critical Audit Matter        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thecritical audit matter communicated below is a matter arising fromthe current period audit of the consolidated financial statementsthat was communicated or required to be communicated to the auditcommittee and that: (1) relates to accounts or disclosures that arematerial to the consolidated financial statements and (2) involvedour especially challenging, subjective, or complex judgments. Thecommunication of a critical audit matter does not alter in any wayour opinion on the consolidated financial statements, taken as awhole, and we are not, by communicating the critical audit matterbelow, providing a separate opinion on the critical audit matter oron the accounts or disclosures to which it relates.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           47          </font>         </div>        </div>        <div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">         <!--page break line-->        </div>        <div id="hdr">         <div style="text-align: right; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px;">         <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">          Evaluation of accrued external research and developmentexpenses         </font>         <br/>        </font>       </div>       <div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px">         Asdiscussed in Note 2 to the consolidated financial statements, thecosts of research and development activities are charged to expenseas incurred, which includes accrued external research anddevelopment expenses incurred under contracts with third parties.At the end of each quarter, the Company reviews the activitiesperformed under all contracts and accrues expenses based upon theestimated amount of work completed considering milestones achieved.Accrued research and development expenses were $1,348,075 as ofJune 30, 2021.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px">         <a name="_Hlk75248809">          <!--anchor-->         </a>         We identified the evaluation ofthe sufficiency of audit evidence over accrued external researchand development expenses as a critical audit matter. Evaluating thesufficiency of audit evidence obtained over accrued externalresearch and development expenses, including the estimated amountof work completed by third parties, required subjective auditorjudgment due to the nature and extent of evidenceavailable.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing are the primary procedures we performed to address thiscritical audit matter. We applied auditor judgment to determine thenature and extent of procedures to be performed over accruedexternal research and development expenses. For a sample of accruedexternal research and development expenses, we evaluatedmanagement’s estimate of the amount of work to be completedby comparing it to relevant third party contracts, invoices, andcommunications. For a selection of third party invoices andcommunications received after year-end, we compared the amounts tothe relevant estimate of costs incurred or estimate of the amountof work completed by third parties as determined by management. Weevaluated the sufficiency of audit evidence obtained by assessingthe results of procedures performed, including the appropriatenessof the nature and extent of such evidence.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         /s/KPMG LLP        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We haveserved as the Company’s auditor since 2002.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Philadelphia,Pennsylvania        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         September28, 2021        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           48          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td colspan="3" rowspan="1" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                <font style="font-weight:bold;">                 PALATIN TECHNOLOGIES, INC                </font>                .               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                andSubsidiary               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                Consolidated                <a name="Balance">                 B                </a>                alance Sheets               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June 30,2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June 30,2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              ASSETS             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Currentassets:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash and cashequivalents             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              60,104,919             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              82,852,270             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accountsreceivable             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,580,443             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Inventories             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,162,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Prepaid expensesand other current assets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              3,059,679             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              738,216             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total currentassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              65,907,041             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              83,590,486             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Property andequipment, net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              94,817             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              140,216             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Right-of-useassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,237,813             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,266,132             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Otherassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              56,916             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              56,916             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totalassets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              67,296,587             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              85,053,750             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              LIABILITIESAND STOCKHOLDERS’ EQUITY             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Currentliabilities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accountspayable             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              640,650             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              715,672             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accruedexpenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              5,797,378             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,899,097             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Short-termoperating lease liabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              351,853             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              312,784             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Other currentliabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              3,721,907             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total currentliabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              10,511,788             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,927,553             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Long-term operatinglease liabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              900,520             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              953,348             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Other long-termliabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              6,232,907             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totalliabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              17,645,215             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              4,880,901             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Commitments andcontingencies (Note 15)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stockholders’equity:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred stock of$0.01 par value – authorized 10,000,000 shares; shares issuedand outstanding designated as follows:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 24px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series AConvertible: authorized 264,000 shares: issued and outstanding4,030 shares as of June 30, 2021 and June 30, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              40             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              40             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Common stock of$0.01 par value – authorized 300,000,000 shares:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              issued andoutstanding 230,049,691 shares as of June 30, 2021 and 229,258,400shares as of June 30, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,300,497             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,292,584             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Additional paid-incapital             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              399,146,232             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              396,079,127             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accumulateddeficit             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (351,795,397             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (318,198,902             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Totalstockholders’ equity             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              49,651,372             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              80,172,849             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total liabilitiesand stockholders’ equity             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              67,296,587             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              85,053,750             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px">         Theaccompanying notes are an integral part of these consolidatedfinancial statements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           49          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td colspan="3" rowspan="1" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                PALATINTECHNOLOGIES, INC.               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                andSubsidiary               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                ConsolidatedStatements of                <a name="Operations">                 O                </a>                perations               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              REVENUES             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Product revenue,net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (283,286             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              License andcontract             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              94,689             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              117,989             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (188,597             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              117,989             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              OPERATINGEXPENSES             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Costof products sold             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              147,840             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Research anddevelopment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              12,926,559             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              13,959,397             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Selling, generaland administrative             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              17,336,913             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              9,765,372             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss on licensetermination agreement             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              2,784,192             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total operatingexpenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              33,195,504             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              23,724,769             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Loss fromoperations             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (33,384,101             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (23,606,780             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              OTHER (EXPENSE)INCOME             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Investmentincome             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              23,572             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,200,898             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Foreign currencyloss             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (212,526             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Interestexpense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (23,440             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (20,141             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total other(expense) income, net             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (212,394             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1,180,757             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              NETLOSS             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (33,596,495             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (22,426,023             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Basic and dilutednet loss per common share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.14             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (0.10             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Weighted averagenumber of common shares outstanding used in computing basic anddiluted net loss per common share             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              236,650,101             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              234,684,776             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theaccompanying notes are an integral part of these consolidatedfinancial statements        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           50          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         PALATIN TECHNOLOGIES, INC.        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">         and Subsidiary        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">         Consolidated Statements of Stockholders’ Equity        </font>       </div>       <br/>       <div style="text-align: left">        <table cellpadding="0" cellspacing="0" style="text-align: left; margin: 0px auto 0px 0px; width: 100%; font-size: inherit; font-family: inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align: bottom; width: 16%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-family: Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-family: Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-family: Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-family: Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Additional               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-family: Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-family: Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: bottom; width: 16%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom; width: 24%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Preferred Stock               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td colspan="2" style="vertical-align: bottom; width: 24%;">            <div>             <font style="text-align: left; display: inline-block; vertical-align: bottom; width: 10%; padding-bottom: 2px; font-size: 11px;">             </font>             <font style="text-align: center; display: inline-block; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); font-size: 11px;">              <div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">               <font>                <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                 Common Stock                </font>               </font>              </div>             </font>             <font style="text-align: left; display: inline-block; vertical-align: bottom; width: 10%; padding-bottom: 2px; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Paid-in               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Accumulated               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px; font-size: 11px;">              <div>               <font style="font-family: Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: bottom; width: 16%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Shares               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Amount               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Shares               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Amount               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Capital               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Deficit               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                Total               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Balance,June 30, 2019             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4,030             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              40             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              226,815,363             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,268,154             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              394,053,929             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (295,772,879             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              100,549,244             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 12px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Stock-basedcompensation             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              614,117             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              6,141             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,132,323             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,138,464             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 12px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Saleof common stock , net of costs             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,895,934             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              18,959             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,562,539             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,581,498             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 12px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Withholdingtaxes related to restricted stock units             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (93,875             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (939             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (121,929             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (122,868             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 12px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Warrantrepurchases             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (2,547,466             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (2,547,466             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 12px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              WarrantExercises             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              26,861             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              269             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (269             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 12px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Netloss             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (22,426,023             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (22,426,023             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              BalanceJune 30, 2020             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              4,030             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              40             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              229,258,400             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,292,584             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              396,079,127             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (318,198,902             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              80,172,849             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 12px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Stock-basedcompensation             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              958,090             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              9,581             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,159,075             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,168,656             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 12px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Withholdingtaxes related to restricted stock units             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (166,799             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (1,668             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (91,970             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (93,638             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; padding-bottom: 2px; margin-left: 12px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Netloss             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (33,596,495             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (33,596,495             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 16%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              BalanceJune 30, 2021             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              4,030             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              40             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              230,049,691             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              2,300,497             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              399,146,232             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (351,795,397             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              49,651,372             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">        <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px;">         <font style="font-family: Times New Roman; font-size: 13px">          The accompanyingnotes are an integral part of these consolidated financialstatements         </font>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           51          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td colspan="3" rowspan="1" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                PALATINTECHNOLOGIES, INC.               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                andSubsidiary               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                ConsolidatedStatements of                <a name="Cash">                 C                </a>                ash Flows               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:94%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:3%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30,               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              CASH FLOWS FROMOPERATING ACTIVITIES:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netloss             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (33,596,495             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (22,426,023             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Adjustmentsto reconcile net loss to net cash             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              (usedin) provided by operating activities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Depreciation andamortization             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              51,121             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              64,203             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash received inexcess of loss on termination agreement             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              19,084,192             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Non-cash interestexpense             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              438             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Decrease inright-of-use asset             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              330,839             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              298,558             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Unrealized foreigncurrency transaction loss             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              212,526             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stock-basedcompensation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,168,656             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,138,464             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Changes inoperating assets and liabilities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accountsreceivable             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (1,580,443             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              60,265,970             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Prepaid expensesand other assets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (1,938,130             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              22,073             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Inventories             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (987,237             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accountspayable             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (75,022             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              210,885             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Accruedexpenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              558,281             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              50,405             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operating leaseliabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (316,279             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (298,558             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Otherliabilities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (7,560,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:60px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net cash (used in)provided by operating activities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (22,647,991             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              41,326,415             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              CASH FLOWS FROMINVESTING ACTIVITIES:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Purchases ofproperty and equipment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (5,722             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (62,880             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:60px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net cash used ininvesting activities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (5,722             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (62,880             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              CASH FLOWS FROMFINANCING ACTIVITIES:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Payment ofwithholding taxes related to restricted             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              stockunits             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (93,638             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (122,868             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Payment on notespayable obligations             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (832,851             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Warrantrepurchases             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (2,547,466             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Proceeds from thesale of common stock,             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:48px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              net ofcosts             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1,581,498             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:60px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Net cash used infinancing activities             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (93,638             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (1,921,687             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              NET (DECREASE)INCREASE IN CASH AND CASH EQUIVALENTS             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (22,747,351             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              39,341,848             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              CASH AND CASHEQUIVALENTS, beginning of year             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              82,852,270             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              43,510,422             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              CASH AND CASHEQUIVALENTS, end of year             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              60,104,919             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              82,852,270             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              SUPPLEMENTAL CASHFLOW INFORMATION:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:36px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash paid forinterest             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              23,440             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              19,222             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theaccompanying notes are an integral part of these consolidatedfinancial statements        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           52          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           <a name="Notes">            N           </a>           otes to Consolidated FinancialStatements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (1)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           ORGANIZATION          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Nature of Business         </font>         - Palatin Technologies, Inc.(“Palatin” or the “Company”) is abiopharmaceutical company developing first-in-class medicines basedon molecules that modulate the activity of the melanocortin andnatriuretic peptide receptor systems. The Company’s productcandidates are targeted, receptor-specific therapeutics for thetreatment of diseases with significant unmet medical need andcommercial potential.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Melanocortin Receptor System.         </font>         The melanocortin receptor(“MCr”) system has effects on food intake, metabolism,sexual function, inflammation, and immune system responses. Thereare five melanocortin receptors, MC1r through MC5r. Modulation ofthese receptors, through use of receptor-specific agonists, whichactivate receptor function, or receptor-specific antagonists, whichblock receptor function, can have significant pharmacologicaleffects.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany’s lead product, Vyleesi®, was approved by theU.S. Food and Drug Administration (“FDA”) in June 2019and was being marketed in North America by AMAG Pharmaceuticals,Inc. (“AMAG”) for the treatment of hypoactive sexualdesire disorder (“HSDD”) in premenopausal womenpursuant to a license agreement between them for Vyleesi for NorthAmerica, which was entered into on January 8, 2017 (the “AMAGLicense Agreement”). As disclosed in Note 4, the AMAG LicenseAgreement was terminated effective July 24, 2020, and the Companyis now marketing Vyleesi in North America.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany’s new product development activities focus primarilyon MC1r agonists, with potential to treat inflammatory andautoimmune diseases such as dry eye disease, which is also known askeratoconjunctivitis sicca, uveitis, diabetic retinopathy, andinflammatory bowel disease. The Company believes that the MC1ragonist peptides in development have broad anti-inflammatoryeffects and appear to utilize mechanisms engaged by the endogenousmelanocortin system in regulation of the immune system andresolution of inflammatory responses. The Company is alsodeveloping peptides that are active at more than one melanocortinreceptor, and MC4r peptide and small molecule agonists withpotential utility in obesity and metabolic-related disorders,including rare disease and orphan indications.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Natriuretic Peptide Receptor System         </font>         . The natriuretic peptidereceptor (“NPR”) system regulates cardiovascularfunctions and tissue homeostasis, and therapeutic agents modulatingthis system have potential to treat cardiovascular and fibroticdiseases. The Company has designed and is developing potential NPRcandidate drugs selective for one or more different natriureticpeptide receptors, including natriuretic peptide receptor-A(“NPR-A”), natriuretic peptide receptor B(“NPR-B”), and natriuretic peptide receptor C(“NPR-C”).        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Business Risks and Liquidity –         </font>         Since inception, theCompany has generally incurred negative cash flows from operations,and has expended, and expects to continue to expend, substantialfunds to develop the capability to market and distribute Vyleesi inthe United States and complete its planned product developmentefforts. As shown in the accompanying consolidated financialstatements, the Company had an accumulated deficit as of June 30,2021 of $351,795,397 and a net loss for the year ended June 30,2021 of $33,596,495, and the Company anticipates incurringsignificant expenses in the future as a result of spending ondeveloping marketing and distribution capabilities for Vyleesi inthe United States and spending on its development programs and willrequire substantial additional financing or revenues to continue tofund its planned developmental activities. To achieve sustainedprofitability, if ever, the Company, alone or with others, mustsuccessfully develop and commercialize its technologies andproposed products, conduct successful preclinical studies andclinical trials, obtain required regulatory approvals andsuccessfully manufacture and market such technologies and proposedproducts. The time required to reach sustained profitability ishighly uncertain, and the Company may never be able to achieveprofitability on a sustained basis, if at all.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           53          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As ofJune 30, 2021, the Company’s cash and cash equivalents were$60,104,919 and current liabilities were $10,511,788. Managementintends to utilize existing capital resources for general corporatepurposes and working capital, including establishing marketing anddistribution capabilities for Vyleesi in the United States andpreclinical and clinical development of the Company’s MC1rand MC4r peptide programs and natriuretic peptide program, anddevelopment of other portfolio products.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Managementbelieves that the Company’s cash and cash equivalents as ofJune 30, 2021 will be sufficient to fund the Company’scurrent operating plans through at least September 2022. TheCompany will need additional funding to complete required clinicaltrials for its other product candidates and, assuming thoseclinical trials are successful, as to which there can be noassurance, to complete submission of required applications to theFDA. If the Company is unable to obtain approval or otherwiseadvance in the FDA approval process, the Company’s ability tosustain its operations could be materially adverselyaffected.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany may seek the additional capital necessary to fund itsoperations through public or private equity offerings,collaboration agreements, debt financings or licensingarrangements. Additional capital that is required by the Companymay not be available on reasonable terms, or at all.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         InMarch 2020, the World Health Organization declared COVID-19, adisease caused by a novel strain of coronavirus, a pandemic. TheCompany has taken steps to ensure the safety and well-being of itsemployees and clinical trial patients to comply with guidance fromfederal, state and local authorities, while working to ensure thesustainability of its business operations as this unprecedentedsituation continues to evolve. In mid-March 2020, the Companytransitioned to a company-wide work from home policy.Business-critical activities continue to be subject to heightenedprecautions to ensure safety of employees. The Company continues toassess its policies, business continuity plans and employeesupport.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany continues to evaluate the impact of COVID-19 on thehealthcare system and work with contract research organizationssupporting its clinical, research, and development programs tomitigate risk to patients and its business and community partners,taking into account regulatory, institutional, and governmentguidance and policies.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany receives a royalty on sales of Vyleesi by our licensees. Wehave licensed third parties to sell Vyleesi in China and Korea. TheCOVID-19 coronavirus could adversely impact the time required toobtain regulatory approvals to sell Vyleesi in China and Korea,which would delay when the Company receives royalty income fromsales in those countries.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany cannot be certain what the overall impact of the COVID-19pandemic will be on its business, including manufacturing,distribution, sales and marketing of Vyleesi, and it has thepotential to materially adversely affect its business, financialcondition and results of operations and cashflows during the fiscalyear ending June 30, 2022 (“fiscal 2022”) andbeyond.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Concentrations –         </font>         Concentrations in the Company’sassets and operations subject it to certain related risks.Financial instruments that subject the Company to concentrations ofcredit risk primarily consist of cash, cash equivalents, andaccounts receivable. The Company’s cash and cash equivalentsare primarily invested in one money market account sponsored by alarge financial institution.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (2)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           SUMMARYOF SIGNIFICANT ACCOUNTING POLICIES          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Principles of Consolidation         </font>         – The consolidatedfinancial statements include the accounts of the Company and itswholly-owned inactive subsidiary. All intercompany accounts andtransactions have been eliminated in consolidation.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Use of Estimates         </font>         – The preparation of consolidatedfinancial statements in conformity with accounting principlesgenerally accepted in the United States of America (“U.S.GAAP”) requires management to make estimates and assumptionsthat affect the reported amounts of assets and liabilities anddisclosure of contingent assets and liabilities at the date of theconsolidated financial statements and the reported amounts ofrevenues and expenses during the reporting period. Actual resultscould differ from those estimates.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           54          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Cash and Cash Equivalents         </font>         – Cash and cash equivalentsinclude cash on hand, cash in banks and all highly liquidinvestments with a purchased maturity of less than three months.Cash equivalents consist of $59,730,428 and $82,406,697 in a moneymarket account at June 30, 2021 and 2020,respectively.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Fair Value of Financial Instruments         </font>         – TheCompany’s financial instruments consist primarily of cashequivalents, accounts receivable and accounts payable. Managementbelieves that the carrying values of cash equivalents, accountsreceivable and accounts payable are representative of theirrespective fair values based on the short-term nature of theseinstruments.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Credit Risk         </font>         – Financial instruments which potentiallysubject the Company to concentrations of credit risk consistprincipally of cash, cash equivalents, and accounts receivable.Total cash and cash equivalent balances have exceeded balancesinsured by the Federal Depository Insurance Company. Currentlyaccounts receivable are due exclusively from AMAG.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 13px;">         <font style="font-family: Times New Roman; font-size: 13px">          <font style="font-style: italic; color: #000000">           Trade AccountsReceivable          </font>          <font style="color: #000000">           - Trade accountsreceivable are amounts owed to the Company by its customers forproduct that has been delivered. The trade accounts receivable isrecorded at the invoice amount, less prompt pay and otherdiscounts, chargebacks, and an allowance for credit losses, if any.Credit losses have not been significant todate.          </font>         </font>         <br/>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Inventories         </font>         – Inventory is stated at the lower of costor net realizable value, with cost being determined on a first-in,first-out basis.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On aquarterly basis, the Company reviews inventory levels to determinewhether any obsolete, expired, or excess inventory exists. If anyinventory is expected to expire prior to being sold, has a costbasis in excess of its net realizable value, is in excess ofexpected sales requirements as determined by internal salesforecasts, or fails to meet commercial sale specifications, theinventory is written down through a charge to operating expenses.Inventory consisting of Vyleesi has a shelf-life of three yearsfrom the date of manufacture.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Property and Equipment         </font>         – Property and equipmentconsists of office and laboratory equipment, office furniture andleasehold improvements and includes assets acquired under financeleases. Property and equipment are recorded at cost. Depreciationis recognized using the straight-line method over the estimateduseful lives of the related assets, generally five years forlaboratory and computer equipment, seven years for office furnitureand equipment and the lesser of the term of the lease or the usefullife for leasehold improvements. Amortization of assets acquiredunder finance leases is included in depreciation expense.Maintenance and repairs are expensed as incurred while expendituresthat extend the useful life of an asset arecapitalized.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Impairment of Long-Lived Assets         </font>         – The Company reviewsits long-lived assets for impairment whenever events or changes incircumstances indicate that the carrying amount of the assets maynot be fully recoverable. To determine recoverability of along-lived asset, management evaluates whether the estimated futureundiscounted net cash flows from the asset are less than itscarrying amount. If impairment is indicated, the long-lived assetwould be written down to fair value. Fair value is determined by anevaluation of available price information at which assets could bebought or sold, including quoted market prices, if available, orthe present value of the estimated future cash flows based onreasonable and supportable assumptions.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Leases         </font>         - At lease inception, the Company determines whetheran arrangement is or contains a lease. Operating leases areincluded in operating lease right-of-use (“ROU”)assets, current operating lease liabilities, and noncurrentoperating lease liabilities in the consolidated financialstatements. ROU assets represent the Company’s right to useleased assets over the term of the lease. Lease liabilitiesrepresent the Company’s contractual obligation to make leasepayments over the lease term. For operating leases, ROU assets andlease liabilities are recognized at the commencement date. Thelease liability is measured as the present value of the leasepayments over the lease term. The Company uses the rate implicit inthe lease if it is determinable. When the rate implicit in thelease is not determinable, the Company uses an estimate based on ahypothetical rate provided by a third party as the Companycurrently does not have issued debt. Operating ROU assets arecalculated as the present value of the remaining lease paymentsplus unamortized initial direct costs plus any prepayments less anyunamortized lease incentives received. Lease terms may includerenewal or extension options to the extent they are reasonablycertain to be exercised. The assessment of whether renewal orextension options are reasonably certain to be exercised is made atlease commencement. Factors considered in determining whether anoption is reasonably certain of exercise include, but are notlimited to, the value of any leasehold improvements, the value ofrenewal rates compared to market rates, and the presence of factorsthat would cause incremental costs to the Company if the optionwere not exercised. Lease expense is recognized on a straight-linebasis over the lease term. The Company has elected not to recognizean ROU asset and obligation for leases with an initial term oftwelve months or less. The expense associated with short termleases is included in selling, general and administrative expensein the statement of operations. To the extent a lease arrangementincludes both lease and non-lease components, the Company haselected to account for the components as a single leasecomponent.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           55          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Revenue Recognition         </font>         – We recognize product revenues inaccordance with Accounting Standards Codification(“ASC”) Topic 606,         <font style="font-style: italic">          Revenue from Contracts with Customers         </font>         .The provisions of ASC 606 require the following steps to determinerevenue recognition: (1) Identify the contract(s) with a customer;(2) Identify the performance obligations in the contract; (3)Determine the transaction price; (4) Allocate the transaction priceto the performance obligations in the contract; and (5) Recognizerevenue when (or as) the entity satisfies a performanceobligation.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inaccordance with ASC 606, we recognize revenue when our performanceobligation is satisfied by transferring control of the product to acustomer. Per our contracts with customers, control of the productis transferred upon the conveyance of title, which occurs when theproduct is sold to and received by a customer. Trade accountsreceivable due to us from contracts with our customers are statedseparately in the balance sheet, net of various allowances asdescribed in the Trade Accounts Receivable policyabove.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Productrevenues consist of sales of Vyleesi in the United States. TheCompany sells Vyleesi to specialty pharmacies at the wholesaleacquisition cost and payment is currently made within approximately30 days. In addition to distribution agreements with customers, theCompany enters into arrangements with healthcare payers thatprovide for privately negotiated rebates, chargebacks, anddiscounts with respect to the purchase of the Company’sproducts.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany records product revenues net of allowances for direct andindirect fees, discounts, co-pay assistance programs, estimatedchargebacks and rebates. Product sales are also subject to returnrights, which have not been significant to date.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Grossproduct sales were offset by product sales allowances for the yearended June 30, 2021 as follows:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr style="background-color:#cceeff;">           <td rowspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Gross productsales             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              4,745,066             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Provisionfor product sales allowances and accruals             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (5,028,352             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Netsales             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              (283,286             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Forlicenses of intellectual property, the Company assesses at contractinception whether the intellectual property is distinct from otherperformance obligations identified in the arrangement. If thelicensing of intellectual property is determined to be distinct,revenue is recognized for nonrefundable, upfront license fees whenthe license is transferred to the customer and the customer can useand benefit from the license. If the licensing of intellectualproperty is determined not to be distinct, then the license isbundled with other promises in the arrangement into one performanceobligation. The Company needs to determine if the bundledperformance obligation is satisfied over time or at a point intime. If the Company concludes that the nonrefundable, upfrontlicense fees will be recognized over time, the Company will need toassess the appropriate method of measuring proportionalperformance.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Regulatorymilestone payments are excluded from the transaction price due tothe inability to estimate the probability of reversal. Revenuerelating to achievement of these milestones is recognized in theperiod in which the milestone is achieved.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           56          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Sales-basedroyalty and milestone payments resulting from customer contractssolely or predominately for the license of intellectual propertywill only be recognized upon occurrence of the underlying sale orachievement of the sales milestone in the future and suchsales-based royalties and milestone payments will be recognized inthe same period earned.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The Company recognizes revenue for reimbursements of research anddevelopment costs under collaboration agreements as the servicesare performed. The Company records these reimbursements as revenueand not as a reduction of research and development expenses as theCompany is the principal in the research and development activitiesbased upon its control of such activities, which is considered partof its ordinary activities.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Development milestone payments are generally due 30 business daysafter the milestone is achieved. Sales milestone payments aregenerally due 45 business days after the calendar year in which thesales milestone is achieved. Royalty payments are generally due ona quarterly basis 20 business days after beinginvoiced.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Research and Development Costs         </font>         – The costs of researchand development activities are charged to expense as incurred,including the cost of equipment for which there is no alternativefuture use.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Accrued Expenses –         </font>         Third parties perform a significantportion of the Company’s development activities. The Companyreviews the activities performed under all contracts each quarterand accrues expenses and the amount of any reimbursement to bereceived from its collaborators based upon the estimated amount ofwork completed considering milestones achieved. Estimating thevalue or stage of completion of certain services requires judgmentbased on available information. If the Company does not identifyservices performed for it but not billed by the service-provider,or if it underestimates or overestimates the value of servicesperformed as of a given date, reported expenses will be understatedor overstated.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Stock-Based Compensation –         </font>         The Company charges toexpense the fair value of stock options and other equity awardsgranted. Compensation costs for stock-based awards with time-basedvesting are determined using the quoted market price of theCompany’s common stock on the date of grant or for stockoptions, the value determined utilizing the Black-Scholes optionpricing model, and are recognized on a straight-line basis, whileawards containing a market condition are valued using multifactorMonte Carlo simulations and are recognized over the derived serviceperiod. Compensation costs for awards containing a performancecondition are determined using the quoted price of theCompany’s common stock on the date of grant or for stockoptions, the value determined utilizing the Black Scholes optionpricing model and are recognized based on the probability ofachievement of the performance condition over the service period.Forfeitures are recognized as they occur.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Income Taxes         </font>         – The Company and its subsidiary fileconsolidated federal and separate-company state income tax returns.Income taxes are accounted for under the asset and liabilitymethod. Deferred tax assets and liabilities are recognized for thefuture tax consequences attributable to differences between thefinancial statement carrying amounts of assets and liabilities andtheir respective tax basis and operating loss and tax creditcarryforwards. Deferred tax assets and liabilities are measuredusing enacted tax rates expected to apply to taxable income in theyears in which those temporary differences or operating loss andtax credit carryforwards are expected to be recovered or settled.The effect on deferred tax assets and liabilities of a change intax rates is recognized in the period that includes the enactmentdate. The Company has recorded and continues to maintain a fullvaluation allowance against its deferred tax assets based on thehistory of losses incurred and lack of experience projecting futureproduct revenue and sales-based royalty and milestonepayments.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Net Loss per Common Share -         </font>         Basic and diluted loss percommon share (“EPS”) are calculated in accordance withthe provisions of Financial Accounting Standards Board(“FASB”) ASC Topic 260,         <font style="font-style: italic">          Earnings per Share         </font>         .        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For theyears ended June 30, 2021 and 2020, no additional common shareswere added to the computation of diluted EPS because to do so wouldhave been anti-dilutive. The potential number of common sharesexcluded from diluted EPS during the year ended June 30, 2021 andJune 30, 2020 was 41,264,736 and 40,890,091respectively.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           57          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Includedin the weighted average common shares used in computing basic anddiluted net loss per common share are 8,164,080 and 7,127,362vested restricted stock units that had not been issued as of June30, 2021 and 2020, respectively, due to a provision in therestricted stock unit agreements to delay delivery.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Translation of foreign currencies         </font>         - Transactions denominatedin currencies other than the Company’s functional currency(US Dollar) are recorded based on exchange rates at the time suchtransactions arise. Subsequent changes in exchange rates result intransaction gains and losses, which are reflected in theconsolidated statements of operations as unrealized (based on theapplicable period-end exchange rate) or realized upon settlement ofthe transactions.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (3)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           NEWAND RECENTLY ADOPTED ACCOUNTING PRONOUNCEMENTS          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         In May 2021, the FASB issued Accounting Standards Update(“ASU”) 2021-04, Earnings Per Share (Topic 260), Debt– Modifications and Extinguishments (Subtopic 470-50),Compensation – Stock Compensation (Topic 718), andDerivatives and Hedging – Contracts in Entity’s OwnEquity (Subtopic 815-40): Issuer’s Accounting for CertainModifications or Exchanges of Freestanding Equity-ClassifiedWritten Call Options. The FASB is issuing this update to clarifyand reduce diversity in an issuer’s accounting formodifications or exchanges of freestanding equity-classifiedwritten call options (for example, warrants) that remain equityclassified after modification or exchange. The amendments in thisupdate are effective for all entities for fiscal years beginningafter December 15, 2021, including interim periods within thosefiscal years. Early adoption is permitted. The Company is currentlyevaluating the impact the adoption of this guidance may have on itsconsolidated financial statements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; background-color: #FFFFFF">          In August 2020, the FASB issued ASU No. 2020-06,         </font>         <font style="font-style: italic; color: #000000; background-color: #FFFFFF">          Debt (Topic 470) and Derivatives and Hedging (Topic 815):Accounting for Convertible Instruments and Contracts in anEntity’s Own Equity.         </font>         <font style="color: #000000; background-color: #FFFFFF">          The amendments in thisupdate address issues identified as a result of the complexityassociated with applying U.S. GAAP for certain financialinstruments with characteristics of liabilities and equity. Theguidance is effective for public entities for fiscal yearsbeginning after December 15, 2021, and for interim periods withinthose fiscal years, with early adoption permitted. The guidance isapplicable to the Company beginning July 1, 2022. The Company iscurrently evaluating the potential effects of this guidance on itsconsolidated financial statements.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; background-color: #FFFFFF">          In December 2019, the FASB issued ASU No. 2019-12,         </font>         <font style="font-style: italic; color: #000000; background-color: #FFFFFF">          IncomeTaxes (Topic 740): Simplifying the Accounting for IncomeTaxes.         </font>         <font style="color: #000000; background-color: #FFFFFF">          The amendments in thisupdate simplify the accounting for income taxes by removing certainexceptions to the general principles in Topic 740. The amendmentsalso improve consistent application and simplify U.S. GAAP forother areas of Topic 740 by clarifying and amending existingguidance. The guidance is effective for public entities for fiscalyears beginning after December 15, 2020, and for interim periodswithin those fiscal years, with early adoption permitted. Theguidance is applicable to the Company beginning July 1, 2021. Theadoption of this standard is not expected to have a material impacton the Company’s consolidated financialstatements.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; background-color: #FFFFFF">          In November 2018, the FASB issued ASU No. 2018-18,         </font>         <font style="font-style: italic; color: #000000; background-color: #FFFFFF">          CollaborativeArrangements (Topic 808): Clarifying the Interaction between Topic808 and Topic 606.         </font>         <font style="color: #000000; background-color: #FFFFFF">         </font>         <font style="color: #000000">          Thisupdate provides clarification on the interaction between RevenueRecognition (Topic 606) and Collaborative Arrangements (Topic 808),including the alignment of unit of account guidance between the twotopics         </font>         <font style="color: #000000; background-color: #FFFFFF">          . The guidance iseffective for public entities for fiscal years beginning afterDecember 15, 2019, and for interim periods within those fiscalyears, with early adoption permitted. The guidance wasapplicable to the Company beginning July 1, 2020. The adoption ofthis standard did not have a material impact on the Company’sconsolidated financial statements.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In June2016, the FASB issued ASU No. 2016-13,         <font style="font-style: italic">          Financial Instruments - Credit Losses:Measurement of Credit Losses on Financial Instruments,         </font>         whichrequires measurement and recognition of expected credit losses forfinancial assets held at the reporting date based on historicalexperience, current conditions, and reasonable and supportableforecasts. This is different from the current guidance as this willrequire immediate recognition of estimated credit losses expectedto occur over the remaining life of many financial assets. The newguidance will be effective for the Company on July 1, 2023 withearly adoption permitted. The adoption of this standard is notexpected to have a material impact on the Company’sconsolidated financial statements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           58          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (4)          </font>         </div>         <div style="display: table-cell; width: 288px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           AGREEMENTSWITHAMAG           <br/>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OnJanuary 8, 2017, the Company entered into the AMAG LicenseAgreement pursuant to which the Company granted AMAG (i) anexclusive license in all countries of North America (the“Territory”), with the right to grant sub-licenses, toresearch, develop, and commercialize products containing Vyleesi(each a “Product”, and collectively,“Products”), (ii) a non-exclusive license in theTerritory, with the right to grant sub-licenses, to manufacture theProducts, and (iii) a non-exclusive license in all countriesoutside the Territory, with the right to grant sub-licenses, toresearch, develop, and manufacture (but not commercialize) theProducts.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Followingthe satisfaction of certain conditions to closing, the AMAG LicenseAgreement became effective on February 2, 2017. Under the AMAGLicense Agreement, in addition to certain initial and milestonepayments, AMAG reimbursed the Company for certain reasonable,documented, direct out-of-pocket expenses incurred by the Companyfollowing February 2, 2017, in connection with development andregulatory activities necessary to file a New Drug Application(“NDA”) for Vyleesi for HSDD in the United States.During year ended June 30, 2020, license and contract revenueincluded additional billings for AMAG related Vyleesi costs of$117,989.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June4, 2018, the FDA accepted the Vyleesi NDA for filing and on June21, 2019, the FDA granted approval of Vyleesi for use in the UnitedStates.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         EffectiveJuly 24, 2020, the Company entered into a termination agreement(the “Termination Agreement”) with AMAG terminating theAMAG License Agreement. Under the terms of the TerminationAgreement, the Company regained all development andcommercialization rights for Vyleesi in the Territory. AMAG made a$12,000,000 payment to the Company at closing of the TerminationAgreement and a $4,300,000 payment to the Company on March 31,2021. The Company initially recorded a liability related toestimated losses on inventory purchase commitments of $18,194,000as well as accrued expenses for an inventory production runobligation assumed of $2,300,000. The Company assumed all Vyleesimanufacturing agreements, and AMAG transferred information, data,and assets related exclusively to Vyleesi to the Company, includingexisting inventory and prepaid expenses with an estimated fairvalue of $5,817,795 as of the date of the TerminationAgreement.         <font style="font-family: Times New Roman; font-size: 13px">          As a result, theCompany initially recorded a net gain for the Termination Agreementof $1,623,795.         </font>         During the three months ended June 30, 2021,the Company reassessed the estimated net realizable value of theinventory, prepaid expenses and losses on the inventory purchasecommitments resulting in recording of a loss on TerminationAgreement of $4,407,987 for the three months ended June 30, 2021and a total loss on the Termination Agreement for the year endedJune 30, 2021 of $2,784,192.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Underthe Termination Agreement, AMAG provided certain transitionalservices to the Company for a period to ensure continued patientaccess to Vyleesi during the transition back to the Company. TheCompany reimbursed AMAG for the agreed upon costs of the transitionservices.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (5)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           MANUFACTURINGSUPPLY AGREEMENTS FOR VYLEESI          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Pursuantto the Termination Agreement, the Company assumed Vyleesimanufacturing contracts with Catalent Belgium S.A.(“Catalent”), a subsidiary of Catalent PharmaSolutions, Inc., to manufacture drug product and prefilled syringesand assemble prefilled syringes into an auto-injector device (the“Catalent Agreement”), Ypsomed AG(“Ypsomed”), to manufacture the auto-injector device(the “Ypsomed Agreement”), and Lonza Ltd.(“Lonza”), to manufacture the active pharmaceuticalingredient peptide (the “LonzaAgreement”).        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OnSeptember 29, 2020, the Company and Catalent entered into anagreement to terminate the Catalent Agreement (the “CatalentTermination Agreement”) in consideration for a one-timepayment of six million euros (€6,000,000) which was paid inOctober 2020 and accrued as part of the estimated losses oninventory purchase commitments assumed as part of the TerminationAgreement as discussed in Note 4.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           59          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany and Catalent then entered into a new Vyleesi manufacturingagreement (the “New Catalent Agreement”) which includesreduced minimum annual purchase requirements (see Note 15) ascompared to the original Catalent Agreement and modification ofother financial terms. The New Catalent Agreement provides thatCatalent will provide manufacturing and supply services to Palatinrelated to production of Vyleesi, including that Catalent willsupply specified minimums of Palatin’s requirements forVyleesi during the term of the New Catalent Agreement throughAugust 21, 2025, unless earlier terminated in accordance with theterms of the New Catalent Agreement. The initial term of the NewCatalent Agreement will be automatically extended for one 24-monthperiod unless either party notifies the other of its desire toterminate as of the end of the initial term. The New CatalentAgreement also includes customary terms and conditions relating toforecasting and minimum commitments, ordering, delivery, inspectionand acceptance, and termination, among other matters.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theterm of the Lonza Agreement is through December 31, 2022. There arespecified minimum purchase requirements under the Lonza Agreement,and under specified circumstances, termination fees may be payableupon termination of the Lonza Agreement by the Company (see Note15).        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theinitial term of the Ypsomed Agreement is through December 31, 2025,with automatic renewal for successive one-year periods unlesseither party terminates the Ypsomed Agreement by ten months’written notice prior to the expiration of the Ypsomed Agreement orany automatic renewal period. There are specified minimum purchaserequirements under the Ypsomed Agreement, and under specifiedcircumstances, termination fees may be payable upon termination ofthe Ypsomed Agreement by the Company (see Note 15).        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (6)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           AGREEMENTWITH FOSUN          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OnSeptember 6, 2017, the Company entered into a license agreementwith Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.(“Fosun”) for exclusive rights to commercialize Vyleesiin China (the “Fosun License Agreement”). Under theterms of the agreement, the Company received $4,500,000 in October2017, which consisted of an upfront payment of $5,000,000 less$500,000 that was withheld in accordance with tax withholdingrequirements in China and recorded as an expense during the yearended June 30, 2018. The Company will receive a $7,500,000milestone payment when regulatory approval in China is obtained,provided that a commercial supply agreement for Vyleesi has beenentered into. The Company has the potential to receive up to$92,500,000 in additional sales related milestone payments and highsingle-digit to low double-digit royalties on net sales in thelicensed territory. All development, regulatory, sales, marketing,and commercial activities and associated costs in the licensedterritory will be the sole responsibility of Fosun.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (7)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           AGREEMENTWITH KWANGDONG          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         OnNovember 21, 2017, the Company entered into a license agreementwith Kwangdong Pharmaceutical Co., Ltd. (“Kwangdong”)for exclusive rights to commercialize Vyleesi in Korea (the“Kwangdong License Agreement”). Under the terms of theagreement, the Company received $417,500 in December 2017,consisting of an upfront payment of $500,000, less $82,500, whichwas withheld in accordance with tax withholding requirements inKorea and recorded as an expense during the year ended June 30,2018. The Company will receive a $3,000,000 milestone payment basedon the first commercial sale in Korea. The Company has thepotential to receive up to $37,500,000 in additional sales relatedmilestone payments and mid-single-digit to low double-digitroyalties on net sales in the licensed territory. All development,regulatory, sales, marketing, and commercial activities andassociated costs in the licensed territory will be the soleresponsibility of Kwangdong. For the year ended June 30, 2021, theCompany recorded $94,689 of license and contractrevenue.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (8)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PREPAIDEXPENSES AND OTHER CURRENT ASSETS          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Prepaidexpenses         <font style="font-weight: bold">         </font>         and othercurrent assets consist of the following:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px; padding-bottom: 2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Clinical /regulatory costs             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              454,750             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              43,625             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Insurancepremiums             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              259,468             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              84,741             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Vyleesi contractualadvances             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,200,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Other             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1,145,461             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              609,850             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:4px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              3,059,679             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              738,216             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           60          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (9)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           FAIRVALUE MEASUREMENTS          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefair value of cash equivalents is classified using a hierarchyprioritized based on inputs. Level 1 inputs are quoted prices(unadjusted) in active markets for identical assets or liabilities.Level 2 inputs are quoted prices for similar assets and liabilitiesin active markets or inputs that are observable for the asset orliability, either directly or indirectly through marketcorroboration, for substantially the full term of the financialinstrument. Level 3 inputs are unobservable inputs based onmanagement’s own assumptions used to measure assets andliabilities at fair value. A financial asset’s orliability’s classification within the hierarchy is determinedbased on the lowest level input that is significant to the fairvalue measurement.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing table provides the assets carried at fairvalue:        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left: 0px; padding-bottom: 2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">              <div>               <font style="font-family: Times New Roman; font-weight: bold;">                CarryingValue               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">              <div>               <font style="font-family: Times New Roman; font-weight: bold;">                Quoted prices inactive markets(Level 1)               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">              <div>               <font style="font-family: Times New Roman; font-weight: bold;">                Otherquoted/observable inputs (Level 2)               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">              <div>               <font style="font-family: Times New Roman; font-weight: bold;">                Significantunobservable inputs(Level 3)               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              June 30,2021:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Money MarketAccount             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              59,730,428             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              59,730,428             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              June 30,2020:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Money MarketAccount             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              82,406,697             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              82,406,697             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (10)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           INVENTORIES          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inventoriesconsist of raw materials and finished goods related to Vyleesi. Thefollowing table summarizes the components of inventories as of June30, 2021:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr style="background-color:#cceeff;">           <td rowspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Rawmaterials             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              526,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Finishedgoods             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              636,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:88%;">            <div style="margin-left:0px;padding-bottom:4px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,162,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (11)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           LEASES          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany has operating leases for office and laboratory space, whichexpire on June 30, 2025 and October 31, 2023, respectively. TheCompany also has operating leases for copier equipment that expireOctober 15, 2021 and phone equipment that expires on June 30,2023.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thecomponents of lease expense are as follows:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Leasecost             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year ended June30, 2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year ended June30, 2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operating leasecost             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              287,440             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              209,226             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Variable leasecost             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              108,023             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              71,297             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Short-term leasecost             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              18,120             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total leasecost             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              395,463             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              298,643             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           61          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Supplementallease term and discount rate information related to leases was asfollows:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June 30,2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June 30,2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Weighted-averageremaining lease term (years)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3.5             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              4.6             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Weighted-averagediscount rate             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              5.50             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              5.51             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              %             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Supplementalcash flow information related to leases was asfollows:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30, 2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30, 2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Cash paid for theamounts included in the measurement of leaseliabilities:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Operatingcash flows for operating leases             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              394,926             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              318,244             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Supplementalnon-cash information on lease liabilities arisng from obtainingright-of-use assets:             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Right-of-useassets obtained in exchange for new lease obligation             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              365,881             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,339,556             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing table summarizes the maturity of the Company’soperating lease liabilities as of June 30, 2021:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Year Ending June30             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              2022             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              410,007             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              2023             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              414,374             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              2024             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              398,042             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              2025             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              265,037             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Less imputedinterest             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (235,087             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:88%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,252,373             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (12)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PROPERTYAND EQUIPMENT, NET          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Propertyand equipment, net, consists of the following:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px; padding-bottom: 2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Officeequipment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,193,162             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,193,162             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Laboratoryequipment             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              648,673             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              648,673             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Leaseholdimprovements             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              756,948             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              751,226             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,598,783             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,593,061             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Less: Accumulateddepreciation and amortization             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (2,503,966             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (2,452,845             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:4px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              94,817             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              140,216             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           62          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (13)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           ACCRUEDEXPENSES          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Accruedexpenses         <font style="font-weight: bold">         </font>         consist of thefollowing:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px; padding-bottom: 2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Clinical /regulatory costs             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              778,705             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,722,729             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Other researchrelated expenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              569,370             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              586,185             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Professionalservices             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              84,094             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              217,662             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Inventorypurchases             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,340,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Sellingexpenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,839,724             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Other             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              185,485             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              372,521             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:4px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              5,797,378             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,899,097             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-weight: bold">            (14)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-weight: bold">            NOTES PAYABLE:           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On July2, 2015, the Company closed on a $10,000,000 venture loan led byHorizon Technology Finance Corporation (“Horizon”). Thedebt facility was a four-year senior secured term loan that boreinterest at a floating coupon rate of one-month LIBOR (floor of0.50%) plus 8.50% and provided for interest-only payments for thefirst eighteen months followed by monthly payments of principal of$333,333 plus accrued interest through August 1, 2019. The lendersalso received five-year immediately exercisable Series G warrantsto purchase 549,450 shares of the Company’s common stockexercisable at an exercise price of $0.91 per share. The Companyrecorded a debt discount of $305,196 equal to the fair value ofthese warrants at issuance, which were amortized to interestexpense over the term of the related debt. This debt discount wasoffset against the note payable balance and was included inadditional paid-in capital on the Company’s balance sheet. Inaddition, a final incremental payment of $500,000 was due on August1, 2019. This final incremental payment was accreted to interestexpense over the term of the related debt and was included in othercurrent liabilities on the consolidated balance sheet as of June30, 2019. The Company incurred $146,115 of costs in connection withthe loan agreement. These costs were capitalized as deferredfinancing costs and were offset against the note payable balance.These debt issuance costs were amortized to interest expense overthe term of the related debt. During the year ended June 30, 2020,the loan matured, and on July 31, 2019, the Company made the finalincremental payment of $500,000.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           63          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (15)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           COMMITMENTSAND CONTINGENCIES          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Inventory Purchases         </font>         - As a result of the TerminationAgreement and subsequent activity, the Company has certain supplyagreements with manufacturers and suppliers, including the NewCatalent Agreement, Lonza Agreement, and Ypsomed Agreement. TheCompany is required to make certain payments for the manufactureand supply of Vyleesi. The following table summarizes thecontractual obligations under the New Catalent Agreement, LonzaAgreement, and Ypsomed Agreement as of June 30, 2021:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Total               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Current               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                1 - 3Years               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                4 - 5Years               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Inventory purchasecommitments             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              10,933,014             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,721,907             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              5,202,307             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,008,800             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As ofJune 30, 2021, the Company has $3,721,907 and $6,232,907 accruedwithin other current and long-term liabilities, respectively, inthe consolidated balance sheet related to estimated losses for firmcommitment contractual obligations under these agreements. Losseson these firm commitment contractual obligations are recognizedbased upon the terms of the respective agreement and similarfactors considered for the write-down of inventory, includingexpected sales requirements as determined by internal salesforecasts.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The commitment contractual obligation amounts above are denominatedin Swiss Francs and Euros and have been translated using period endexchange rates. The Company may experience a negative impact onfuture earnings and equity solely as a result of future foreigncurrency exchange rate fluctuations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           64          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Employment Agreements         </font>         – The Company has employmentagreements with two executive officers which provide a statedannual compensation amount, subject to annual increases, and annualbonus compensation in an amount to be approved by theCompany’s Board of Directors. Each agreement allows theCompany or the employee to terminate the agreement in certaincircumstances. In some circumstances, early termination by theCompany may result in severance pay to the employee for a period of18 to 24 months at the salary then in effect, continuation ofhealth insurance premiums over the severance period and immediatevesting of all stock options and restricted stock units.Termination following a change in control will result in a lump sumpayment of one and one-half to two times the salary then in effectand immediate vesting of all stock options and restricted stockunits.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Employee Retirement Savings Plan         </font>         – The Companymaintains a defined contribution 401(k) plan for the benefit of itsemployees. The Company currently matches a portion of employeecontributions to the plan. For the years ended June 30, 2021 and2020 Company contributions were $168,210 and $116,807,respectively.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Contingencies         </font>         – The Company accounts for litigationlosses in accordance with ASC 450-20,         <font style="font-style: italic">          Loss Contingencies         </font>         . In addition, theCompany is subject to other contingencies, such as productliability, arising in the ordinary course of business. Losscontingency provisions are recorded for probable losses whenmanagement is able to reasonably estimate the loss. Any outcomeupon settlement that deviates from the Company’s bestestimate may result in additional expense or in a reduction inexpense in a future accounting period. The Company records legalexpenses associated with such contingencies asincurred.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany is involved, from time to time, in various claims and legalproceedings arising in the ordinary course of its business. TheCompany is not currently a party to any such claims or proceedingsthat, if decided adversely to it, would either individually or inthe aggregate have a material adverse effect on its business,financial condition, or results of operations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (16)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           STOCKHOLDERS’EQUITY          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Series A Convertible Preferred Stock         </font>         – As of June30, 2021, 4,030 shares of Series A Convertible Preferred Stock wereoutstanding. Each share of Series A Convertible Preferred Stock isconvertible at any time, at the option of the holder, into thenumber of shares of common stock equal to $100 divided by theSeries A Conversion Price. As of June 30, 2021, the Series AConversion Price was $6.10, so each share of Series A ConvertiblePreferred Stock is currently convertible into approximately 16.4shares of common stock. The Series A Conversion Price is subject toadjustment, under certain circumstances, upon the sale or issuanceof common stock for consideration per share less than either (i)the Series A Conversion Price in effect on the date of such sale orissuance, or (ii) the market price of the common stock as of thedate of such sale or issuance. The Series A Conversion Price isalso subject to adjustment upon the occurrence of a merger,reorganization, consolidation, reclassification, stock dividend orstock split which will result in an increase or decrease in thenumber of shares of common stock outstanding. Shares of Series AConvertible Preferred Stock have a preference in liquidation,including certain merger transactions, of $100 per share, or$403,000 in the aggregate as of June 30, 2021. Additionally, theCompany may not pay a dividend or make any distribution to holdersof any class of stock unless the Company first pays a specialdividend or distribution of $100 per share to holders of the SeriesA Convertible Preferred Stock.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Financing Transactions         </font>         –         <font style="color: #000000">          On June 21, 2019, the Company entered into anequity distribution agreement with Canaccord Genuity LLC(“Canaccord”) (the “2019 Equity DistributionAgreement”), pursuant to which the Company may, from time totime, sell shares of the Company’s common stock         </font>         <font style="color: #000000">          at market prices by methods deemed tobe an “at-the-market offering” as defined in Rule 415promulgated under the Securities Act of 1933, as amended. The 2019Equity Distribution Agreement and related prospectus is limited tosales of up to an aggregate maximum $40.0 million of shares of theCompany’s common stock. The Company pays Canaccord 3.0% ofthe gross proceeds as a commission.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           65          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Proceeds raised under the 2019 Equity Distribution Agreement are asfollows:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30, 2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Cumulative frominception               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Shares               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Proceeds               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Shares               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Proceeds               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Grossproceeds             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,895,934             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,723,195             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              9,460,509             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              12,330,242             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Fees             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (51,697             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (369,908             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Expenses             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (90,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (90,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Netproceeds             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:4px;width:10%;font-size:13px;">             </font>             <font style="text-align: left; border-bottom:double 4px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; border-bottom:double 4px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,895,934             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:4px;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:4px;width:10%;font-size:13px;">             </font>             <font style="text-align: left; border-bottom:double 4px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; border-bottom:double 4px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,581,498             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:4px;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:4px;width:10%;font-size:13px;">             </font>             <font style="text-align: left; border-bottom:double 4px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; border-bottom:double 4px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              9,460,509             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:4px;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:4px;width:10%;font-size:13px;">             </font>             <font style="text-align: left; border-bottom:double 4px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; border-bottom:double 4px #000000;font-weight:bold;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              11,870,334             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;font-weight:bold;padding-bottom:4px;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Noproceeds were raised under the 2019 Equity Distribution Agreementduring the year ended June 30, 2021.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Stock Purchase Warrants         </font>         – On September 13, 2019, theCompany’s Board of Directors approved a plan to offer topurchase and terminate certain outstanding common stock purchasewarrants through privately negotiated transactions. The purchaseand termination program has no time limit and may be suspended forperiods or discontinued at any time.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringthe year ended June 30, 2020, the Company entered into severalwarrant termination agreements to repurchase and cancel thefollowing previously issued Series F, Series H, and Series Jwarrants for the following aggregate buyback prices:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td colspan="2" rowspan="1" style="vertical-align:bottom;width:24%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 90%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30, 2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 5%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Warrants               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Buybackprice               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series FWarrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              297,352             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              62,712             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series HWarrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,466,432             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              577,373             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series JWarrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              4,774,889             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              1,907,381             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:4px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              6,538,673             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              2,547,466             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Duringthe year ended June 30, 2020, the Company issued 26,861 shares ofcommon stock upon the cashless exercise provisions of 666,666Series D warrants at an exercise price of $0.75 pershare.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As ofJune 30, 2021, the Company had outstanding warrants exercisable forshares of common stock as follows:        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="font-family:inherit;margin-right:0px;margin-left:0px;width:100%;font-size:inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:38%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 11px;">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family:Times New Roman;font-weight:bold;">                 Shares ofCommon                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 11px;">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-family:Times New Roman;font-weight:bold;">                 Exercise Priceper                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:38%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-size: 11px;">              <font style="font-weight: bold; font-family: Times New Roman">               LatestTermination              </font>             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:38%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-size: 11px;">              <font style="font-weight: bold; font-family: Times New Roman">               Descripton              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 11px;">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">               <div>                <font style="font-family:Times New Roman;font-weight:bold;">                 Stock                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 11px;">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">               <div>                <font style="font-family:Times New Roman;font-weight:bold;">                 Share                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:38%;">            <div style="text-align: center; text-indent: 0px; margin-right: 0px; margin-left: 0px; border-bottom: 2px solid rgb(0, 0, 0);">             <font style="font-size: 11px;">              <font style="font-weight: bold; font-family: Times New Roman">               Date              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:38%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series H warrants*             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              7,974,881             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.70             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:38%;">            <div style="text-align: center; margin-left:0px;">             <font style="font-size: 13px; font-family: Times New Roman">              August 4,2021**             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:38%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Financial serviceswarrants             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              25,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.70             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:38%;">            <div style="text-align: center; margin-left:0px;">             <font style="font-size: 13px; font-family: Times New Roman">              August 4,2021**             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:38%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Series Jwarrants*             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              4,639,614             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; padding-bottom: 2px;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; padding-bottom: 2px;">              0.80             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:38%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              December 6,2021             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:38%;">            <div style="padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              12,639,495             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 5%; padding-bottom: 4px;">             </font>             <font style="text-align: right; font-family: Times New Roman; vertical-align: bottom; font-size: 13px; display: inline-block; width: 75%; padding-bottom: 4px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:38%;">            <div style="padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:38%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:38%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="4" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:2%;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:96%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                *Subject to a limitation on their exercise if the holder and itsaffiliates would beneficially own 9.99% of the total number of theCompany's shares of common stock following suchexercise.               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:2%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="4" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:2%;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:96%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                **Expired unexercised on August 4, 2021.               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:2%;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Stock Plan –         </font>         The Company’s 2011 Stock IncentivePlan (“2011 Stock Plan”) was approved by theCompany’s stockholders at the annual meeting of stockholdersheld in May 2011 and amended at the annual meeting of stockholdersheld on June 8, 2017, June 26, 2018, and again at the annualmeeting of stockholders held on June 25, 2020. The 2011 StockIncentive Plan, as amended, provides for incentive and nonqualifiedstock option grants, restricted stock unit awards and otherstock-based awards to employees, non-employee directors andconsultants for up to 42,500,000 shares of common stock. The 2011Stock Incentive Plan is administered under the direction of theBoard of Directors, which may specify grant terms and recipients.Options granted by the Company generally expire ten years from thedate of grant and generally vest over three to four years. TheCompany’s former 2005 Stock Plan was terminated and replacedby the 2011 Stock Incentive Plan, and shares of common stock thatwere available for grant under the 2005 Stock Plan became availablefor grant under the 2011 Stock Incentive Plan. No new awards can begranted under the 2005 Stock Plan, but awards granted under the2005 Stock Plan remain outstanding in accordance with their terms.As of June 30, 2021, 738,817 shares were available for grant underthe 2011 Stock Incentive Plan. The Company expects to settle optionexercises under any of its plans with authorized but currentlyunissued shares.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           66          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing table summarizes option activity and related informationfor the years ended June 30, 2021 and 2020:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Number ofShares               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Weighted AverageExercise Price               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Weighted AverageRemaining Term in Years               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                AggregateIntrinsic Value               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Outstanding - June30, 2019             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              14,435,650             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.85             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              7.3             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Granted             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              5,779,850             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.58             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Forfeited             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (235,950             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.86             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Exercised             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Expired             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (77,100             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              2.72             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Outstanding - June30, 2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              19,902,450             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.76             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              7.4             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Granted             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,546,100             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.56             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Forfeited             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (568,300             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.75             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Exercised             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Expired             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (997,750             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              0.95             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Outstanding - June30, 2021             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              21,882,500             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.72             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              7.2             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              1,034,273             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Exercisable at June30, 2021             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              13,229,109             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.75             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              6.0             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              733,738             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align:bottom;width:52%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:96px;">             <font style="font-family: Times New Roman; font-size: 13px">              Expected to vest atJune 30, 2021             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              8,653,391             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              0.68             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              9.1             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              300,535             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Stockoptions granted to the Company’s executive officers andemployees generally vest over a 48-month period, while stockoptions granted to its non-employee directors vest over a 12-monthperiod.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Includedin the options outstanding above are 1,994,500 and 188,084performance-based options granted in June 2020 to executiveofficers and employees, respectively. The performance-based optionsvest on performance criteria relating to advancement of MC1rprograms, including initiation of clinical trials and licensing ofVyleesi in additional countries or regions.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           67          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Alsoincluded in the table above are 1,075,000 and 117,500performance-based options granted in December 2017 to executiveofficers and employees, respectively, which were eligible to vestduring a performance period ended on December 31, 2020, if and uponeither i) as to 100% of the target number of shares uponachievement of a closing price for the Company’s common stockequal to or greater than $1.50 per share for 20 consecutive tradingdays, which is considered a market condition; or ii) as to thirtypercent (30%) of the target number of shares, upon the acceptancefor filing by the FDA of an NDA for Vyleesi for HSDD inpremenopausal women during the performance period, which isconsidered a performance condition; iii) as to fifty percent (50%)of the target number of shares, upon the approval by the FDA of anNDA for Vyleesi for HSDD in premenopausal women during theperformance period, which is also considered a performancecondition; iv) as to twenty percent (20%) of the target number ofshares, upon entry into a licensing agreement during theperformance period for the commercialization of Vyleesi for FemaleSexual Dysfunction (“FSD”) in at least two of thefollowing geographic areas (a) four or more countries in Europe,(b) Japan, (c) two or more countries in Central and/or SouthAmerica, (d) two or more countries in Asia, excluding Japan andChina, and (e) Australia, which is also considered a performancecondition. The fair value of these options was $602,760. TheCompany amortized the fair value over the derived service period of1.1 years or upon the attainment of the performance condition.Pursuant to the FDA acceptance of the NDA filing of Vyleesi, 30% ofthe target number of options vested in June 2018 and 50% of thetarget number of options vested in June 2019 upon FDA approval ofVyleesi. During the year ended June 30, 2021, the performanceperiod ended for the remaining performance-based stock options. Asa result, 240,000 unearned stock options were forfeited and addedback to the 2011 Stock Plan and available for futuregrant.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For theyears ended June 30, 2021 and 2020, the fair value of option grantswas estimated at the grant date using the Black-Scholes model or amulti-factor Monte Carlo simulation. The Company’s weightedaverage assumptions for the years ended June 30, 2021 and 2020 wereas follows:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Risk-free interestrate             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.0             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.5             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Volatilityfactor             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              68.3             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              67.1             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Dividendyield             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              %             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              %             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Expected optionlife (years)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              6.1             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              6.1             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Weighted averagegrant date fair value             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.34             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.33             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Expectedvolatilities are based on the Company’s historicalvolatility. The expected term of options is based upon thesimplified method, which represents the average of the vesting termand the contractual term. The risk-free interest rate is based onU.S. Treasury yields for securities with terms approximating theexpected term of the option.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For theyears ended June 30, 2021 and 2020, the Company recordedstock-based compensation related to stock options of $1,863,266 and$1,372,931, respectively. As of June 30, 2021, there was $3,154,522of unrecognized compensation cost related to unvested options,which is expected to be recognized over a weighted-average periodof 2.6 years.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Restricted Stock Units –         </font>         The following tablesummarizes restricted stock award activity for the years ended June30, 2021 and 2020.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         For theyears ended June 30, 2021 and 2020, the Company recordedstock-based compensation related to restricted stock units of$1,305,390 and $1,765,533, respectively.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Includedin outstanding restricted stock units in the table above are8,164,080 vested shares that have not been issued as of June 30,2021 due to a provision in the restricted stock unit agreements todelay delivery.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           68          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Year Ended June30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px; padding-bottom: 2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Outstanding atbeginning of year             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              12,965,570             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              10,327,833             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Granted             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,244,350             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              3,397,950             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Forfeited             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (411,068             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              (123,438             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:24px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Vested             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (958,090             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              (636,775             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Outstanding at endof year             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              14,840,762             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              12,965,570             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Time-basedrestricted stock units granted to the Company’s executiveofficers, employees and non-employee directors generally vest over48 months, 48 months, and 12 months, respectively.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In June2021, the Company granted 414,500 performance-based restrictedstock units to its executive officers and 144,080 performance-basedrestricted stock units to other employees which vest during aperformance period ending June 22, 2025. The performance-basedrestricted stock units vest on performance criteria relating toadvancement of MC1r programs, including initiation of clinicaltrials and licensing of Vyleesi in additional countries orregions.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In June2021, the Company granted 450,000 performance-based restrictedstock units to its executive officers which vest if, prior to June22, 2023, the price per share of the Company’s common stock,as traded on the NYSE American, was at least $2.00 for at leasttwenty consecutive trading days.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In June2020, the Company granted 1,203,500 performance-based restrictedstock units to its executive officers and 113,484 performance-basedrestricted stock units to other employees which vest during aperformance period ending June 24, 2024. The performance-basedrestricted stock units vest on performance criteria relating toadvancement of MC1r programs, including initiation of clinicaltrials and licensing of Vyleesi in additional countries orregions.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         In June2019, the Company granted 438,000 performance-based restrictedstock units to its executive officers and 182,725 performance-basedrestricted stock units to other employees which vest during aperformance period ending June 24, 2023. The performance-basedrestricted stock units vest on performance criteria relating toadvancement of MC1r programs, including initiation of clinicaltrials and licensing of Vyleesi in additional countries orregions.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         InDecember 2017, the Company granted 1,075,000 performance-basedrestricted stock units to its executive officers and 670,000performance-based restricted stock units to other employees whichwere eligible to vest during a performance period, ended onDecember 31, 2020, if and upon either i) as to 100% of the targetnumber of shares upon achievement of a closing price for theCompany’s common stock equal to or greater than $1.50 pershare for 20 consecutive trading days, which is considered a marketcondition; or ii) as to thirty percent (30%) of the target numberof shares, upon the acceptance for filing by the FDA of an NDA forVyleesi for HSDD in premenopausal women during the performanceperiod, which is considered a performance condition; iii) as tofifty percent (50%) of the target number of shares, upon theapproval by the FDA of an NDA for Vyleesi for HSDD in premenopausalwomen during the performance period, which is also considered aperformance condition; iv) as to twenty percent (20%) of the targetnumber of shares, upon entry into a licensing agreement during theperformance period for the commercialization of Vyleesi for FSD inat least two of the following geographic areas (a) four or morecountries in Europe, (b) Japan, (c) two or more countries inCentral and/or South America, (d) two or more countries in Asia,excluding Japan and China, and (e) Australia, which is alsoconsidered a performance condition. The fair value of these awardswas $913,750 and $569,500, respectively. The Company amortized thefair value over the derived service period of 1.1 years or upon theattainment of the performance condition. Pursuant to the FDAacceptance of the NDA filing for Vyleesi, 30% of the target numberof shares vested in June 2018. Pursuant to the FDA approval ofVyleesi, 50% of the target number of shares vested in June 2019.During the year ended June 30, 2021, the performance period endedfor the remaining performance based restricted stock units. As aresult, 319,500 unearned restricted stock units were forfeited andadded back to the 2011 Stock Plan and available for futuregrant.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           69          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inconnection with the vesting of restricted share units during theyears ended June 30, 2021 and 2020, the Company withheld 166,799and 93,875, shares, respectively, with aggregate values of $93,638and $122,868, respectively, in satisfaction of minimum taxwithholding obligations.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           (17)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           INCOMETAXES          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Forfiscal 2021 and 2020, the Company recorded no income tax expense asa result of the generation of operating losses that were subject toa full valuation allowance.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Deferredtax assets and liabilities are determined based on the estimatedfuture tax effect of differences between the financial statementand tax reporting basis of assets and liabilities, as well as for,net operating loss carryforwards and research and developmentcredit carryforwards, given the provisions of existing taxlaws.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As ofJune 30, 2021, the Company had state net operating losscarryforwards of approximately $128,200,000, which will expire, ifnot utilized, between 2034 and 2041, federal net operating losscarryforwards of approximately $109,800,000 and federal researchand development credits of approximately $6,500,000, which expire,if not utilized, between 2035 and 2041, and foreign tax credits of$582,500, which expire, if not utilized, in 2028.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Inassessing the realizability of deferred tax assets, the Companyconsiders whether it is more likely than not that some portion orall of the deferred tax assets will not be realized. The ultimaterealization of deferred tax assets is dependent upon the generationof future taxable income and the application of loss limitationprovisions related to ownership changes. The Company assesses theavailable positive and negative evidence to estimate if sufficientfuture taxable income will be generated to use the existingdeferred tax assets. The Company also considers the scheduledreversal of deferred tax liabilities (including the impact ofavailable carryback and carryforward periods), projected futuretaxable income, and tax-planning strategies in making thisassessment. Based on a history of losses incurred, the Company hasrecognized a full valuation allowance against its net deferred taxassets during the years ended June 30, 2021 and 2020. The Company'svaluation allowance increased by $9,513,000 and $5,837,000 for theyears ended June 30, 2021 and 2020,respectively.         <br/>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Asustained period of profitability in the Company’s operationsis required before it would change its judgment regarding the needfor a full valuation allowance against its net deferred tax assets.Until such time, the use of net operating loss carryforwards andtax credits to offset profits, if any, will reduce the overalllevel of deferred tax assets subject to valuationallowance.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         The TaxReform Act of 1986 (the “Act”) provides for limitationon the use of the Company’s net operating loss and researchand development tax credit carryforwards following certainownership changes (as defined by the Act) that could limit theCompany’s ability to utilize these carryforwards. Since itsinception, the Company has completed several financings and salesof common stock which has resulted in multiple ownership changesdefined by Section 382 of the Act. Accordingly, the Company’sability to utilize the aforementioned carryforwards are subject tolimitation under Section 382.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         If theCompany undergoes a future ownership change or as it completes itsSection 382 limitation assessments, any unutilized carryforwardsthat were not previously subject to a Section 382 limitation maybecome subject to limitation which may result in a significantlimitation and loss of net operating loss carryforwards andresearch and development credits.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Additionally,U.S. tax laws limit the time during which these carryforwards maybe applied against future taxes; therefore, the Company may not beable to take full advantage of these carryforwards for federalincome tax purposes. Accordingly, a portion of the carryforwardsmay expire unutilized.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           70          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           PALATIN TECHNOLOGIES, INC.          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           and Subsidiary          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">           Notes to Consolidated Financial Statements          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div>          <font style="font-family: Times New Roman; font-size: 10">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany’s net deferred tax assets are asfollows:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                June 30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                June 30,               </font>              </div>             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left: 0px; padding-bottom: 2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                2021               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman; color: rgb(0, 0, 0);">                2020               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Netoperating loss carryforwards             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              32,169,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              24,321,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Researchand development and AMT tax credits             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              6,461,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              6,443,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Foreigntax credits             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              583,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              583,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Basisdifferences in fixed assets and other             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              2,723,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              1,076,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              41,936,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:5%;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:75%;font-size:13px;">              32,423,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Valuationallowance             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (41,936,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">             </font>             <font style="text-align: right; color:#000000;border-bottom:solid 2px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              (32,423,000             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              )             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:0px;">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              Netdeferred tax assets             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:5%;font-family:Times New Roman;font-size:13px;">              $             </font>             <font style="text-align: right; color:#000000;border-bottom:double 4px #000000;vertical-align:bottom;display:inline-block;width:75%;font-family:Times New Roman;font-size:13px;">              -             </font>             <font style="text-align: left; color:#000000;font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         TheCompany recognizes interest expense and penalties on uncertainincome tax positions as a component of interest expense. Nointerest expense or penalties were recorded for uncertain incometax matters in fiscal 2021 or 2020. As of June 30, 2021 and 2020,the Company had no liabilities for uncertain income taxmatters.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           71          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 9. Changes in and Disagreements with Accountants on         <a name="item9">          A         </a>         ccounting and FinancialDisclosure.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         None.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 9A.  Controls and         <a name="item9a">          P         </a>         rocedures.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourmanagement carried out an evaluation, with the participation of ourChief Executive Officer and our Chief Financial Officer, of theeffectiveness of our disclosure controls and procedures (as definedin Rules 13a-15(e) or 15d-15(e) of the Exchange Act) as of the endof the period covered by this report. Based upon this evaluation,our Chief Executive Officer and our Chief Financial Officerconcluded that, as of June 30, 2021, our disclosure controls andprocedures were effective.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Acontrol system, no matter how well designed and operated, cannotprovide absolute assurance that the objectives of the controlsystem are met, and no evaluation of controls can provide absoluteassurance that all control issues and instances of fraud, if any,within a company have been detected.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-style: italic; font-family: Times New Roman; font-size: 13px">         Management’s Report on Internal Control Over FinancialReporting        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Managementis responsible for establishing and maintaining adequate internalcontrol over financial reporting as defined in Rule 13a-15(f) or15d-15(f) of the Exchange Act. Our internal control system wasdesigned to provide reasonable assurance to management and theboard of directors regarding the preparation and fair presentationof published financial statements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Allinternal control systems, no matter how well designed, haveinherent limitations. Therefore, even those systems determined tobe effective can provide only reasonable assurance with respect tofinancial statement preparation and presentation.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Therewas no change in our internal control over financial reportingduring the fourth quarter of the period covered by this AnnualReport that has materially affected, or is reasonably likely tomaterially affect, our internal control over financialreporting.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Managementassessed the effectiveness of our internal control over financialreporting as of June 30, 2021. In making this assessment, it usedthe criteria set forth by the Committee of Sponsoring Organizationsof the Treadway Commission (COSO) in         <font style="font-style: italic">          Internal Control-Integrated Framework asadopted in 2013         </font>         . Based on its assessment, managementbelieves that, as of June 30, 2021, our internal control overfinancial reporting is effective based on thosecriteria.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 9B.  Other         <a name="item9b">          I         </a>         nformation.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         None.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           72          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         PART III        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 10.         <a name="item10">          D         </a>         irectors, ExecutiveOfficers and Corporate Governance.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Identification of Directors        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing table sets forth the names, ages, positions and committeememberships of our current directors. All directors hold officeuntil the next annual meeting of stockholders or until theirsuccessors have been elected and qualified. All current directorswere elected at our annual stockholders’ meeting on June 8,2021.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:44%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Name              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="font-size: 11px">              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 Age                </font>               </div>              </font>              <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:44%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Position with Palatin              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Carl Spana,Ph.D.             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              59             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Chief ExecutiveOfficer, President and a Director             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              John K.A.Prendergast, Ph.D. (3)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              67             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Director, Chairmanof the Board of Directors             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Robert K. deVeer,Jr. (1) (2)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              75             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              J. Stanley Hull (1)(2)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              69             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Alan W. Dunton,M.D. (1) (2)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              67             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Arlene M. Morris(2) (3)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              69             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Anthony M. Manning,Ph.D. (1) (3)             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              59             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:44%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="3" style="vertical-align:bottom;width:100%;">            <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-size:13px;font-family:Times New Roman;">              (1) Member of theaudit committee.             </font>            </div>            <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-size:13px;font-family:Times New Roman;">              (2) Member of thecompensation committee.             </font>            </div>            <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">             <font style="font-size:13px;font-family:Times New Roman;">              (3) Member of thenominating and corporate governance committee.             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         CARLSPANA, Ph.D., co-founder of Palatin, has been our Chief ExecutiveOfficer and President since June 14, 2000. He has been a directorof Palatin since June 1996 and has been a director of our whollyowned subsidiary, RhoMed Incorporated, since July 1995. From June1996 through June 14, 2000, Dr. Spana served as an executive vicepresident and our chief technical officer. From June 1993 to June1996, Dr. Spana was vice president of Paramount CapitalInvestments, LLC, a biotechnology and biopharmaceutical merchantbanking firm, and of The Castle Group Ltd., a medical venturecapital firm. Through his work at Paramount Capital Investments andThe Castle Group, Dr. Spana co-founded and acquired several privatebiotechnology firms. From July 1991 to June 1993, Dr. Spana was aResearch Associate at Bristol-Myers Squibb, a publicly heldpharmaceutical company, where he was involved in scientificresearch in the field of immunology. Dr. Spana received his Ph.D.in molecular biology from The Johns Hopkins University and his B.S.in biochemistry from Rutgers University.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Dr.Spana’s qualifications for our board include his scientificexpertise, leadership experience, business judgment, and industryknowledge. As a senior executive of Palatin for over twenty years,he provides in-depth knowledge of our company, our drug productsunder development and the competitive and corporate partneringlandscape.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         JOHNK.A. PRENDERGAST, Ph.D., has served as the non-executive Chairmanof the board since June 14, 2000, and as a director since August1996. While Mr. Prendergast has served as a member of the board, hedoes not, and has not, served in a management or operational rolewith the company. Dr. Prendergast has been president and solestockholder of Summercloud Bay, Inc., an independent consultingfirm providing services to the biotechnology industry, since 1993.Dr. Prendergast is lead director of Heat Biologics, Inc., apublicly traded clinical stage immunotherapy company, and adirector and non-executive chairman of Recce Pharmaceuticals Ltd.,a publicly traded Australian pharmaceutical company developing anew class of anti-infective agents. He was previously a member ofthe board of the life science companies AVAX Technologies, Inc.,Avigen, Inc. and MediciNova, Inc. From October 1991 throughDecember 1997, Dr. Prendergast was a managing director of TheCastle Group Ltd., a medical venture capital firm. Dr. Prendergastreceived his M.Sc. and Ph.D. from the University of New SouthWales, Sydney, Australia and a C.S.S. in administration andmanagement from Harvard University.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Dr.Prendergast brings a historical perspective to our board coupledwith extensive industry experience in corporate development andfinance in the life sciences field. His prior service on otherpublicly traded company boards provides experience relevant to goodcorporate governance practices.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           73          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         ROBERTK. deVEER, Jr. has been a director of Palatin since November 1998.Since January 1997, Mr. deVeer has been the president of deVeerCapital LLC, a private investment company. He was a director ofSolutia Inc., a publicly held chemical-based materials company,until its merger with Eastman Chemical Company in July 2012. From1995 until his retirement in 1996, Mr. deVeer served as ManagingDirector, Head of Industrial Group, at New York-based LehmanBrothers. From 1973 to 1995, he held increasingly responsiblepositions at New York-based CS First Boston, including Head ofProject Finance, Head of Industrials and Head of Natural Resources.He was a managing director, member of the investment bankingcommittee and a trustee of the First Boston Foundation. He receiveda B.A. in economics from Yale University and an M.B.A. in financefrom Stanford Graduate School of Business.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Mr.deVeer has extensive experience in investment banking and corporatefinance, including the financing of life sciences companies, andserves as the audit committee’s financialexpert.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         J.STANLEY HULL has been a director of Palatin since September 2005.Mr. Hull has over three decades of experience in the field ofsales, marketing, and drug development. Mr. Hull joinedGlaxoSmithKline, a research-based pharmaceutical company, inOctober 1987 and retired as Senior Vice President, Pharmaceuticals– North America in May 2010. Mr. Hull was responsible for allcommercial activities including sales, marketing, sales training,and office operations. Previously Mr. Hull served in the R&amp;Dorganization of Glaxo Wellcome as Vice President and WorldwideDirector of Therapeutic Development and Product Strategy –Neurology and Psychiatry. Prior to his service in the R&amp;Dorganization he was Vice President of Marketing – InfectiousDiseases and Gastroenterology for Glaxo Wellcome-U.S. Mr. Hullstarted his career in the pharmaceutical industry with SmithKlineand French Laboratories in 1978. Mr. Hull received his B.S. inbusiness administration from the University of North Carolina atGreensboro.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Mr.Hull has extensive experience in commercial operations,development, and marketing of pharmaceutical drugs and corporatealliances between pharmaceutical companies and biotechnologycompanies.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         ALANW. DUNTON, M.D., has been a director of Palatin since June 2011. Hefounded Danerius, LLC, a biotechnology consulting company, in 2006.From November 2015 through March 2018, he was senior vice presidentof research, development, and regulatory affairs for Purdue PharmaL.P., with responsibilities for overall research strategy anddevelopment programs. From January 2007 to March 2009, Dr. Duntonserved as president and chief executive officer of PanacosPharmaceuticals Inc. and he served as a managing director ofPanacos from March 2009 to January 2011. Dr. Dunton is currently amember of the board of directors of the publicly traded companiesRecce Pharmaceuticals Ltd (ASX: RCE), CorMedix Inc. (NYSE: CRMD)and Oragenics, Inc. (NYSE: OGEN). He previously served on the boardof directors of the publicly traded companies Targacept, Inc.,EpiCept Corporation (as Non-Executive Chairman), Adams RespiratoryTherapeutics, Inc. (acquired by Reckitt Benckiser Group plc),MediciNova, Inc. and Panacos Pharmaceuticals, Inc. Dr. Dunton hasserved as a director or executive officer of various pharmaceuticalcompanies, and from 1994 to 2001, Dr. Dunton was a senior executivein various capacities in the Pharmaceuticals Group of Johnson &amp;Johnson, including president and managing director of the JanssenResearch Foundation, the primary global R&amp;D organization forJohnson &amp; Johnson. Dr. Dunton received his M.D. degree from NewYork University School of Medicine, where he completed hisresidency in internal medicine. He also was a Fellow in ClinicalPharmacology at the New York Hospital/Cornell University MedicalCenter.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Dr.Dunton has extensive drug development, regulatory, and clinicalresearch experience, having played a key role in the development ofmore than 20 products to regulatory approval, and also hasextensive experience as an executive and officer for both largepharmaceutical companies and smaller biotechnology andbiopharmaceutical companies.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         ARLENEM. MORRIS has been a director of Palatin since June 2015. Since May2015 she has served as the chief executive officer of WillowAdvisors, LLC. From April 2012 until May 2015, she was Presidentand Chief Executive Officer of Syndax Pharmaceuticals, Inc., aprivately held biopharmaceutical company focused on the developmentand commercialization of an epigenetic therapy fortreatment-resistant cancers, and was a member of the board ofdirectors from May 2011 until May 2015. From 2003 to January 2011,Ms. Morris served as the President, Chief Executive Officer and amember of the board of directors of Affymax, Inc., a publiclytraded biotechnology company. Ms. Morris has also held variousmanagement and executive positions at Clearview Projects, Inc., acorporate advisory firm, Coulter Pharmaceutical, Inc., a publiclytraded pharmaceutical company, Scios Inc., a publicly tradedbiopharmaceutical company, and Johnson &amp; Johnson, a publiclytraded healthcare company. She is currently a member of the boardof directors of Viveve Medical, Inc., a publicly traded femalehealthcare medical device company, Viridian Therapeutics, Inc., apublicly traded microRNA therapeutics company, and CogentBiosciences, Inc., a publicly traded oncology biopharmaceuticalcompany, and was a director of Neovacs SA, a publicly traded Frenchcompany, Biodel Inc., a publicly traded specialty pharmaceuticalcompany, from 2015 until its merger with Albireo Limited in 2016,and Dimension Therapeutics, Inc., a publicly traded gene therapycompany, until its acquisition by Ultragenyx Pharmaceutical Inc. in2017. Ms. Morris received a B.A. in Biology and Chemistry fromCarlow College.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           74          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ms.Morris has extensive experience in the biotechnology industry,including prior leadership positions, senior management, and boardservice, and experience as chief executive officer of companieswith product candidates in phase 3 clinical trials.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         ANTHONYM. MANNING, Ph.D., has been a director of Palatin since September2017. Since March 2021 Dr. Manning has been providing scientificand strategic advice to biotechnology companies as the principal ofManning Bio Worldwide LLC. From 2013 until March 2021, Dr. Manningwas senior vice president of research, and since 2018 was chiefscientific officer, at Momenta Pharmaceuticals, Inc., a publiclytraded biopharmaceutical company developing innovative therapeuticsfor rare immune-related diseases which was acquired by Johnson&amp; Johnson in October 2020. From 2011 to 2013, he was seniorvice president of research and development at Aileron Therapeutics,Inc., a publicly traded biopharmaceutical company developingstapled peptide therapeutics for cancers and other diseases. From2007 to 2011, he was vice president and head of inflammation andautoimmune diseases research at Biogen, Inc., a publicly tradedbiopharmaceutical company developing medicines for neurological andneurodegenerative conditions. From 2002 to 2007, he was vicepresident and global therapy area head for Inflammation,Autoimmunity and Transplantation Research at Roche Pharmaceuticals,the pharmaceutical division of Roche Holding AG, and from 2000 to2002 he was vice president of Pharmacia, a global pharmaceuticalcompany acquired by Pfizer in 2002. Dr. Manning received his Ph.D.,M.Sc. and B.Sc. from the University of Otago, Dunedin, NewZealand.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Dr.Manning has extensive experience in translational research anddevelopment of new pharmaceutical products, and in pharmaceuticaland biotechnology research, development, and businessstrategy.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         The Board and Its Committees        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Committees and meetings         </font>         . The board has an audit committee, acompensation committee, and a nominating and corporate governancecommittee. During fiscal 2021, the board met six times, the auditcommittee met four times, the compensation committee met two timesand the nominating and corporate governance committee met twotimes. Each director attended at least 75% of the total number ofmeetings of the board and committees of the board on which heserved. The independent directors meet in executive sessions atleast annually, following the annual board meeting. We do not havea policy requiring our directors to attend stockholder meetings.With the exception of Drs. Prendergast and Spana, the directors didnot attend the virtual annual meeting of stockholders held on June8, 2021.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Audit committee         </font>         . The audit committee reviews the engagementof the independent registered public accounting firm and reviewsthe independence of the independent registered public accountingfirm. The audit committee also reviews the audit and non-audit feesof the independent registered public accounting firm and theadequacy of our internal control procedures. The audit committee iscurrently composed of four independent directors, Mr. deVeer(chair), and Dr. Dunton, Dr. Manning and Mr. Hull. The board hasdetermined that the members of the audit committee are independent,as defined in the listing standards of the NYSE American, andsatisfy the requirements of the NYSE American as to financialliteracy and expertise. The board has determined that at least onemember of the committee, Mr. deVeer, is the audit committeefinancial expert as defined by Item 407 of Regulation S-K. Theresponsibilities of the audit committee are set forth in a writtencharter adopted by the board and updated as of October 1, 2013, acopy of which is available on our web site atwww.palatin.com/about-us/.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Compensation committee.         </font>         The compensation committee reviewsand recommends to the board on an annual basis employmentagreements and compensation for our officers, directors, and someemployees, and administers our 2011 Plan and the options stilloutstanding which were granted under previous stock option plans.The compensation committee is composed of Dr. Dunton (chair), Ms.Morris and Messrs. deVeer and Hull. The board has determined thatthe members of the compensation committee are independent, asdefined in the listing standards of the NYSE American. Our ChiefExecutive Officer aids the compensation committee by providingannual recommendations regarding the compensation of all executiveofficers, other than himself. Our Chief Financial Officer supportsthe committee in its work by gathering, analyzing, and presentingdata on our compensation arrangements and compensation in themarketplace.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           75          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theresponsibilities of the compensation committee are set forth in awritten charter adopted by the board effective October 1, 2013, acopy of which is available on our web site atwww.palatin.com/about-us/. The committee administers our 2011 Plan,under which it has delegated to an officer its authority to grantstock options to employees and to a single-member committee of theboard its authority to grant restricted stock units to officers andto grant options and restricted stock units to our consultants, butin either instance not to grant options or restricted stock unitsto themselves, any member of the board or officer, or any personsubject to Section 16 of the Exchange Act.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Nominating and corporate governance committee.         </font>         Thenominating and corporate governance committee assists the board inrecommending nominees for directors, and in determining thecomposition of committees. It also reviews, assesses, and makesrecommendations to the board concerning policies and guidelines forcorporate governance, including relationships of the board, thestockholders and management in determining our direction andperformance. The responsibilities of the nominating and corporategovernance committee are set forth in a written charter adopted bythe board and updated as of October 1, 2013, a copy of which isavailable on our web site at www.palatin.com/about-us/. Thenominating and corporate governance committee is composed of Dr.Prendergast (chair), Ms. Morris and Dr. Manning, each of whom meetsthe independence requirements established by the NYSEAmerican.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Duration of Office.         </font>         Unless a director resigns, all directorshold office until the next annual meeting of stockholders or untiltheir successors have been elected and qualified. Directors serveas members of committees as the board determines from time totime.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">         <br/>        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Communicating With Directors        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Generally,stockholders or other interested parties who have questions orconcerns should contact Stephen T. Wills, Secretary, PalatinTechnologies, Inc., 4B Cedar Brook Drive, Cranbury, NJ 08512.However, any stockholder or other interest party who wishes toaddress questions regarding our business directly to the board ofdirectors, or any individual director, including the Chairman ornon-management directors as a group, can direct questions to theboard members or a director by regular mail to the Secretary at theaddress above or by e-mail at boardofdirectors@palatin.com.Stockholders or other interested parties may also submit theirconcerns anonymously or confidentially by postal mail.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Communicationsare distributed to the board, or to any individual directors asappropriate, depending on the facts and circumstances outlined inthe communication, unless the Secretary determines that thecommunication is unrelated to the duties and responsibilities ofthe board, such as product inquiries, resumes, advertisements orother promotional material. Communications that are unduly hostile,threatening, illegal or similarly unsuitable will also not bedistributed to the board or any director. All communicationsexcluded from distribution will be retained and made available toany non-management director upon request.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Board Role in Risk Oversight        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Ourboard, as part of its overall responsibility to oversee themanagement of our business, considers risks generally whenreviewing our strategic plan, financial results, businessdevelopment activities, legal and regulatory matters. The boardsatisfies this responsibility through regular reports directly fromour officers responsible for oversight of particular risks. Theboard’s risk management oversight also includes full and opencommunications with management to review the adequacy andfunctionality of the risk management processes used by management.The board’s role in risk oversight has no effect on theboard’s leadership structure. In addition, committees of theboard assist in its risk oversight responsibility,including:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 36px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           The audit committeeassists the board in its oversight of the integrity of thefinancial reporting and our compliance with applicable legal andregulatory requirements. It also oversees our internal controls andcompliance activities and meets privately with representatives fromour independent registered public accounting firm.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 36px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 36px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           The compensationcommittee assists the board in its oversight of risk relating tocompensation policies and practices. The compensation committeeannually reviews our compensation policies, programs, andprocedures, including the incentives they create and mitigatingfactors that may reduce the likelihood of excessive risk taking, todetermine whether they present a significant risk to ourcompany.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           76          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Board Leadership Structure        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Since2000, the roles of chairman of the board and chief executiveofficer have been held by separate persons. John K.A. Prendergast,Ph.D., a non-employee director, has served as Chairman of the boardsince June 2000. Carl Spana, Ph.D., has been our Chief ExecutiveOfficer and President since June 2000. Generally, the chairman isresponsible for advising the chief executive officer, assisting inlong-term strategic planning, and presiding over meetings of theboard, and the chief executive officer, together with our chieffinancial officer and chief operating officer, is responsible forleading our day-to-day performance and operations. While we do nothave a written policy with respect to separation of the roles ofchairman of the board and chief executive officer, the boardbelieves that the existing leadership structure, with theseparation of these roles, provides several important advantages,including: enhancing the accountability of the chief executiveofficer to the board; strengthening the board’s independencefrom management; assisting the board in reaching consensus onparticular strategies and policies; and facilitating robustdirector, board, and executive officer evaluationprocesses.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Code of Corporate Conduct and Ethics        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         We haveadopted a code of corporate conduct and ethics, updated as of March8, 2021, that applies to all of our directors, officers andemployees, including our Chief Executive Officer and ChiefFinancial Officer. You can view the code of corporate conduct andethics at our website, www.palatin.com/about-us/. We will discloseany amendments to, or waivers from, provisions of the code ofcorporate conduct and ethics that apply to our directors, principalexecutive and financial officers in a current report on Form 8-K,unless the rules of the NYSE American permit website posting of anysuch amendments or waivers.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Executive Officers        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Executiveofficers are appointed by the board and serve at the discretion ofthe board. Each officer holds his position until his successor isappointed and qualified. The current executive officers hold officeunder employment agreements.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 31%; border-left: 0.75pt solid #FFFFFF; border-top: 0.75pt solid #FFFFFF; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-family: Times New Roman;">               Name              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 12%; border-left: 0.75pt solid #FFFFFF; border-top: 0.75pt solid #FFFFFF; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-family: Times New Roman;">               Age              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 58%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-top: 0.75pt solid #FFFFFF; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-family: Times New Roman;">               Position withPalatin              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 31%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              CarlSpana, Ph.D.             </font>            </div>           </td>           <td style="vertical-align: top; width: 12%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              59             </font>            </div>           </td>           <td style="vertical-align: top; width: 58%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ChiefExecutive Officer, President and Director             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 31%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              StephenT. Wills, MST, CPA             </font>            </div>           </td>           <td style="vertical-align: top; width: 12%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              64             </font>            </div>           </td>           <td style="vertical-align: top; width: 58%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ChiefFinancial Officer, Chief Operating Officer, Executive VicePresident, Secretary and Treasurer             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Additionalinformation about Dr. Spana is included above under the heading“Identification of Directors.”        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         STEPHENT. WILLS, CPA, MST, currently serves as the Chief Financial Officer(since 1997), Chief Operating Officer (since 2011), Treasurer andSecretary of Palatin. Mr. Wills has served on the board ofdirectors of MediWound Ltd. (Nasdaq: MDWD), a biopharmaceuticalcompany focused on treatment in the fields of severe burns, chronicand other hard to heal wounds, since April 2017, and as Chairmansince January 2018, and also has served on the board of directorsof Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immunetherapeutics company, since March 2019 (chairman of audit committeeand member of the compensation, and finance committee), and ofAmryt Pharma, a biopharmaceutical company focused on developing anddelivering treatments to help improve the lives of patients withrare and orphan diseases, since September 2019 (chairman of auditcommittee and member of the compensation and finance committee).Mr. Wills also serves on the board of trustees and executivecommittee of The Hun School of Princeton, a college preparatory dayand boarding school, since 2013, and as its Chairman since June2018. Mr. Wills served as Executive Chairman and Interim PrincipalExecutive Officer of Derma Sciences, Inc., a provider of advancedwound care products, from December 2015 to February 2017, whenDerma Sciences was acquired by Integra Lifesciences (Nasdaq: IART).Previously, Mr. Wills served on the board of directors of DermaSciences as the lead director and chairman of the audit committeefrom June 2000 to December 2015. Mr. Wills served as the ChiefFinancial Officer of Derma Sciences from 1997 to 2000. Mr. Willsserved as the President and Chief Operating Officer of Wills, Owens&amp; Baker, P.C., a public accounting firm, from 1991 to 2000. Mr.Wills, a certified public accountant, earned his Bachelor ofScience in accounting from West Chester University, and a Master ofScience in taxation from Temple University.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           77          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Delinquent Section 16(A) Reports        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Therules of the SEC require us to disclose failures to file or latefilings of reports of stock ownership and changes in stockownership required to be filed by our directors, officers, andholders of more than 10% of our common stock. To the best of ourknowledge, all of the filings for our directors, officers andholders of more than 10% of our common stock were made on a timelybasis in fiscal 2021, except that a report on Form 4 relating to adisposition of our common stock by a director was filed one daylate on behalf of Robert K. deVeer, Jr. on October 2,2020.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 11.         <a name="item11">          E         </a>         xecutiveCompensation.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Fiscal 2021 Summary Compensation Table        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing table summarizes the compensation earned by or paid toour principal executive officer and our principal financialofficer, who constitute all of our executive officers, for fiscal2021 and fiscal 2020. We have no defined benefit or actuarialpension plan, and no deferred compensation plan.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Name and Principal Position              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:10%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Fiscal              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Year              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:10%;">            <div>             <font style="font-size: 11px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 Salary                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 ($)                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:10%;">            <div>             <font style="font-size: 11px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 Stock                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 awards (1) ($)                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:10%;">            <div>             <font style="font-size: 11px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 Option                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 awards (1) ($)                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:10%;">            <div>             <font style="font-size: 11px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 Nonequity incentive plan compensation (2) ($)                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:10%;">            <div>             <font style="font-size: 11px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 All                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 other                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 compensation                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 (3) ($)                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:10%;">            <div>             <font style="font-size: 11px">              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>              <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000000;display:inline-block;">               <div>                <font style="font-family: Times New Roman;">                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 Total                </font>               </div>               <div>                <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">                 ($)                </font>               </div>              </font>              <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td rowspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Carl Spana, Ph.D.,Chief Executive Officer and President             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">              2021             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              620,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              542,538             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              193,766             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              290,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              14,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,660,804             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td rowspan="1" style="width:40%;vertical-align:bottom;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Carl Spana, Ph.D.,Chief Executive Officer and President             </font>            </div>           </td>           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">              2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              600,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              712,443             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              712,559             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              252,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              15,615             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,292,617             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td rowspan="1" style="vertical-align:bottom;width:40%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stephen T. Wills,MST, CPA, Chief Financial Officer, Chief Operating Officer andExecutive Vice President             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">              2021             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              570,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              466,064             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              167,482             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              267,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              14,933             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,485,479             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td rowspan="1" style="width:40%;vertical-align:bottom;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Stephen T. Wills,MST, CPA, Chief Financial Officer, Chief Operating Officer andExecutive Vice President             </font>            </div>           </td>           <td style="vertical-align:bottom;width:40%;">            <div style="text-align: center; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-weight: bold; font-style: italic; font-family: Times New Roman; font-size: 13px">              2020             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              550,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              613,814             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              613,805             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              231,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              16,207             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              2,024,826             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:40%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:10%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (1)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Amounts in thesecolumns represent the aggregate grant date fair value for stockawards and option awards computed using either the Black-Scholesmodel or a multifactor Monte Carlo simulation. The aggregate grantdate fair value of the performance-based restricted stock unitsgranted in fiscal 2021, assuming that the highest level ofperformance would be achieved, was as follows: for Dr. Spana,$155,063; and for Mr. Wills, $131,114. The aggregate grant datefair value of the performance-based stock options andperformance-based restricted stock units granted in fiscal 2020,assuming that the highest level of performance would be achieved,was as follows: for Dr. Spana, $337,500 for performance-based stockoptions and $337,500 for performance-based restricted stock units;and for Mr. Wills, $290,750 for performance-based stock options and$290,750 for performance-based restricted stock units. For adescription of the assumptions we used to calculate these amounts,see Note 16 to the consolidated financial statements included inthis Annual Report.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (2)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Annual incentiveamounts.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (3)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Consists ofmatching contributions to 401(k) plan.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Base Salary        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thesalary for each named executive officer is based, among otherfactors, upon job responsibilities, level of experience, individualperformance, comparisons to the salaries of executives in similarpositions obtained from market surveys, and internal comparisons.The compensation committee considers changes in the base salariesof our named executive officers annually. Effective July 1, 2021,the compensation committee approved increases in base salaries to$640,000 for Dr. Spana and $590,000 for Mr. Wills.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           78          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Annual Incentive Program        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Weprovide annual incentive opportunities to our named executiveofficers to promote the achievement of annual performanceobjectives. Each year, the compensation committee establishes thetarget annual incentive opportunity for each named executiveofficer, which is based on a percentage of his base salary. Forfiscal 2021 and fiscal 2020, the target annual incentiveopportunity for each named executive officer equaled 60% of hisannual base salary.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefiscal 2021 annual incentive bonus for the named executive officerswas determined based on corporate performance and individualachievements and performance, as warranted. In determining theannual incentive bonus opportunity for executives, theexecutive’s annual base salary is multiplied by the targetbonus percentage. The resulting amount is then multiplied by thecorporate performance percentage approved by the compensationcommittee, which is dependent on the achievement of corporateperformance goals, and also potentially adjusted upwards ordownwards for individual executives based on their individualcontribution toward the corporate results during the relevant year.The corporate objectives are established so that target attainmentis not assured. Instead, our executives are required to demonstratesignificant effort, dedication, and achievement to attain paymentfor performance at target or above.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing table briefly describes each category of corporateobjectives, the relative weighting of each objective, and therelated achievement level:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 36%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Corporate Objectives              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Related to:              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Weight              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Achievement Level              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Discretionary Adjustments*              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman;">               Total Weighted Achievement              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 36%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Vyleesi(bremelanotide) FSD Program             </font>            </div>           </td>           <td style="vertical-align: top; width: 10%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              25.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              90.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              10.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              25.0%             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 36%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Anti-InflammatoryPrograms             </font>            </div>           </td>           <td style="vertical-align: top; width: 10%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              7.5%             </font>            </div>           </td>           <td style="vertical-align: top; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              30.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              0.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              2.0%             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 36%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              OcularPrograms             </font>            </div>           </td>           <td style="vertical-align: top; width: 10%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              32.5%             </font>            </div>           </td>           <td style="vertical-align: top; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              95.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              0.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              31.0%             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 36%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              OtherCorporate             </font>            </div>           </td>           <td style="vertical-align: top; width: 10%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              35.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              57.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              0.0%             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              20.0%             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td colspan="4" style="vertical-align: top; width: 80%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 48px">             <font style="font-family: Times New Roman; font-size: 13px">              TotalPayout             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              78.0%             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         *Discretionaryadjustment for Vyleesi was related to the restructuring of a CMCcontract.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Forfiscal 2021, the compensation committee determined that our namedexecutive officers achieved 78.0% of their target objectives. As aresult, each named executive officer received a payout under the2021 annual incentive program equal to 78.0% of his target annualincentive opportunity, or $290,000 for Dr. Spana and $267,000 forMr. Wills (subject to rounding conventions).        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Long-Term Incentive Program        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thetotal direct compensation levels for our named executive officersare heavily weighted to long-term incentive opportunities. Thisstructure is intended to align executives’ interests withthose of our stockholders, enhance our retention incentives andfocus our executives on delivering sustainable performance over thelonger-term.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thedesign of this program has evolved over the past several years toreflect core performance metrics and an incentive structure thecompensation committee believes is necessary to drive our long-termsuccess and that reflects feedback received from investors duringour stockholder engagement process.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Eachyear, the compensation committee establishes the target long-termincentive opportunity for each named executive officer, which isbased on a percentage of his base salary. For both fiscal 2020 andfiscal 2021, the target long-term incentive opportunity for eachnamed executive officer equaled 250% of base salary for Dr. Spanaand 235% of base salary for Mr. Wills.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           79          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June16, 2020, as part of our fiscal 2021 long-term incentive program,we granted 646,500 time-based restricted stock units and 646,500performance-based restricted stock units to Dr. Spana, and 557,000time-based restricted stock units and 557,000 performance-basedrestricted stock units to Mr. Wills. The time-based restrictedstock units vest as to 25% of the number of shares granted at eachanniversary of the date of grant. The performance-based restrictedstock units vest on performance criteria relating to advancement ofMC1r programs, including initiation of clinical trials, andlicensing of Vyleesi in additional countries orregions.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June16, 2020, we also granted 1,071,500 time-based options and1,071,500 performance-based options to Dr. Spana, and 923,000time-based options and 923,000 performance-based options to Mr.Wills, a portion of which were contingent on increasing the sharesreserved for grant under the 2011 Stock Incentive Plan, which wasapproved by the stockholders at a meeting on June 25, 2020. Thetime-based options vest as to 25% of the number of shares grantedat each anniversary of the date of grant. The performance-basedoptions vest on performance criteria relating to advancement ofMC1r programs, including initiation of clinical trials, andlicensing of Vyleesi in additional countries or regions. Theoptions have an exercise price of $0.58, the fair market value ofthe common stock on the business day immediately preceding the dateof grant, and they expire on June 16, 2030.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June22, 2021, as part of our fiscal 2022 long-term incentive program,we granted 704,500 time-based restricted stock units and 472,350performance-based restricted stock units to Dr. Spana, and 609,000time-based restricted stock units and 392,150 performance-basedrestricted stock units to Mr. Wills. The time-based restrictedstock units vest as to 25% of the number of shares granted at eachanniversary of the date of grant. The performance-based restrictedstock units vest as to 450,000 restricted stock units, comprising250,000 to Dr. Spana and 200,000 to Mr. Wills, on performancecriteria only if within two years of the date of grant for a twentyconsecutive trading day period the price of common stock on theNYSE American for Palatin Technologies, Inc. closes at $2.00 pershare or greater (a market condition), and as to 414,500 restrictedstock units on annual performance criteria relating to corporateobjectives, including stock appreciation, advancement ofdevelopment programs, and licensing of Vyleesi in additionalcountries or regions (a performance condition). Additionally onJune 22, 2021, we granted 1,150,000 performance-based stock optionsand 232,150 performance-based restricted stock units to Dr. Spanaand 994,000 performance-based stock options and 216,850performance-based restricted stock units to Mr. Wills, which aresubject to an increase in our authorized shares and shares reservedunder our 2011 Stock Incentive Plan, and which vest based on annualperformance criteria relating to corporate objectives, includingstock appreciation, advancement of development programs, andlicensing of Vyleesi in additional countries or regions (aperformance condition).        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June22, 2021, we granted 575,000 time-based stock options to Dr. Spanaand 497,000 time-based stock options to Mr. Wills, which vest as to25% of the number of shares granted on each anniversary of the dateof grant. Additionally on June 22, 2021, we granted 575,000time-based stock options to Dr. Spana and 497,000 time-based stockoptions to Mr. Wills, which are subject to an increase in ourauthorized shares and shares reserved under our 2011 StockIncentive Plan, and which vest as to 25% of the number of sharesgranted on each anniversary of the date of grant. The options havean exercise price of $0.55, the fair market value of the commonstock on the business day immediately preceding the date of grant,and they expire on June 22, 2031.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Employment Agreements        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         EffectiveJuly 1, 2019, we entered into employment agreements with Dr. Spanaand Mr. Wills which continue through June 30, 2022 unlessterminated earlier. Under these agreements Dr. Spana is serving asChief Executive Officer and President at an initial base salary of$600,000 per year and Mr. Wills is serving as Chief FinancialOfficer and Chief Operating Officer at an initial base salary of$550,000 per year. Each agreement also providesfor:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           annualdiscretionary bonus compensation, in an amount to be decided by thecompensation committee and approved by the board, based onachievement of yearly performance objectives;and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           participation inall benefit programs that we establish, to the extent theexecutive’s position, tenure, salary, age, health and otherqualifications make him eligible to participate.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Eachagreement allows us or the executive to terminate the agreementupon written notice and contains other provisions for terminationby us for “cause,” or by the employee for “goodreason” or due to a “change in control” (as theseterms are defined in the employment agreements and set forthbelow). Early termination may, in some circumstances, result inseverance pay at the salary then in effect, plus continuation ofmedical and dental benefits then in effect for a period of twoyears. In addition, the agreements provide that options andrestricted stock units granted to these officers accelerate upontermination of employment except for voluntary resignation by theofficer or termination for cause. In the event of retirement,termination by the officer for good reason, or termination by usother than for “cause”, options may be exercised untilthe earlier of twenty-four months following termination orexpiration of the option term. Arrangements with our namedexecutive officers in connection with a termination following achange in control are described below. Each agreement includesnon-competition, non-solicitation and confidentialitycovenants.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           80          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Other Compensation Practices and Policies        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         At ourlast annual meeting of stockholders on June 8, 2021, ournon-binding stockholder advisory vote to approve the compensationof our named executive officers (commonly known as a“Say-on-Pay” vote) was supported by approximately 66%of the votes cast for or against advisory approval. We continue toevaluate our executive compensation program and solicit input fromour largest investors. Following is a summary of our currentcompensation practices and policies.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Retain an Independent CompensationAdvisor.           </font>           The compensation committee engaged AonConsulting, Inc. through its Aon Rewards Solutions division(“Aon Rewards”), a nationally recognized global humanresources consulting firm, as its independent compensation advisorin April 2021. Aon Rewards principally provided analysis, advice,and recommendations on named executive officers and non-employeedirector compensation. Our compensation peer group for namedexecutive officer awards made in June 2021 was designed to reflectthe industry and sector in which Palatin competes, as well ascompanies comparable to Palatin in terms of company life cycle,phase of development of potential products, market capitalizationand talent market, and consists of:          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="column-count: 2; -webkit-column-count: 2; -moz-column-count: 2; column-gap: 48px; -webkit-column-gap: 48px; -moz-column-gap: 48px">        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          AcelRxPharmaceuticals, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          AldeyraTherapeutics, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          Ardelyx,Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          CalitheraBiosciences, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          ClearsideBiomedical, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          CrineticsPharmaceuticals, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          CymaBayTherapeutics, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          GeronCorporation         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          KalaPharmaceuticals, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 96px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          KezarLife Sciences, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          LaJolla Pharmaceutical Company         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          MEIPharma, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          MeiraGTxHoldings plc         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          OysterPoint Pharma, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          ParatekPharmaceuticals, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          RAPTTherapeutics, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          SavaraInc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          SyndaxPharmaceuticals, Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>        <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">         <font style="font-family: Times New Roman; font-size: 13px">          Verastem,Inc.         </font>        </div>        <div>         <font style="font-family: Times New Roman; font-size: 10">         </font>        </div>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Compensation at Risk.           </font>           Ourexecutive compensation program is designed so that a significantportion of compensation is “at risk” based on ourperformance, as well as short-term cash and long-term equityincentives to align the interests of our executive officers andstockholders. Long-term equity incentives will be no less than basesalaries, with at least half of long-term equity incentives beingperformance-based.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Use a Pay-for-PerformancePhilosophy.           </font>           The compensation committee employs amixture of compensation elements designed to balance short-termgoals with longer-term performance. Our executive compensationprogram includes these principal elements:          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 72px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           o          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Base salary, whichtargets the comparable position median salary for our peergroup;          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 72px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           o          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           An annual incentivecompensation opportunity, with a target bonus payout of no lessthan 60% of base salary, depending on performance;and,          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 72px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-family: Times New Roman; font-size: 13px">           o          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           A long-termincentive program consisting of stock option and restricted stockunit awards. In fiscal 2021, approximately 50% of all long-termincentive awards were allocated to performance-based stock optionsand performance-based restricted share units.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           81          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Maintain a Stock OwnershipPolicy.           </font>           We adopted a stock ownership policy effectiveApril 1, 2019, that requires our named executive officers, as wellas our board members, to maintain a minimum ownership level of ourcommon stock. As of June 30, 2021, the most recent“Determination Date” under the stock ownership policy,all current named executive officers and board members meet thetarget ownership levels of shares with a value equal to at leastfive times the annual base salary of named executive officers andat least two times the annual retainer for board members. Our stockownership policy is on our website at www.palatin.com/about-us/. Inaddition, certain time-based and performance-based restricted stockunit awards contain deferred delivery provisions providing fordelivery of the common stock after the grantee’s separationfrom service or a defined changed in control.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Maintain a Clawback Policy.           </font>           Wehave adopted a clawback policy allowing Palatin to recover relatedcompensation should the board determine that compensation paid tonamed executive officers resulted from material noncompliance withfinancial reporting requirements under federal securities law. Ourclawback policy is on our website atwww.palatin.com/about-us/.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Maintain an Independent CompensationCommittee.           </font>           The compensation committee consists entirelyof independent directors.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            Annual Executive CompensationReview.           </font>           The compensation committee conducts an annualreview and approval of our compensation strategy, utilizing anindependent compensation advisor. This review, including a peergroup review, is intended to ensure that our compensation programsappropriately reward corporate growth without encouraging excessiveor inappropriate risk-taking.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            “Double Trigger” Feature forAcceleration of CEO and CFO/COO Equity Awards.           </font>           Underemployment agreements with our named executive officers,outstanding equity awards granted to our named executive officersprovide that, upon a change in control of Palatin, the vesting ofsuch awards will accelerate only in the event of a subsequentinvoluntary termination of employment (a“double-trigger” provision).          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            No Excise Tax Gross-Ups.           </font>           Prior toJuly 1, 2019, our employment agreements for the named executiveofficers provided that they were entitled to a tax gross-up for anygolden parachute excise tax imposed on payments received inconnection with a change in control. Most investors disfavor thistype of tax gross-up benefit. In response to stockholder feedback,effective with new employment agreements for our named executiveofficers commencing July 1, 2019, we removed all golden parachuteexcise tax gross-up provisions. As a result, the Company no longerprovides tax gross-ups for named executive officers or any otheremployees in the event they are subject to golden parachute excisetaxes on payments received in connection with a change incontrol.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            No Stock Option Re-pricing.           </font>           Our2011 Stock Incentive Plan does not permit options to purchaseshares of our common stock to be repriced to a lower exercise orstrike price without the approval of our stockholders.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            No Dividends or Dividend Equivalents Payableon Unvested or Undelivered Equity Awards.           </font>           Under ourrestricted share unit agreements, we do not pay dividends ordividend equivalents on unvested RSU awards or vested RSU awardssubject to delayed delivery.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            No Executive Retirement Plans.           </font>           Wedo not offer pension arrangements or retirement plans orarrangements to our executive officers that are different from orin addition to those offered to our other employees.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 24px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="font-style: italic">            No Special Welfare or HealthBenefits.           </font>           Our executive officers participate inbroad-based Company-sponsored health and welfare benefit programson the same basis as our other full-time, salariedemployees.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Outstanding Equity Awards at 2021 Fiscal Year-End        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing table summarizes all of the outstanding equity-basedawards granted to our named executive officers as of June 30, 2021,the end of our fiscal year.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           82          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left">        <table cellpadding="0" cellspacing="0" style="text-align: left; font-family: inherit; margin: 0px auto 0px 0px; width: 100%; font-size: inherit;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align: bottom; width: 10%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; display: inline-block; padding-bottom: 2px;">              <div>               <font style="font-weight:bold;font-size:11px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:9%;">            <div style="padding-bottom:2px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 11px; font-weight: bold">             </font>            </div>           </td>           <td colspan="5" rowspan="1" style="vertical-align: bottom; width: 45%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:2%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:96%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Option awards (1)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:2%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>           <td colspan="4" rowspan="1" style="vertical-align:bottom;width:36%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:2%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:96%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Stock awards (2)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:2%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: bottom; width: 10%;">            <div>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-size:11px;font-weight:bold;">                <font style="font-family:Times New Roman;font-weight:bold;">                </font>               </font>              </div>              <div>               <font style="font-weight:bold;">                <font style="font-weight:bold;">                 <font style="font-size:11px;font-weight:bold;">                  <font style="font-family:Times New Roman;font-weight:bold;">                  </font>                 </font>                </font>               </font>              </div>              <div>               <font style="font-weight:bold;">                <font style="font-weight:bold;">                 <font style="font-size:11px;font-weight:bold;">                  <font style="font-family:Times New Roman;font-weight:bold;">                  </font>                 </font>                </font>               </font>              </div>              <div>               <font style="font-weight:bold;">                <font style="font-weight:bold;">                 <font style="font-size:11px;font-weight:bold;">                  <font style="font-family:Times New Roman;font-weight:bold;">                  </font>                 </font>                </font>               </font>              </div>              <div>               <font style="font-weight:bold;">                <font style="font-weight:bold;">                 <font style="font-size:11px;font-weight:bold;">                  <font style="font-family:Times New Roman;font-weight:bold;">                  </font>                 </font>                </font>               </font>              </div>              <div>               <font style="font-weight:bold;">                <font style="font-weight:bold;">                 <font style="font-size:11px;font-weight:bold;">                  <font style="font-family:Times New Roman;font-weight:bold;">                  </font>                 </font>                </font>               </font>              </div>              <div>               <font style="font-weight:bold;">                <font style="font-weight:bold;">                 <font style="font-size:11px;font-weight:bold;">                  <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                   Name                  </font>                 </font>                </font>               </font>              </div>             </font>             <font style="text-align: left; padding-bottom:2px;width:10%;vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-size: 11px; font-weight: bold">              <font style="font-family: Times New Roman; font-weight: bold">              </font>             </font>            </div>            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-family: Times New Roman; font-weight: bold">                </font>               </font>              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-variant: small-caps; font-family: Times New Roman; font-weight: bold">                 Option or                </font>               </font>              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-variant: small-caps; font-family: Times New Roman; font-weight: bold">                 stock                </font>               </font>              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-variant: small-caps; font-family: Times New Roman; font-weight: bold">                 award                </font>               </font>              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-variant: small-caps; font-family: Times New Roman; font-weight: bold">                 grant                </font>               </font>              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-variant: small-caps; font-family: Times New Roman; font-weight: bold">                 date                </font>               </font>              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Number of               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                securities               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                underlying               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                unexercised               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                options               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                (#)               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                exercisable               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Number of               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                securities               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                underlying               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                unexercised               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                options               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                (#)               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                unexercisable               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-family:Times New Roman;font-weight:bold;">               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Equity incentive plan award: number of securities underlyingunexercised unearned options (#)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-family:Times New Roman;font-weight:bold;">               </font>              </div>              <div>               <font style="font-family:Times New Roman;font-weight:bold;">               </font>              </div>              <div>               <font style="font-family:Times New Roman;font-weight:bold;">               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Option               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                exercise               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                price               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                ($)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-size: 11px; font-weight: bold">              <font style="font-family: Times New Roman; font-weight: bold">              </font>             </font>            </div>            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-family: Times New Roman; font-weight: bold">                </font>               </font>              </font>             </font>            </div>            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-family: Times New Roman; font-weight: bold">                </font>               </font>              </font>             </font>            </div>            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-family: Times New Roman; font-weight: bold">                </font>               </font>              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-variant: small-caps; font-family: Times New Roman; font-weight: bold">                 Option                </font>               </font>              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-variant: small-caps; font-family: Times New Roman; font-weight: bold">                 expiration                </font>               </font>              </font>             </font>            </div>            <div style="text-align: center; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:0px;">             <font style="font-weight: bold">              <font style="font-weight: bold">               <font style="font-size: 11px; font-weight: bold">                <font style="font-variant: small-caps; font-family: Times New Roman; font-weight: bold">                 date                </font>               </font>              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-family:Times New Roman;font-weight:bold;">               </font>              </div>              <div>               <font style="font-family:Times New Roman;font-weight:bold;">               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Number of shares or units of stock that have notvested               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                (#)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-family:Times New Roman;font-weight:bold;">               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Market value of shares or units of stock that have notvested               </font>              </div>              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                ($) (3)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Equity incentive plan awards: number of unearned shares, unit orother rights that have not vested (#)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;font-weight:bold;width:80%;border-bottom:solid 2px #000;display:inline-block;">              <div>               <font style="font-weight:bold;font-variant:small-caps;font-family:Times New Roman;">                Equity incentive plan awards: market or payout value of unearnedshares, units or other rights that have not vested($)(3)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;font-weight:bold;width:10%;padding-bottom:2px;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align: bottom; width: 10%;">            <div style="margin-left:0px;">             <font style="text-align: left; vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;display:inline-block;">              <div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 0px">               <font style="font-family: Times New Roman; font-size: 13px">                CarlSpana               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              07/17/12             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              150,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.72             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              07/17/22             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/27/13             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              275,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.62             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/27/23             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/25/14             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              175,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.02             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/25/24             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/11/15             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              300,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.08             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/11/25             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              09/07/16             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              432,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.68             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              09/07/26             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/20/17             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              938,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.37             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/20/27             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/17             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              468,750             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              156,250             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.85             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/27             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/17             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              500,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.85             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/27             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/26/18             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              399,750             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              133,250             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.00             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/26/28             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/24/19             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              372,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              372,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.34             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/24/29             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/20             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              267,875             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              803,625             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.58             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/30             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/20             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              208,942             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              862,558             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.58             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/30             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/22/21             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              575,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.55             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/22/31             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/17             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              156,250             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              95,313             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/24/19             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              118,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              71,980             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              132,927             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              81,085             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/20             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              484,875             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              295,774             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              520,432             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              317,464             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/22/21             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              704,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              429,745             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              472,350             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              288,134             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <font style="text-align: center; display:inline-block;vertical-align:bottom;">             <div style="text-align: left; margin-left: 0px; text-indent: 0px; margin-right: 0px;">              <font style="font-family: Times New Roman; font-size: 13px">               Total Stock Awards              </font>             </div>            </font>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,463,625             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              892,812             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1,125,709             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              686,683             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <div>            </div>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align: bottom; width: 10%;">            <div style="margin-left:0px;">             <font style="text-align: left; vertical-align:bottom;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;display:inline-block;">              <div style="text-align: justify; text-indent: 0px; margin-right: 0px; margin-left: 12px">               <font style="font-family: Times New Roman; font-size: 13px">                Stephen T.Wills               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              07/17/12             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              135,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.72             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              07/17/22             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/27/13             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              250,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.62             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/27/23             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/25/14             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              150,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.02             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/25/24             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/11/15             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              270,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.08             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/11/25             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              09/07/16             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              396,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.68             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              09/07/26             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/20/17             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              859,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.37             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/20/27             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/17             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              431,250             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              143,750             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.85             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/27             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/17             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              372,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.85             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/27             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/26/18             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              340,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              113,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.00             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/26/18             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/24/19             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              319,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              319,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              1.34             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/24/29             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/20             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              230,750             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              692,250             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.58             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/30             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/20             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              179,985             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              743,015             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.58             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/30             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/22/21             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              497,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.55             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/22/31             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              12/12/17             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              143,750             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              87,688             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              -             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/24/19             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              101,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              61,610             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              113,776             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              69,403             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/16/20             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              417,750             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              254,828             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              448,385             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              273,515             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="text-align: left; text-indent: 0px; margin-right: 0px; margin-left: 0px;">             <font style="font-family: Times New Roman; font-size: 13px">              06/22/21             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              609,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              371,490             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              392,150             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              239,212             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td colspan="1" style="vertical-align: bottom; width: 10%;">            <br/>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div style="border-bottom: 2px solid rgb(0, 0, 0);">             <div>              Total Stock Awards              <br/>             </div>            </div>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">             </font>            </div>           </td>           <td colspan="1" style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 5%; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: right; vertical-align: bottom; width: 75%; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; display: inline-block; padding-bottom: 2px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 5%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: right; vertical-align: bottom; width: 75%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 5%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: right; vertical-align: bottom; width: 75%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%;">            <div style="margin-left: 0px; padding-bottom: 2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 5%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: right; vertical-align: bottom; width: 75%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">              1,271,500             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 5%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: right; vertical-align: bottom; width: 75%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">              775,616             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 5%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: right; vertical-align: bottom; width: 75%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">              954,311             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:9%;">            <div>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: left; vertical-align: bottom; width: 5%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>             <font style="text-align: right; vertical-align: bottom; width: 75%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">              582,130             </font>             <font style="text-align: left; vertical-align: bottom; width: 10%; font-size: 13px; font-family: Times New Roman; display: inline-block; padding-bottom: 2px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (1)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Stock optionvesting schedules: all options granted on or before December 11,2017 have fully vested. Options granted after December 11, 2017vest over four years with 1/4 of the shares vesting per yearstarting on the first anniversary of the grant date, provided thatthe named executive officer remains an employee; see“Termination and Change-In-Control Arrangements” belowfor a description of events that could accelerate vesting, exceptfor performance-based options granted on June 16, 2020, which vestaccording to the terms of the grant described above.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (2)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Time-based stockaward vesting schedule: restricted stock units granted on December12, 2017, as to 625,000 shares for Dr. Spana and 575,000 shares forMr. Wills, which vest in equal amounts over a four year period,provided that the named executive officer remains an employee;restricted stock units granted on June 24, 2019 as to 236,000shares for Dr. Spana and 202,000 shares for Mr. Wills; restrictedstock units granted on June 16, 2020 as to 646,500 shares for Dr.Spana and 557,000 shares for Mr. Wills and restricted stock unitsgranted on June 22, 2021 as to 704,500 shares to Dr. Spana and609,000 shares for Mr. Wills, which vest in equal amounts over afour year period, provided that the named executive officer remainsan employee. Both time-based and performance-based restricted stockunit awards prior to fiscal 2019 contain deferred deliveryprovisions providing for delivery of the common stock after thegrantee’s separation from service or a defined change incontrol. See “Stock Options and Restricted Stock UnitAwards” above and “Termination and Change-In-ControlArrangements” below.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (3)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Calculated bymultiplying the number of restricted stock units by $0.61, theclosing market price of our common stock on June 30, 2021, the lasttrading day of our most recently completed fiscalyear.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           83          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Termination and Change-In-Control Arrangements        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Theemployment agreements, stock option agreements and restricted stockunit agreements with Dr. Spana and Mr. Wills contain the followingprovisions concerning severance compensation and the vesting ofstock options and restricted stock units upon termination ofemployment or upon a change in control. The executive’sentitlement to severance, payment of health benefits andaccelerated vesting of options is contingent on the executiveexecuting a general release of claims against us.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px;">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          Termination Without SeveranceCompensation         </font>         <font style="color: #000000">          . Regardless ofwhether there has been a change in control, if we terminateemployment for cause or the executive terminates employment withoutgood reason (as those terms are defined in the employment agreementand set forth below), then the executive will receive only hisaccrued salary and vacation benefits through the date oftermination. He may also elect to receive medical and dentalbenefits pursuant to COBRA for up to two years but must remit thecost of coverage to us. Under the terms of our outstanding optionsand restricted stock units, all unvested options and restrictedstock units would terminate immediately, and vested options wouldbe exercisable for three months aftertermination.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; font-size: 13px">         </font>         <font style="font-style: italic; color: #000000">          SeveranceCompensation After Death or Disability.         </font>         <font style="color: #000000">          In the event of the executive’s deathor disability, we will provide lump sum severance pay equal to 24months of base pay, as well as the opportunity for COBRA benefitsas described above under “Termination Without SeveranceCompensation.”         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; font-size: 13px">         </font>         <font style="font-style: italic; color: #000000">          SeveranceCompensation Without a Change in Control         </font>         <font style="color: #000000">          . If we terminate or fail to extend the employmentagreement without cause, or the executive terminates employmentwith good reason, then the executive will receive as severance payhis salary then in effect, paid in a lump sum, plus medical anddental benefits at our expense, for a period of two years after thetermination date. In addition, upon such event all unvested optionswould immediately vest and be exercisable for two years after thetermination date or, if earlier, the expiration of the option term,and all unvested restricted stock units would accelerate and becomefully vested.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           84          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">         </font>         <font style="font-style: italic; color: #000000">          SeveranceCompensation After a Change in Control         </font>         <font style="color: #000000">          . If, within one year after a change in control,we terminate employment or the executive terminates employment withgood reason, then the executive will receive as severance pay 200%of his salary then in effect, paid in a lump sum, plus medical anddental benefits at our expense, for a period of two years after thetermination date. We would also reimburse the executive for up to$25,000 in fees and expenses during the six months followingtermination, for locating employment. All unvested options wouldimmediately vest and be exercisable for two years after thetermination date or, if earlier, the expiration of the option term.All unvested restricted stock units would vest upon a change incontrol, without regard to whether the executive’s employmentis terminated.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic; color: #000000">          Option and Restricted Stock Unit Vesting Upon a Change inControl         </font>         <font style="color: #000000">          . Pursuant to theemployment agreements, options and restricted stock units grantedunder the 2011 Stock Incentive Plan vest upon termination of theemployee within twelve months following a change in control. If anyoptions granted under the 2005 Stock Plan are to be terminated inconnection with a change in control, those options will vest infull immediately before the change in control.         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; font-size: 13px">         </font>         <font style="font-style: italic; color: #000000">          Definitions         </font>         <font style="color: #000000">          . Under the employment agreements, a “changein control,” “cause” and “goodreason” are defined as follows:         </font>         <font style="color: #000000; font-size: 13px">         </font>        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000">          A “change in control” occurswhen:         </font>         <font style="color: #000000; font-size: 13px">         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (a)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            any person or entity acquires more than 50% of thevoting power of our outstanding securities;           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (b)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            the individuals who, during any twelve-monthperiod, constitute our board of directors cease to constitute atleast a majority of the board of directors;           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (c)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            the consummation of a merger or consolidation;or           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (d)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           wesell substantially all our assets.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="color: #000000; font-size: 13px">         </font>         <font style="color: #000000">          The term“cause” means:         </font>         <font style="color: #000000; font-size: 13px">         </font>        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (a)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            the occurrence of (i) the executive’smaterial breach of, or habitual neglect or failure to perform thematerial duties which he is required to perform under, the terms ofhis employment agreement; (ii) the executive’s materialfailure to follow the reasonable directives or policies establishedby or at the direction of our board of directors; or (iii) theexecutive’s engaging in conduct that is materiallydetrimental to our interests such that we sustain a material lossor injury as a result thereof, provided that the breach or failureof performance is not cured, to the extent cure is possible, withinten days of the delivery to the executive of written noticethereof;           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (b)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            the willful breach by the executive of hisobligations to us with respect to confidentiality, invention andnon-disclosure, non-competition or non-solicitation;or           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (c)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            the conviction of the executive of, or the entryof a pleading of guilty or nolo contendere by the executive to, anycrime involving moral turpitude or any felony.           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The term “good reason” means the occurrence of any ofthe following, with our failure to cure such circumstances within30 days of the delivery to us of written notice by the executive ofsuch circumstances:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (a)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            any material adverse change in theexecutive’s duties, authority or responsibilities, whichcauses the executive’s position with us to become ofsignificantly less responsibility, or assignment of duties andresponsibilities inconsistent with the executive’sposition;           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (b)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            a material reduction in the executive’ssalary;           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (c)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            our failure to continue in effect any materialcompensation or benefit plan in which the executive participates,unless an equitable arrangement has been made with respect to suchplan, or our failure to continue the executive’sparticipation therein (or in a substitute or alternative plan) on abasis not materially less favorable, both in terms of the amount ofbenefits provided and the level of the executive’sparticipation relative to other participants;           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (d)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            our failure to continue to provide the executivewith benefits substantially similar to those enjoyed by theexecutive under any of our health and welfare insurance, retirementand other fringe-benefit plans, the taking of any action by uswhich would directly or indirectly materially reduce any of suchbenefits, or our failure to provide the executive with the numberof paid vacation days to which he is entitled;or           </font>           <font style="color: #000000; font-size: 13px">           </font>          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table; margin-left: 48px">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           <font style="color: #000000">            (e)           </font>          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="color: #000000; font-family: Times New Roman; font-size: 13px">           therelocation of the executive to a location which is a materialdistance from Cranbury, New Jersey.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           85          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Director Compensation        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing table sets forth the compensation we paid to alldirectors during fiscal 2021, except for Dr. Spana, whosecompensation is set forth above in the Summary Compensation Tableand related disclosure. Dr. Spana did not receive any separatecompensation for his services as a director.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: bottom; width: 31%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-family: Times New Roman;">               Name              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 21%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-family: Times New Roman;">               Fees earned orpaid in cash ($)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 17%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-family: Times New Roman;">               Stock awards ($)(1) (2)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-family: Times New Roman;">               Optionawards              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-family: Times New Roman;">               ($) (1)(2)              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 12%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-family: Times New Roman;">               Total($)              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 31%">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              JohnK.A. Prendergast, Ph.D.             </font>            </div>           </td>           <td style="vertical-align: middle; width: 21%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              97,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              57,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              57,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 12%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              212,500             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 31%">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              RobertK. deVeer, Jr.             </font>            </div>           </td>           <td style="vertical-align: middle; width: 21%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              66,250             </font>            </div>           </td>           <td style="vertical-align: middle; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 12%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              151,250             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 31%">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              J.Stanley Hull             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              57,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 12%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              142,500             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 31%">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Alan W.Dunton, M.D.             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              69,750             </font>            </div>           </td>           <td style="vertical-align: middle; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 12%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              154,750             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 31%">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              AngelaRossetti (3)             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              53,750             </font>            </div>           </td>           <td style="vertical-align: middle; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              -             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              -             </font>            </div>           </td>           <td style="vertical-align: middle; width: 12%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              53,750             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 31%">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ArleneMorris             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              53,750             </font>            </div>           </td>           <td style="vertical-align: middle; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 12%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              138,750             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 31%; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 12px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              AnthonyManning, Ph.D.             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              47,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 17%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: top; width: 20%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              42,500             </font>            </div>           </td>           <td style="vertical-align: middle; width: 12%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              132,500             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (1)          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           The aggregatenumber of shares underlying option awards and unvested stock awardsoutstanding at June 30, 2021 for each director was:          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td rowspan="1" style="vertical-align:bottom;width:76%;">            <div style="margin-left:0px;padding-bottom:2px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Optionawards               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>           <td rowspan="1" style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px;">              <div>               <font style="font-weight: bold; font-family: Times New Roman;">                Stockawards               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Dr.Prendergast             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              866,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              265,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Mr.deVeer             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              536,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              157,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Mr.Hull             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              536,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              157,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Dr.Dunton             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              536,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              147,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Ms.Morris             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              476,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              127,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:76%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">              Dr.Manning             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              404,000             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              105,500             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (2)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Amounts in thesecolumns represent the aggregate grant date fair value for stockawards and option awards. For a description of the assumptions weused to calculate these amounts, see Note 16 to the consolidatedfinancial statements included in this Annual Report. Amounts inthis column include options granted on June 22, 2021 for ourcurrent fiscal year ending June 30, 2022.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (3)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Angela Rossettiresigned as a director effective December 17, 2020, but under anagreement with the board in connection with her resignation waspaid cash retainers she would have received had she remained on theboard through June 30, 2021.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         Our director compensation program is designed to enhance ourability to attract and retain highly qualified directors and toalign their interests with the long-term interests of ourstockholders. The program includes an equity component, which isdesigned to align the interests of non-employee directors andstockholders, and a cash component, which is designed to compensatenon-employee directors for their service on the board. Directorswho are employees of the Company receive no additional compensationfor their service on the board.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #000000; font-family: Times New Roman; font-size: 13px">         The compensation committee annually reviews compensation paid toour non-employee directors and makes recommendations foradjustments, as appropriate, to the full board. As part of thisannual review, the compensation committee considers the significanttime commitment and skill level required by each non-employeedirector in serving on the board and its various committees. Thecompensation committee seeks to maintain a market competitivedirector compensation program and, with the assistance of itsindependent compensation consultant, Aon Rewards, benchmarks ourdirector compensation program against the peer group we use toevaluate our executive compensation program.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           86          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Non-Employee Directors’ Equity Grants.         </font>         Ournon-employee directors receive an annual equity grant at the boardmeeting closest to the beginning of each fiscal year, or such otherdate as may be determined by the board.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June22, 2021, the Chairman of the board received 105,000 restrictedstock units which vest on June 22, 2022 and an option to purchase173,000 shares of common stock, and each other serving non-employeedirector received 77,000 restricted stock units which vest on June22, 2022 and an option to purchase 128,000 shares of common stock.All of the options have an exercise price of $0.55 per share, theclosing price of our common stock on the business day immediatelypreceding the date of grant, vest in twelve monthly installmentsbeginning July 31, 2021, expire ten years from the date of grantand provide for accelerated vesting in the event of involuntarytermination as a director following a change in control, withexercise permitted following accelerated vesting for up to theearlier of one year after termination or the expiration date of theoption.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         On June16, 2020, the Chairman of the board received 99,000 restrictedstock units which vest on June 16, 2021 and an option to purchase172,000 shares of common stock, and each other serving non-employeedirector received 73,000 restricted stock units which vest on June16, 2021 and an option to purchase 127,000 shares of common stock.All of the options have an exercise price of $0.58 per share, theclosing price of our common stock on the business day immediatelypreceding the date of grant, vest in twelve monthly installmentsbeginning July 31, 2020, expire ten years from the date of grantand provide for accelerated vesting in the event of involuntarytermination as a director following a change in control, withexercise permitted following accelerated vesting for up to theearlier of one year after termination or the expiration date of theoption.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Non-Employee Directors’ Cash Compensation         </font>         . Dr.Prendergast serves as Chairman of the board and for fiscal 2021received an annual retainer of $87,500, payable quarterly. Othernon-employee directors received an annual base retainer of $40,000,payable on a quarterly basis. The chairperson of the auditcommittee received an additional annual retainer of $17,500, thechairperson of the compensation committee received an additionalannual retainer of $17,500 and the chairperson of the corporategovernance committee received an additional annual retainer of$10,000. Members of the foregoing committees, other than thenon-employee Chairman, received an additional retainer of one-halfthe retainer payable to the committee chairperson. For the fiscalyear ending June 30, 2022, Dr. Prendergast serves as Chairman ofthe board and will received an annual retainer of $87,500, payablequarterly. Other non-employee directors will receive an annual baseretainer of $40,000, payable on a quarterly basis. The chairpersonof the audit committee will receive an additional annual retainerof $20,000, the chairperson of the compensation committee willreceive an additional annual retainer of $20,000 and thechairperson of the corporate governance committee will receive anadditional annual retainer of $10,000. Members of the foregoingcommittees, other than the non-employee Chairman, receive anadditional retainer of one-half the retainer payable to thecommittee chairperson.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theboard also formed a program development committee, charged withreviewing new product opportunities and product developmentstrategy. The chairperson of the program development committeereceives $3,500 per day of service, and members of the committeereceive $2,500 per day of service.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Non-Employee Directors’ Expenses.         </font>         Non-employeedirectors are reimbursed for expenses incurred in performing theirduties as directors, including attending all meetings of the boardand any committees on which they serve.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Employee Directors.         </font>         Employee directors are not separatelycompensated for services as directors but are reimbursed forexpenses incurred in performing their duties as directors,including attending all meetings of the board and any committees onwhich they serve.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           87          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 12. Security         <a name="item12">          O         </a>         wnership ofCertain Beneficial Owners and Management and Related StockholderMatters.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Securities Authorized for Issuance Under Equity CompensationPlans.         </font>         The table below provides information on our equitycompensation plans as of June 30, 2021:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="margin-right:0px;width:100%;font-size:inherit;font-family:inherit;margin-left:0px;">         <tbody>          <tr>           <td colspan="4" rowspan="1" style="vertical-align:bottom;width:100%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:2%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:96%;display:inline-block;">              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                EquityCompensation Plan Information               </font>              </div>              <div>               <font style="font-weight:bold;font-size:13px;font-family:Times New Roman;">                asof June 30, 2021               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:2%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:64%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Plancategory             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">              <div>               <font style="font-family: Times New Roman; font-weight: bold;">                Number ofsecurities to be issued upon exercise of outstanding options,warrants and rights               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">              <div>               <font style="font-family: Times New Roman; font-weight: bold;">                Weighted-averageexercise price of outstanding options, warrants andrights               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>             <font style="text-align: center; vertical-align: bottom; width: 80%; border-bottom: 2px solid rgb(0, 0, 0); display: inline-block; font-size: 11px; font-weight: bold;">              <div>               <font style="font-family: Times New Roman; font-weight: bold;">                Number ofsecurities remaining available for future issuance under equitycompensation plans (excluding securities reflected in column(a)               </font>              </div>             </font>             <font style="text-align: left; padding-bottom: 2px; width: 10%; vertical-align: bottom; display: inline-block; font-size: 11px; font-weight: bold;">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align:bottom;width:64%;">            <div style="margin-left:0px;">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                (a)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                (b)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>             <font style="text-align: center; vertical-align:bottom;width:80%;display:inline-block;">              <div>               <font style="font-size:13px;font-family:Times New Roman;">                (c)               </font>              </div>             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:64%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Equity compensationplans approved by security holders             </font>            </div>           </td>           <td style="vertical-align: top; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              36,723,262             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              <font style="font-size: 70%; vertical-align: top">               (1)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">              $             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              0.72             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">              <font style="font-size: 70%; vertical-align: top">               (2)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: left; vertical-align:bottom;width:5%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>             <font style="text-align: right; vertical-align:bottom;width:75%;font-size:13px;font-family:Times New Roman;display:inline-block;">              738,817             </font>             <font style="text-align: left; vertical-align:bottom;width:10%;font-size:13px;font-family:Times New Roman;display:inline-block;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#ffffff;">           <td style="vertical-align:bottom;width:64%;">            <div style="text-align: left; text-indent:0px;margin-right:0px;padding-bottom:2px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Equity compensationplans not approved by security holders             </font>            </div>           </td>           <td style="vertical-align: top; width: 12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              25,000             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">              <font style="font-size: 70%; vertical-align: top">               (3)              </font>             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">              $             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              0.70             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:solid 2px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:solid 2px #000000;">              -             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:2px;font-size:13px;">             </font>            </div>           </td>          </tr>          <tr style="background-color:#cceeff;">           <td style="vertical-align:bottom;width:64%;">            <div style="text-align: justify; text-indent:0px;margin-right:0px;padding-bottom:4px;margin-left:12px;">             <font style="font-family: Times New Roman; font-size: 13px">              Total             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              36,748,262             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>           <td style="vertical-align:bottom;width:12%;">            <div>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:5%;border-bottom:double 4px #000000;">             </font>             <font style="text-align: right; font-family:Times New Roman;vertical-align:bottom;font-size:13px;display:inline-block;width:75%;border-bottom:double 4px #000000;">              738,817             </font>             <font style="text-align: left; font-family:Times New Roman;vertical-align:bottom;display:inline-block;width:10%;padding-bottom:4px;font-size:13px;">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (1)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Includes 21,882,500options and 14,840,762 restricted stock units granted under our2011 Stock Incentive Plan.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (2)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           The amount incolumn (a) for equity compensation plans approved by securityholders includes 14,376,762 shares reserved for issuance on vestingof outstanding restricted stock units, granted under our 2011 StockIncentive Plan, which vest on various dates through June 22, 2025,subject to the fulfillment of service, market conditions, orperformance conditions. Because no exercise price is required forissuance of shares on vesting of the restricted stock units, theweighted-average exercise price in column (b) does not take therestricted stock units into account.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (3)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Consists of twowarrants to purchase 12,500 shares at $0.70 per share issued inconnection with a contract for financial advisory services. Thesewarrants expired unexercised on August 4, 2021.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Beneficial Ownership Tables.         </font>         The tables below show thebeneficial stock ownership and voting power, as of September 24,2021, of:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           each director, eachof the named executive officers, and all current directors andofficers as a group; and          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="margin-left: 48px; display: table">        <div style="display: table-row">         <div style="text-align: left; display: table-cell; width: 24px">          <font style="font-size: 13px">           ●          </font>         </div>         <div style="text-align: justify; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           all persons who, toour knowledge, beneficially own more than five percent of thecommon stock or Series A preferred stock.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         “Beneficialownership” here means direct or indirect voting or investmentpower over outstanding stock and stock which a person has the rightto acquire now or within 60 days after September 24, 2021. See thefootnotes for more detailed explanations of the holdings. Except asnoted, to our knowledge, the persons named in the tablesbeneficially own and have sole voting and investment power over allshares listed.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thecommon stock has one vote per share and the Series A preferredstock has approximately 16 votes per share of Series A preferredstock. Voting power is calculated on the basis of the aggregate ofcommon stock and Series A preferred stock outstanding as ofSeptember 24, 2021, on which date         <font style="font-family: Times New Roman">         </font>         231,258,137 shares ofcommon stock and 4,030 shares of Series A preferred stock,convertible into 66,059 shares of common stock, wereoutstanding.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Underour Insider Trading and Securities Law Compliance Policy directorsand officers may not engage in hedging, monetization or pledgingtransactions of our securities. None of the shares of ourmanagement and directors shown on the table below arepledged.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theaddress for all members of our management and directors is c/oPalatin Technologies, Inc., 4B Cedar Brook Drive, Cranbury, NJ08512. Addresses of other beneficial owners are in thetable.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           88          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         MANAGEMENT:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: bottom; width: 15%; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Class              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 38%; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Name of beneficial owner              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 21%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Amount and nature of beneficial ownership              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 13%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Percent of class              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 14%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Percent of total voting power              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Common             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              CarlSpana, Ph.D.             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8,552,677              <font style="font-size: 70%; vertical-align: top">               (1)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              3.6%             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Common             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              StephenT. Wills             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              7,640,464              <font style="font-size: 70%; vertical-align: top">               (2)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              3.2%             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Common             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              JohnK.A. Prendergast, Ph.D.             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              1,404,933              <font style="font-size: 70%; vertical-align: top">               (3)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Common             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              RobertK. deVeer, Jr.             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              845,306              <font style="font-size: 70%; vertical-align: top">               (4)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Common             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              J.Stanley Hull             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              807,966              <font style="font-size: 70%; vertical-align: top">               (5)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Common             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Alan W.Dunton, M.D.             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              818,518              <font style="font-size: 70%; vertical-align: top">               (6)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Common             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ArleneM. Morris             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              730,666              <font style="font-size: 70%; vertical-align: top">               (7)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Common             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              AnthonyM. Manning, Ph.D.             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              520,666              <font style="font-size: 70%; vertical-align: top">               (8)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 15%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #000000">            <br/>           </td>           <td style="vertical-align: middle; width: 38%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Allcurrent directors and executive officers as a group (eightpersons)             </font>            </div>           </td>           <td style="vertical-align: top; width: 21%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              21,321,196              <font style="font-size: 70%; vertical-align: top">               (9)              </font>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8.6%             </font>            </div>           </td>           <td style="vertical-align: top; width: 14%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              1.8%             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         *Lessthan one percent.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (1)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Includes 4,487,318shares of common stock underlying outstanding options and 2,859,750shares of common stock underlying restricted stock units, all ofwhich shares of common stock underlying restricted stock units havevested but not been delivered under deferred delivery provisionsproviding for delivery after the grantee’s separation fromservice or a defined change in control, but does not include sharesof common stock underlying outstanding options or restricted stockunit awards that have not vested and will not vest within 60days.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (2)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Includes 3,933,985shares of common stock underlying outstanding options and 2,519,750shares of common stock underlying restricted stock units, all ofwhich shares of common stock underlying restricted stock units havevested but not been delivered under deferred delivery provisionsproviding for delivery after the grantee’s separation fromservice or a defined change in control, but does not include sharesof common stock underlying outstanding options or restricted stockunit awards that have not vested and will not vest within 60days.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (3)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Includes 751,166shares of common stock underlying outstanding options and 160,000shares of common stock underlying restricted stock units, all ofwhich shares of common stock underlying restricted stock units havevested but not been delivered under deferred delivery provisionsproviding for delivery after the grantee’s separation fromservice or a defined change in control, but does not include sharesof common stock underlying outstanding options or restricted stockunit awards that have not vested and will not vest within 60days.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (4)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Includes 451,166shares of common stock underlying outstanding options and 80,000shares of common stock underlying restricted stock units, all ofwhich shares of common stock underlying restricted stock units havevested but not been delivered under deferred delivery provisionsproviding for delivery after the grantee’s separation fromservice or a defined change in control, but does not include sharesof common stock underlying outstanding options or restricted stockunit awards that have not vested and will not vest within 60days.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (5)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Includes 451,166shares of common stock underlying outstanding options and 80,000shares of common stock underlying restricted stock units, all ofwhich shares of common stock underlying restricted stock units havevested but not been delivered under deferred delivery provisionsproviding for delivery after the grantee’s separation fromservice or a defined change in control, but does not include sharesof common stock underlying outstanding options or restricted stockunit awards that have not vested and will not vest within 60days.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (6)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Includes 451,166shares of common stock underlying outstanding options and 70,000shares of common stock underlying restricted stock units, all ofwhich shares of common stock underlying restricted stock units havevested but not been delivered under deferred delivery provisionsproviding for delivery after the grantee’s separation fromservice or a defined change in control, but does not include sharesof common stock underlying outstanding options or restricted stockunit awards that have not vested and will not vest within 60days.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (7)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Consists of 391,166shares of common stock underlying outstanding options and 50,000shares of common stock underlying restricted stock units, all ofwhich shares of common stock underlying restricted stock units havevested but not been delivered under deferred delivery provisionsproviding for delivery after the grantee’s separation fromservice or a defined change in control, but does not include sharesof common stock underlying outstanding options or restricted stockunit awards that have not vested and will not vest within 60days.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (8)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Consists of 318,666shares of common stock underlying outstanding options and 28,500shares of common stock underlying restricted stock units, all ofwhich shares of common stock underlying restricted stock units havevested but not been delivered under deferred delivery provisionsproviding for delivery after the grantee’s separation fromservice or a defined change in control, but does not include sharesof common stock underlying outstanding options or restricted stockunit awards that have not vested and will not vest within 60days.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           (9)          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Includes 17,083,799shares of common stock underlying outstanding options andrestricted stock units.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           89          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         MORE THAN 5% BENEFICIAL OWNERS:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: bottom; width: 10%; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Class              </font>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 46%; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Name and address of beneficial owner              </font>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 18%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Amount and nature of beneficial ownership (1)              </font>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 13%; border-bottom: 2px solid #000000">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Percent              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               of class              </font>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 13%; border-bottom: 2px solid #000000">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               Percent of total voting              </font>             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-weight: bold; font-variant: small-caps; color: rgb(79, 129, 189); font-family: Times New Roman;">               power              </font>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-size: 11px">              <font style="font-family: Times New Roman;">              </font>             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              StevenN. Ostrovsky             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              43Nikki Ct.             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Morganville,NJ 07751             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              500             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              12.4%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ThomasL. Cassidy IRA Rollover             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              38Canaan Close             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              NewCanaan, CT 06840             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              500             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              12.4%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              JonathanE. Rothschild             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              300Mercer St., #28F             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              NewYork, NY 10003             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              500             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              12.4%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ArthurJ. Nagle             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              19Garden Avenue             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Bronxville,NY 10708             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              250             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              6.2%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ThomasP. and Mary E. Heiser, JTWROS             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              10Ridge Road             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Hopkinton,MA 01748             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              250             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              6.2%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Carl F.Schwartz             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              31 West87th St.             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              NewYork, NY 10016             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              250             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              6.2%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              MichaelJ. Wrubel             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              3650 N.36 Avenue, #39             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Hollywood,FL 33021             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              250             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              6.2%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              MyronM. Teitelbaum, M.D.             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              175Burton Lane             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Lawrence,NY 11559             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              250             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              6.2%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              LauraGold Galleries Ltd. Profit Sharing Trust Park South Gallery atCarnegie Hall             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              154West 57th Street, Suite 114             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              NewYork, NY 10019             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              250             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              6.2%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              LauraGold             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              180 W.58th Street             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              NewYork, NY 10019             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              250             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              6.2%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              SeriesA             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Preferred             </font>            </div>            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px; width: 100%; border-bottom: solid 1px #000000">             <!--Rule Below Paragraph-->            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 46%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              NadjiT. Richmond             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              20 E.Wedgewood Glen             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              TheWoodlands, TX 77381             </font>            </div>           </td>           <td style="vertical-align: top; width: 18%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: right; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              230             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              5.7%             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%; border-left: 0.75pt solid #FFFFFF; border-right: 0.75pt solid #FFFFFF; border-bottom: 2px solid #ffffff">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              *             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 48px; margin-right: 0px; text-indent: -48px">        <font style="font-family: Times New Roman; font-size: 13px">         *Lessthan one percent.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         (1)Unless otherwise indicated by footnote, all share amounts representoutstanding shares of the class indicated, and all beneficialowners listed have, to our knowledge, sole voting and dispositivepower over the shares listed.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 13. Certain         <a name="item13">          R         </a>         elationships andRelated Transactions, and Director Independence.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theboard of directors has determined that all the directors except forDr. Spana (our Chief Executive Officer and President) areindependent directors, as defined in the listing standards of theNYSE American.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         As acondition of employment, we require all employees to disclose inwriting actual or potential conflicts of interest, includingrelated party transactions. Our code of corporate conduct andethics, which applies to employees, officers and directors,requires that the audit committee review and approve related partytransactions. Since July 1, 2015, there have been notransactions or proposed transactions in which we were or are to bea participant, in which any related person had or will have adirect or indirect material interest.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 14. Principal Accounting Fees and         <a name="item14">          S         </a>         ervices.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         KPMGLLP (“KPMG”), served as our independent registeredpublic accounting firm for fiscal 2021 and fiscal2020.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Audit Fees         </font>         . For fiscal 2021, fees for professional servicesrendered for the audit of our annual consolidated financialstatements and review of our consolidated financial statements inour Forms 10-Q were$398,000. For fiscal 2020, fees for professional services renderedfor the audit of our annual consolidated financial statements,review of our consolidated financial statements in our Forms 10-Q,and services provided in connection with comfort letters were$329,000.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           90          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Audit-Related Fees         </font>         . For fiscal 2021 and fiscal 2020, KPMGdid not perform or bill us for any audit-relatedservices.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Tax Fees         </font>         . For fiscal 2021, KPMG billed us $18,600 us for professionalservices rendered for tax compliance services. For fiscal 2020,KPMG billed us $23,600 for professional services rendered for taxcompliance services.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          All Other Fees         </font>         . KPMG did not perform or bill us for anyservices other than those described above for fiscal 2021 andfiscal 2020.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         <font style="font-style: italic">          Policy on Audit Committee Pre-Approval of Audit and PermissibleNon-Audit Services of Independent Auditors         </font>         . Consistent withSEC policies regarding auditor independence, the audit committeehas responsibility for appointing, setting compensation for andoverseeing the work of the independent registered public accountingfirm. In recognition of this responsibility, the audit committeehas established a policy to pre-approve all audit and permissiblenon-audit services provided by the independent registered publicaccounting firm.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theaudit committee pre-approves fees for each category of service. Thefees are budgeted and the audit committee requires the independentregistered public accounting firm and management to report actualfees versus the budget periodically throughout the year by categoryof service. During the year, circumstances may arise when it maybecome necessary to engage the independent registered publicaccounting firm for additional services not contemplated in theoriginal pre-approval. In those instances, the audit committeerequires specific pre-approval before engaging the independentregistered public accounting firm.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Theaudit committee may delegate pre-approval authority to one or moreof its members. The member to whom such authority is delegated mustreport, for informational purposes only, any pre-approval decisionsto the audit committee at its next scheduled meeting.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           91          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         PART IV        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 15. Exhibits,         <a name="item15">          F         </a>         inancialStatement Schedules.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         (a)     Documents filed as part of thereport:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           1.          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Financialstatements: The following consolidated financial statements arefiled as a part of this report under Item 8 – FinancialStatements and Supplementary Data:          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         —Report of Independent Registered Public AccountingFirm        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         —Consolidated Balance Sheets        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         —Consolidated Statements of Operations        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         —Consolidated Statements of Stockholders’ Equity        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         —Consolidated Statements of Cash Flows        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         —Notes to Consolidated Financial Statements        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           2.          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           Financial statementschedules: None.          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           92          </font>         </div>        </div>        <div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">         <!--page break line-->        </div>        <div id="hdr">         <div style="text-align: right; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 48px">          <font style="font-family: Times New Roman; font-size: 13px">           3.          </font>         </div>         <div style="text-align: left; display: table-cell">          <font style="font-family: Times New Roman; font-size: 13px">           List ofExhibits          </font>         </div>        </div>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Thefollowing exhibits are incorporated by reference or filed as partof this report:        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: bottom; width: 10%; border-bottom: 2px solid #231f20">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #231F20; font-family: Times New Roman; font-size: 13px">              Exhibit Number             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 38%; border-bottom: 2px solid #231f20">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #231F20; font-family: Times New Roman; font-size: 13px">              Description             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 11%; border-bottom: 2px solid #231f20">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #231F20; font-family: Times New Roman; font-size: 13px">              Filed Herewith             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 9%; border-bottom: 2px solid #231f20">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #231F20; font-family: Times New Roman; font-size: 13px">              Form             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 19%; border-bottom: 2px solid #231f20">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #231F20; font-family: Times New Roman; font-size: 13px">              Filing Date             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: bottom; width: 13%; border-bottom: 2px solid #231f20">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; color: #231F20; font-family: Times New Roman; font-size: 13px">              SEC File No.             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495418004204/ptn_ex11.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                1.1               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Equity Distribution Agreement, dated April 20, 2018, by and betweenPalatin Technologies, Inc. and Canaccord Genuity LLC             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              April 20, 2018             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495419007555/ptn_ex11.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                1.2               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Equity Distribution Agreement, dated June 21, 2019, by and betweenPalatin Technologies, Inc. and Canaccord Genuity LLC             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              June 21, 2019             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448813005466/ptn_ex301.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                3.1               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Restated Certificate of Incorporation of Palatin Technologies,Inc., as amended.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              September 27, 2013             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495421010197/ptn_ex31.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                3.2               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Amended and Restated Bylaws of Palatin Technologies,Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              September 17, 2021             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000138713112002083/ex-4_1.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                4.1               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Series A 2012 Warrant.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              July 6, 2012             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000138713112002083/ex-4_2.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                4.2               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Series B 2012 Warrant.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              July 6, 2012             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448814006361/ptn_ex41.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                4.3               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSeries C 2014 Common Stock Purchase Warrant.             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              December30,             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              2014             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448814006361/ptn_ex42.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                4.4               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSeries D 2014 Common Stock Purchase Warrant.             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              December30,             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              2014             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815003275/ptn_ex41.htm">               <font style="font-family: Times New Roman; font-size: 13px">                4.5               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSeries E 2015 Common Stock Purchase Warrant.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              July 7,2015             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815003275/ptn_ex42.htm">               <font style="font-family: Times New Roman; font-size: 13px">                4.6               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSeries F 2015 Common Stock Purchase Warrant.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">              <br/>             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              July 7,2015             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815003275/ptn_ex43.htm">               <font style="font-family: Times New Roman; font-size: 13px">                4.7               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSeries G 2015 Common Stock Purchase Warrant.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">              <br/>             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              July 7,2015             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495416001118/ptn_ex41.htm">               <font style="font-family: Times New Roman; font-size: 13px">                4.8               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSeries H 2016 Common Stock Purchase Warrant.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              August2, 2016             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495416001118/ptn_ex42.htm">               <font style="font-family: Times New Roman; font-size: 13px">                4.9               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSeries I 2016 Common Stock Purchase Warrant.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              August2, 2016             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495416004499/ptn_ex42.htm">               <font style="font-family: Times New Roman; font-size: 13px">                4.10               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofSeries J 2016 Common Stock Purchase Warrant.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              December1, 2016             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495417000945/ptn_ex41.htm">               <font style="font-family: Times New Roman; font-size: 13px">                4.11               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Form ofwarrant issued to PSL Business Development Consulting and SARLAvisius in connection with a contract for financial advisoryservices.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              February10, 2017             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495419010679/ptn_ex412.htm">               <font style="font-family: Times New Roman; font-size: 13px">                4.12               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Descriptionof Securities             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              10-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              September12, 2019             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802009000050/ex10-1.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.1†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              1996 Stock Option Plan, as amended.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">              <br/>             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              September 28, 2009             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-1.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.2†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Option Certificate (Incentive Option) Under the 2005 StockPlan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              September 21, 2011             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-2.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.3†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Incentive Stock Option Under the 2005 StockPlan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              September 21, 2011             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-3.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.4†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Opinion Certificate (Non-Qualified Opinion) Under the 2005Stock Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              September 21, 2011             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802005000063/ex10-4.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.5†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Non-Qualified Stock Option Agreement Under the 2005 StockPlan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              September 21, 2011             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="null">        <font>        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           93          </font>         </div>        </div>        <div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">         <!--page break line-->        </div>        <div id="hdr">         <div style="text-align: right; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>        </div>       </div>       <div style="null">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="null">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000006/ex10-4.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.6†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              2007 Change in Control Severance Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              February 8, 2008             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802009000025/ex10-1.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.7†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              2005 Stock Plan, as amended.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              May 15, 2009             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000022/ex10-1.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.8†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Executive Officer Option Certificate.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              May 14, 2008             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000022/ex10-2.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.9†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Amended Restricted Stock Unit Agreement.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              May 14, 2008             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802008000022/ex10-3.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.10†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Amended Option Certificate (Incentive Option) Under the2005 Stock Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              May 14, 2008             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495417005448/ptn_ex101.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.11†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              2011 Stock Incentive Plan, as amended and restated.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              June 29, 2020             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802011000031/ex10-1.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.12†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Restricted Share Unit Agreement Under the 2011 StockIncentive Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              May 13, 2011             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802011000031/ex10-3.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.13†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Nonqualified Stock Option Agreement under the 2011 StockIncentive Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              May 13, 2011             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000108802011000031/ex10-4.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.14†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Incentive Stock Option Agreement under the 2011 StockIncentive Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              May 13, 2011             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815005517/ptn_ex101.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.15†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Restricted Share Unit Agreement under the 2011 StockIncentive Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              December 11, 2015             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815005517/ptn_ex102.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.16†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Performance-Based Restricted Share Unit Agreement under the2011 Stock Incentive Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              December 11, 2015             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815005517/ptn_ex103.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.17†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Restricted Share Unit Agreement for Non-Employee Directorsunder the 2011 Stock Incentive Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              December 11, 2015             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448816006209/ptn_ex101.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.18†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Amended form of Restricted Share Unit Agreement under the 2011Stock Incentive Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              February 12, 2016             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448816006209/ptn_ex102.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.19†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Amended form of Performance-Based Restricted Share Unit Agreementunder the 2011 Stock Incentive Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              February 12, 2016             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448816006209/ptn_ex103.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.20†               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Amended form of Restricted Share Unit Agreement for Non-EmployeeDirectors under the 2011 Stock Incentive Plan.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              February 12, 2016             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815003531/ex_406.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.21               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Form of Indenture.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              S-3             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              August 17, 2018             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              333-226905             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000135448815003275/ptn_ex103.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.22               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Amended and Restated Venture Loan and Security Agreement, datedJuly 2, 2015, by and between Palatin Technologies, Inc. and HorizonTechnology Finance Corporation, Fortress Credit Co LLC, HorizonCredit II LLC and Fortress Credit Opportunities V CLOLimited.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <br/>             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              July 7,2015             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              <br/>             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495416002272/ptn_ex1037.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.23††               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Termination and Release Agreement dated September 29, 2020, by andbetween Catalent Belgium S.A. and Palatin Technologies,Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              November 16, 2020             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           94          </font>         </div>        </div>        <div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">         <!--page break line-->        </div>        <div id="hdr">         <div style="text-align: right; width: 100%">          <font style="font-family: Times New Roman; font-size: 11px">          </font>         </div>        </div>       </div>       <div style="null">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495416002272/ptn_ex1038.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.24††               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Commercial Supply Agreement dated September 29, 2020, by andbetween Catalent Belgium S.A. and Palatin Technologies,Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              November 16, 2020             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495417000945/ptn_ex101.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.25††               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              License Agreement, dated January 8, 2017, by and between AMAGPharmaceuticals, Inc. and Palatin Technologies, Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              February 10, 2017             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495417010398/ptn_ex101.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.26††               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              License Agreement, dated September 6, 2017, by and between ShanghaiFosun Pharmaceutical Industrial Development Co., Ltd. and PalatinTechnologies, Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              November 13, 2017             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495419007674/ptn_ex101.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.27†               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Employment Agreement, effective as of July 1, 2019, between CarlSpana and Palatin Technologies, Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              June 26, 2019             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495419007674/ptn_ex102.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.28†               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Employment Agreement, effective as of July 1, 2019, between StephenT. Wills and Palatin Technologies, Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              June 26, 2019             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420008026/ptn_ex101.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.29               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Termination Agreement between Palatin Technologies, Inc. And AMAGPharmaceuticals, Inc., dated July 24, 2020.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              8-K             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              July 27, 2020             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420010471/ptn_ex1030.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.30†††               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Manufacturing Serves Agreement, dated as of June 1, 2019, by andbetween Palatin Technologies, Inc. (as assignee from AMAGPharmaceuticals, Inc.) and Lonza Ltd.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-K             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              September 25, 2020             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420010471/ptn_ex1031.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.31†††               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Supply Agreement, dated as of December 20, 2018, by and betweenPalatin Technologies, Inc. (as assignee from AMAG Pharmaceuticals,Inc.) and Ypsomed AG.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-K             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              September 25, 2020             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420012486/ptn_ex102.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.32               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Commercial Supply Agreement dated September 29, 2020, by andbetween Catalent Belgium S.A. and Palatin Technologies,Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              November 16, 2020             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font>              <a href="http://www.sec.gov/Archives/edgar/data/911216/000165495420012486/ptn_ex101.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                10.33†††               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Termination and Release Agreement dated September 29, 2020, by andbetween Catalent Belgium S.A. and Palatin Technologies,Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              10-Q             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              November 16, 2020             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              001-15543             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: rgb(0, 0, 0);">              <a href="ptn_ex21.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                21               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Subsidiary of Palatin Technologies, Inc.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: rgb(0, 0, 0);">              <a href="ptn_23.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                23               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Consent of KPMG LLP.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: rgb(0, 0, 0);">              <a href="ptn_311.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                31.1               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Certification of Chief Executive Officer.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <br/>           </td>           <td style="vertical-align: top; width: 13%">            <br/>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: rgb(0, 0, 0);">              <a href="ptn_312.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                31.2               </font>              </a>             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Certification of Chief Financial Officer.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <br/>           </td>           <td style="vertical-align: top; width: 19%">            <br/>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: rgb(0, 0, 0);">              <a href="ptn_321.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                32.1               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Certification of principal executive officer pursuant to U.S.C.Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: rgb(0, 0, 0);">              <a href="ptn_322.htm">               <font style="font-family: Times New Roman; font-size: 13px;">                32.2               </font>              </a>             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              Certification of principal financial officer pursuant to U.S.C.Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>            <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              101.INS             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              XBRL Instance Document.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px;">              101.SCH             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              XBRL Taxonomy Extension Schema Document.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              101.CAL             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              XBRL Taxonomy Extension Calculation Linkbase Document.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              101.LAB             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              XBRL Taxonomy Extension Label Linkbase Document.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr style="background-color: rgb(204, 238, 255);">           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              101.PRE             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              XBRL Taxonomy Extension Presentation LinkbaseDocument.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 10%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              101.DEF             </font>            </div>           </td>           <td style="vertical-align: top; width: 38%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">              XBRL Taxonomy Extension Definition Linkbase Document.             </font>            </div>           </td>           <td style="vertical-align: top; width: 11%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="color: #000000; font-family: Times New Roman; font-size: 13px">              X             </font>            </div>           </td>           <td style="vertical-align: top; width: 9%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 13%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #231F20; font-family: Times New Roman; font-size: 13px">         † Management contract or compensatory plan orarrangement.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         ††Confidential treatment granted as to certain portions of theexhibit, which portions are omitted and filed separately with theSEC.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         †††Portions of the exhibit are omitted pursuant to Regulation S-K Item601(b)(10). Palatin agrees to furnish to the U.S. Securities andExchange Commission a copy of any omitted schedule and/or exhibitupon request. The confidential portions of this exhibit wereomitted by means of marking such portions with asterisks becausethe identified confidential portions (i) are not material and (ii)would be competitively harmful if publicly disclosed.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="color: #27405E; font-family: Times New Roman; font-size: 13px">         Item 16. Form 10-K         <a name="item16">          S         </a>         ummary.        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px;">        </font>       </div>       <div style="text-align: left; margin-left: 48px; margin-right: 0px; text-indent: -48px">        <font style="font-family: Times New Roman; font-size: 13px">         None.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           95          </font>         </div>        </div>        <div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>        <div id="hdr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>        </div>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         SIGNATURES        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Pursuantto the requirements of Section 13 or 15(d) of the SecuritiesExchange Act of 1934, the registrant has duly caused this report tobe signed on its behalf by the undersigned, thereunto dulyauthorized.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">         PALATIN TECHNOLOGIES, INC.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="display: table">        <div style="display: table-row">         <div style="display: table-cell; width: 144px">          <font style="font-family: Times New Roman; font-size: 13px">           By:           <font style="text-decoration: underline">            /s/ Carl Spana           </font>          </font>         </div>        </div>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         CarlSpana, Ph.D.        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         President and ChiefExecutive Officer        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 48px">        <font style="font-family: Times New Roman; font-size: 13px">         (principalexecutive officer)        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Date:September 28, 2021        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">         Pursuantto the requirements of the Securities Exchange Act of 1934, thisreport has been signed below by the following persons on behalf ofthe registrant and in the capacities and on the datesindicated.        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div>        <table cellpadding="0" cellspacing="0" style="width: 100%; font-family: Times New Roman; font-size: 13px">         <tbody>          <tr>           <td style="vertical-align: top; width: 34%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Signature             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Title             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">              Date             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              /s/Carl Spana             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              President,Chief Executive Officer and Director             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              September28, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              CarlSpana             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              (principalexecutive officer)             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              /s/Stephen T. Wills             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ExecutiveVice President, Chief Financial Officer             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              September28, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              StephenT. Wills             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              andChief Operating Officer (principal financial and accountingofficer)             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              /s/John K. A. Prendergast             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Chairmanand Director             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              September28, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              John K.A. Prendergast             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              /s/Robert K. deVeer, Jr.             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              September28, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              RobertK. deVeer, Jr.             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              /s/ J.Stanley Hull             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              September28, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              J.Stanley Hull             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              /s/              <font style="font-size: 13px">              </font>              Alan W. Dunton             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              September29, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Alan W.Dunton             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              /s/Arlene M. Morris             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              September28, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              ArleneM. Morris             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%; border-bottom: 2px solid #000000">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              /s/Anthony M. Manning             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              Director             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              September28, 2021             </font>            </div>           </td>          </tr>          <tr>           <td style="vertical-align: top; width: 34%">            <div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">             <font style="font-family: Times New Roman; font-size: 13px">              AnthonyM. Manning             </font>            </div>           </td>           <td style="vertical-align: top; width: 47%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>           <td style="vertical-align: top; width: 19%">            <div>             <font style="font-family: Times New Roman; font-size: 13px">             </font>            </div>           </td>          </tr>         </tbody>        </table>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">        <font style="font-family: Times New Roman; font-size: 13px">        </font>       </div>       <div>        <font style="font-family: Times New Roman; font-size: 10">        </font>       </div>       <div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">        <div id="ftr">         <div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">          <font style="font-family: Times New Roman; font-size: 13px">          </font>         </div>         <div id="pn" style="text-align: center">          <font style="font-family: Times New Roman; font-size: 13px">           96          </font>         </div>        </div>        <div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">         <!--page break-->        </div>       </div>      </text>     </description>    </filename>   </sequence>  </type> </document></body>